INDUCING CELLULAR IMMUNE RESPONSES TO HEPATITIS C VIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare HCV epitopes, and to develop epitope-based vaccines directed towards HCV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HCV infection.

Description: INDUCING CELLULAR IMMUNE RESPONSES TO HEPATITIS C VIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT This invention was funded, in part, by the United States government under grants with the National Institutes of Health. The U.S. government has certain rights in this invention. INDEX I. Background of the Invention II. Summary of the Invention III. Brief Description of the Figures IV. Detailed Description of the Invention A. Definitions B. Stimulation of CTL and HTL responses C. Binding Affinity of Peptide Epitopes for HLA Molecules D. Peptide Epitope Binding Motifs and Supermotifs 1. HLA-A1 supermotif 2. HLA-A2 supermotif 3. HLA- A3 supermotif 4. HLA-A24 supermotif 5. HLA-B7 supermotif 6. HLA-B27 supermotif 7. HLA-B44 supermotif 8. HLA-B58 supermotif 9. HLA-B62 supermotif 10. HLA-A1 motif 11. HLA-A2.1 motif 12. HLA- A3 motif 13. HLA-A11 motif 14. HLA-A24 motif 15. HLA-DR- 1-4-7 supermotif 16. HLA-DR3 motifs E. Enhancing Population Coverage of the Vaccine F. Immune Response-Stimulating Peptide Epitope Analogs G. Computer Screening of Protein Sequences from Disease-Related Antigens for Supermotif- or Motif-Containing Epitopes H. Preparation of Peptide Epitopes I. Assays to Detect T-Cell Responses J. Use of Peptide Epitopes for Evaluating Immune Responses K. Vaccine Compositions 1. Minigene Vaccines 2. Combinations of CTL Peptides with Helper Peptides L. Administration of Vaccines for Therapeutic or Prophylactic Purposes M. Kits V. Examples VI. Claims VII. Abstract I. BACKGROUND OF THE INVENTION Hepatitis C virus (HCV) infection is a global human health problem with approximately 150,000 new reported cases each year in the U.S. alone. HCV is a single stranded RNA virus, and is the etio logical agent identified in most cases of non-A, non-B post-transfusion and post-transplant hepatitis, and is a common cause of acute sporadic hepatitis (Choo et al, Science 244:359, 1989; Kuo et al, Science 244:362, 1989; and Alter et al., in: Current Perspective in Hepatology, p. 83, 1989). It is estimated that more than 50% of patients infected with HCV become chronically infected and, of those, 20% develop cirrhosis of the liver within 20 years (Davis et al., New Engl. J. Med. 321:1501, 1989; Alter et al, in: Current Perspective in Hepatology, p. 83, 1989; Alter et al, New Engl. J. Med. 327:1899, 1992; and Dienstag, J. L. Gastroenterology 85:430, 1983). Moreover, the only therapy available for treatment of HCV infection is interferon-α. Most patients are unresponsive, however, and among the responders, there is a high recurrence rate within 6-12 months of cessation of treatment (Liang et al, J. Med. Virol. 40:69, 1993). Ribaviron, a guanosine analog with a broad spectrum activity against many RNA and DNA viruses, has been shown in clinical trials to be effective against chronic HCV infection when used in combination with interferon- α (see, e.g., Poynard et al, Lancet 352:1426-1432, 1998; Reichard et al, Lancet 351:83-87, 1998) However, the response rate is still well below 50%. Virus-specific, human leukocyte antigen (HLA) class I-restricted cytotoxic T lymphocytes (CTL) are known to play a major role in the prevention and clearance of virus infections in vivo (Oldstone et al, Nature, 321:239, 1989; Jamieson et al, J. Virol. 61:3930, 1987; Yap et al, Nature 273:238, 1978; Lukacher et al, J. Exp. Med. 160:814, 1994; McMichael et al, N Engl J. Med. 309: 13, 1983; Sethi et al, J. Gen. Virol. 64:443, 1983; Watari et al, J. Exp. Med. 165:459, 1987; Yasukawa et al, J. Immunol 143:2051, 1989; Tigges et al, J. Virol. 66:1622, 1993; Reddenhase et al, J. Virol. 55:263, 1985; Quinnan et al, N. Engl. J. Med. 307:6, 1982). HLA class I molecules are expressed on the surface of almost all nucleated cells. Following intracellular processing of antigens, epitopes from the antigens are presented as a complex with the HLA class I molecules on the surface of such cells. CTL recognize the peptide-HLA class I complex, which then results in the destruction of the cell bearing the HLA-peptide complex directly by the CTL and/or via the activation of non-destructive mechanisms e.g., the production of interferon, that inhibit viral replication. In view of the heterogeneous immune response observed with HCV infection, induction of a multi-specific cellular immune response directed simultaneously against multiple HCV epitopes appears to be important for the development of an efficacious vaccine against HCV. There is a need, however, to establish vaccine embodiments that elicit immune responses that correspond to responses seen in patients that clear HCV infection. The information provided in this section is intended to disclose the presently understood state of the art as of the filing date of the present application. Information is included in this section which was generated subsequent to the priority date of this application. Accordingly, information in this section is not intended, in any way, to delineate the priority date for the invention. II. SUMMARY OF THE INVENTION This invention applies our knowledge of the mechanisms by which antigen is recognized by T cells, for example, to develop epitope-based vaccines directed towards HCV. More specifically, this application communicates our discovery of specific epitope pharmaceutical compositions and methods of use in the prevention and treatment of HCV infection. Upon development of appropriate technology, the use of epitope-based vaccines has several advantages over current vaccines, particularly when compared to the use of whole antigens in vaccine compositions. There is evidence that the immune response to whole antigens is directed largely toward variable regions of the antigen, allowing for immune escape due to mutations. The epitopes for inclusion in an epitope-based vaccine are selected from conserved regions of viral or tumor-associated antigens, which thereby reduces the likelihood of escape mutants. Furthermore, immunosuppressive epitopes that may be present in whole antigens can be avoided with the use of epitope-based vaccines. An additional advantage of an epitope-based vaccine approach is the ability to combine selected epitopes (CTL and HTL), and further, to modify the composition of the epitopes, achieving, for example, enhanced immunogenicity. Accordingly, the immune response can be modulated, as appropriate, for the target disease. Similar engineering of the response is not possible with traditional approaches. Another major benefit of epitope-based immune-stimulating vaccines is their safety. The possible pathological side effects caused by infectious agents or whole protein antigens, which might have their own intrinsic biological activity, is eliminated. An epitope-based vaccine also provides the ability to direct and focus an immune response to multiple selected antigens from the same pathogen. Thus, patient-by-patient variability in the immune response to a particular pathogen may be alleviated by inclusion of epitopes from multiple antigens from that pathogen in a vaccine composition. A "pathogen" may be an infectious agent or a tumor associated molecule. One of the most formidable obstacles to the development of broadly efficacious epitope-based immunotherapeutics, however, has been the extreme polymorphism of HLA molecules. To date, effective non-genetically biased coverage of a population has been a task of considerable complexity; such coverage has required that epitopes be used that are specific for HLA molecules corresponding to each individual HLA allele, therefore, impractically large numbers of epitopes would have to be used in order to cover ethnically diverse populations. Thus, there has existed a need for peptide epitopes that are bound by multiple HLA antigen molecules for use in epitope-based vaccines. The greater the number of HLA antigen molecules bound, the greater the breadth of population coverage by the vaccine. Furthermore, as described herein in greater detail, a need has existed to modulate peptide binding properties, for example, so that peptides that are able to bind to multiple HLA antigens do so with an affinity that will stimulate an immune response. Identification of epitopes restricted by more than one HLA allele at an affinity that correlates with immunogenicity is important to provide thorough population coverage, and to allow the elicitation of responses of sufficient vigor to prevent or clear an infection in a diverse segment of the population. Such a response can also target a broad array of epitopes. The technology disclosed herein provides for such favored immune responses. In a preferred embodiment, epitopes for inclusion in vaccine compositions of the invention are selected by a process whereby protein sequences of known antigens are evaluated for the presence of motif or supermotif-bearing epitopes. Peptides corresponding to a motif- or supermotif-bearing epitope are then synthesized and tested for the ability to bind to the HLA molecule that recognizes the selected motif. Those peptides that bind at an intermediate or high affinity i.e. , an IC 50 (or a K D value) of 500 nM or less for HLA class I molecules or 1000 nM or less for HLA class II molecules, are further evaluated for their ability to induce a CTL or HTL response. Immunogenic peptide epitopes are selected for inclusion in vaccine compositions. Supermotif-bearing peptides may additionally be tested for the ability to bind to multiple alleles within the HLA supertype family. Moreover, peptide epitopes may be analogued to modify binding affinity and/or the ability to bind to multiple alleles within an HLA supertype. The invention also includes an embodiment comprising a method for monitoring or evaluating an immune response to HCV in a patient having a known HLA-type, the method comprising incubating a T lymphocyte sample from the patient with a peptide composition comprising an HCV epitope consisting essentially of an amino acid sequence described in Tables VII to Table XX or Table XXII which binds the product of at least one HLA allele present in said patient, and detecting for the presence of a T lymphocyte that binds to the peptide. A CTL peptide epitope may, for example, comprise a tetrameric complex. An alternative modality for defining the peptide epitopes in accordance with the invention is to recite the physical properties, such as length; primary structure; or charge, which are correlated with binding to a particular allele-specific HLA molecule or group of allele-specific HLA molecules. A further modality for defining peptide epitopes is to recite the physical properties of an HLA binding pocket, or properties shared by several allele-specific HLA binding pockets (e.g. pocket configuration and charge distribution) and reciting that the peptide epitope fits and binds to said pocket or pockets. As will be apparent from the discussion below, other methods and embodiments are also contemplated. Further, novel synthetic peptides produced by any of the methods described herein are also part of the invention. III. BRIEF DESCRIPTION OF THE FIGURES Figure 1: Figure 1 provides a graph of total frequency of genotypes as a function of the number of HCV candidate epitopes bound by HLA-A and B molecules, in an average population. Figure 2: Figure 2 illustrates the position of peptide epitopes in an experimental model minigene construct. IV. DETAILED DESCRIPTION OF THE INVENTION The peptide epitopes and corresponding nucleic acid compositions of the present invention are useful for stimulating an immune response to HCV by stimulating the production of CTL or HTL responses. The peptide epitopes, which are derived directly or indirectly from native HCV amino acid sequences, are able to bind to HLA molecules and stimulate an immune response to HCV. The complete polyprotein sequence from HCV and its variants can be obtained from Genbank. Peptide epitopes and analogs thereof can also be readily determined from sequence information that may subsequently be discovered for heretofore unknown variants of HCV, as will be clear from the disclosure provided below. The peptide epitopes of the invention have been identified in a number of ways, as will be discussed below. Also discussed in greater detail is that analog peptides have been derived and the binding activity for HLA molecules modulated by modifying specific amino acid residues to create peptide analogs exhibiting altered immunogenicity. Further, the present invention provides compositions and combinations of compositions that enable epitope-based vaccines that are capable of interacting with HLA molecules encoded by various genetic alleles to provide broader population coverage than prior vaccines. IV.A. Definitions The invention can be better understood with reference to the following definitions, which are listed alphabetically: A "computer" or "computer system" generally includes: a processor; at least one information storage/retrieval apparatus such as, for example, a hard drive, a disk drive or a tape drive; at least one input apparatus such as, for example, a keyboard, a mouse, a touch screen, or a microphone; and display structure. Additionally, the computer may include a communication channel in communication with a network. Such a computer may include more or less than what is listed above. "Cross-reactive binding" indicates that a peptide is bound by more than one HLA molecule; a synonym is degenerate binding. A "cryptic epitope" elicits a response by immunization with an isolated peptide, but the response is not cross-reactive in vitro when intact whole protein which comprises the epitope is used as an antigen. A "dominant epitope" is an epitope that induces an immune response upon immunization with a whole native antigen (see, e.g., Sercarz, et al., Annu. Rev. Immunol. 11 \129-166, 1993). Such a response is cross-reactive in vitro with an isolated peptide epitope. With regard to a particular amino acid sequence, an "epitope" is a set of amino acid residues which is involved in recognition by a particular immunoglobulin, or in the context of T cells, those residues necessary for recognition by T cell receptor proteins and/or Major Histocompatibility Complex (MHC) receptors. In an immune system setting, in vivo or in vitro, an epitope is the collective features of a molecule, such as primary, secondary and tertiary peptide structure, and charge, that together form a site recognized by an immunoglobulin, T cell receptor or HLA molecule. Throughout this disclosure epitope and peptide are often used interchangeably. It is to be appreciated that protein or peptide molecules that comprise an epitope of the invention as well as additional amino acid(s) are still within the bounds of the invention. In certain embodiments, there is a limitation on the length of a peptide of the invention which is not otherwise a construct. An embodiment that is length-limited occurs when the protein/peptide comprising an epitope of the invention comprises a region (i.e., a contiguous series of amino acids) having 100% identity with a native sequence. In order to avoid the definition of epitope from reading, e.g., on whole natural molecules, there is a limitation on the length of any region that has 100% identity with a native peptide sequence. Thus, for a peptide comprising an epitope of the invention and a region with 100% identity with a native peptide sequence (and is not otherwise a construct), the region with 100% identity to a native sequence generally has a length of: less than or equal to 600 amino acids, often less than or equal to 500 amino acids, often less than or equal to 400 amino acids, often less than or equal to 250 amino acids, often less than or equal to 100 amino acids, often less than or equal to 85 amino acids, often less than or equal to 75 amino acids, often less than or equal to 65 amino acids, and often less than or equal to 50 amino acids. In certain embodiments, an "epitope" of the invention is comprised by a peptide having a region with less than 51 amino acids that has 100% identity to a native peptide sequence, in any increment of (49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5) down to 5 amino acids. Accordingly, peptide or protein sequences longer than 600 amino acids are within the scope of the invention, so long as they do not comprise any contiguous sequence of more than 600 amino acids that have 100% identity with a native peptide sequence, if they are not otherwise a construct. For any peptide that has five contiguous residues or less that correspond to a native sequence, there is no limitation on the maximal length of that peptide in order to fall within the scope of the invention. It is presently preferred that a CTL epitope be less than 600 residues long in any increment down to eight amino acid residues. "Human Leukocyte Antigen" or "HLA" is a human class I or class II Major Histocompatibility Complex (MHC) protein (see, e.g., Stites, et al, IMMUNOLOGY, 8 TH ED., Lange Publishing, Los Altos, CA (1994). An "HLA supertype or family", as used herein, describes sets of HLA molecules grouped on the basis of shared peptide-binding specificities. HLA class I molecules that share somewhat similar binding affinity for peptides bearing certain amino acid motifs are grouped into HLA supertypes. The terms HLA superfamily, HLA supertype family, HLA family, and HLA xx-like supertype molecules (where xx denotes a particular HLA type), are synonyms. Throughout this disclosure, results are expressed in terms of "IC 50 's." IC 50 is the concentration of peptide in a binding assay at which 50% inhibition of binding of a reference peptide is observed. Given the conditions in which the assays are run (i.e., limiting HLA proteins and labeled peptide concentrations), these values approximate K D values. Assays for determining binding are described in detail, e.g., in PCT publications WO 94/20127 and WO 94/03205. It should be noted that IC 50 values can change, often dramatically, if the assay conditions are varied, and depending on the particular reagents used (e.g., HLA preparation, etc.). For example, excessive concentrations of HLA molecules will increase the apparent measured IC 50 of a given ligand. Alternatively, binding is expressed relative to a reference peptide. Although as a particular assay becomes more, or less, sensitive, the IC 50 's of the peptides tested may change somewhat, the binding relative to the reference peptide will not significantly change. For example, in an assay run under conditions such that the IC 50 of the reference peptide increases 10-fold, the IC 50 values of the test peptides will also shift approximately 10-fold. Therefore, to avoid ambiguities, the assessment of whether a peptide is a good, intermediate, weak, or negative binder is generally based on its IC 0 , relative to the IC 50 of a standard peptide. Binding may also be determined using other assay systems including those using: live cells (e.g., Ceppellini et al, Nature 339:392, 1989; Christnick et al, Nature 352:67, 1991; Busch et al, Int. Immunol 2:443, 19990; Hill et al, J. Immunol 147:189, 1991; del Guercio et al, J. Immunol. 154:685, 1995), cell free systems using detergent lysates (e.g., Cerundolo et al, J. Immunol 21:2069, 1991), immobilized purified MHC (e.g., Hill et al, J. Immunol 152, 2890, 1994; Marshall et al, J. Immunol. 152:4946, 1994), ELISA systems (e.g., Reay et al, EMBOJ. 11:2829, 1992), surface plasmon resonance (e.g., Khilko et al, J. Biol. Chem. 268:15425, 1993); high flux soluble phase assays (Hammer et al, J. Exp. Med. 180:2353, 1994), and measurement of class I MHC stabilization or assembly (e.g., Ljunggren et al, Nature 346:476, 1990; Schumacher et al, Cell 62:563, 1990; Townsend et al, Cell 62:285, 1990; Parker et al, J. Immunol 149:1896, 1992). As used herein, "high affinity" with respect to HLA class I molecules is defined as binding with an IC 50 , or K D value, of 50 nM or less; "intermediate affinity" is binding with an IC 50 or K D value of between about 50 and about 500 nM. "High affinity" with respect to binding to HLA class II molecules is defined as binding with an IC 50 or KQ value of 100 nM or less; "intermediate affinity" is binding with an IC 50 or K D value of between about 100 and about 1000 nM. The terms "identical" or percent "identity," in the context of two or more peptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues that are the same, when compared and aligned for maximum correspondence over a comparison window, as measured using a sequence comparison algorithm or by manual alignment and visual inspection. An "immunogenic peptide" or "peptide epitope" is a peptide that comprises an allele-specific motif or supermotif such that the peptide will bind an HLA molecule and induce a CTL and/or HTL response. Thus, immunogenic peptides of the invention are capable of binding to an appropriate HLA molecule and thereafter inducing an HLA- restricted cytotoxic or helper T cell response to the antigen from which the immunogenic peptide is derived. The phrases "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany the material as it is found in its native state. Thus, isolated peptides in accordance with the invention preferably do not contain materials normally associated with the peptides in their in situ environment. An "isolated" epitope refers to an epitope that does not include the whole sequence of the antigen or polypeptide from which the epitope was derived. Typically the "isolated" epitope does not have attached thereto additional amino acids that result in a sequence that has 100% identity with a native sequence. The native sequence can be a sequence such as a tumor-associated antigen from which the epitope is derived. "Major Histocompatibility Complex" or "MHC" is a cluster of genes that plays a role in control of the cellular interactions responsible for physiologic immune responses. In humans, the MHC complex is also known as the HLA complex. For a detailed description of the MHC and HLA complexes, see, Paul, FUNDAMENTAL IMMUNOLOGY, 3 RD ED., Raven Press, New York, 1993. The term "motif refers to the pattern of residues in a peptide of defined length, usually a peptide of from about 8 to about 13 amino acids for a class I HLA motif and from about 6 to about 25 amino acids for a class II HLA motif, which is recognized by a particular HLA molecule. Peptide motifs are typically different for each protein encoded by each human HLA allele and differ in the pattern of the primary and secondary anchor residues. A "negative binding residue" is an amino acid which, if present at certain positions (typically not primary anchor positions) in a peptide epitope, results in decreased binding affinity of the peptide for the peptide 's corresponding HLA molecule. A "non-native" sequence or "construct" refers to a sequence that is not found in in nature ("non-naturally occurring"). Such sequences include, e.g., peptides that are lipidated or otherwise modifed and polyepitopic compositions that contain epitopes that are non contiguous in a native protein sequence. The term "peptide" is used interchangeably with "oligopeptide" in the present specification to designate a series of residues, typically L-amino acids, connected one to the other, typically by peptide bonds between the -amino and carboxyl groups of adjacent amino acids. The preferred CTL-inducing peptides of the invention are 13 residues or less in length and usually consist of between about 8 and about 11 residues, preferably 9 or 10 residues. The preferred HTL-inducing oligopeptides are less than about 50 residues in length and usually consist of between about 6 and about 30 residues, more usually between about 12 and 25, and often between about 15 and 20 residues. "Pharmaceutically acceptable" refers to a generally non-toxic, inert, and/or physiologically compatible composition. A "pharmaceutical excipient" comprises a material such as an adjuvant, a carrier, pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservative, and the like. A "primary anchor residue" is an amino acid at a specific position along a peptide sequence which is understood to provide a contact point between the immunogenic peptide and the HLA molecule. One to three, usually two, primary anchor residues within a peptide of defined length generally defines a "motif for an immunogenic peptide. These residues are understood to fit in close contact with peptide binding grooves of an HLA molecule, with their side chains buried in specific pockets of the binding grooves themselves. In one embodiment, the primary anchor residues are located at position 2 (from the amino terminal position) and at the carboxyl terminal position of a 9-residue peptide epitope in accordance with the invention. The primary anchor positions for each motif and supermotif are set forth in Table 1. For example, analog peptides can be created by altering the presence or absence of particular residues in these primary anchor positions. Such analogs are used to modulate the binding affinity of a peptide comprising a particular motif or supermotif. "Promiscuous recognition" is where a distinct peptide is recognized by the same T cell clone in the context of various HLA molecules. Promiscuous recognition or binding is synonymous with cross-reactive binding. A "protective immune response" or "therapeutic immune response" refers to a CTL and/or an HTL response to an antigen derived from an infectious agent or a tumor antigen, which prevents or at least partially arrests disease symptoms or progression. The immune response may also include an antibody response which has been facilitated by the stimulation of helper T cells. The term "residue" refers to an amino acid or amino acid mimetic incorporated into an oligopeptide by an amide bond or amide bond mimetic. A "secondary anchor residue" is an amino acid at a position other than a primary anchor position in a peptide which may influence peptide binding. A secondary anchor residue occurs at a significantly higher frequency amongst bound peptides than would be expected by random distribution of amino acids at one position. The secondary anchor residues are said to occur at "secondary anchor positions." A secondary anchor residue can be identified as a residue which is present at a higher frequency among high or intermediate affinity binding peptides, or a residue otherwise associated with high or intermediate affinity binding. For example, analog peptides can be created by altering the presence or absence of particular residues in these secondary anchor positions. Such analogs are used to finely modulate the binding affinity of a peptide comprising a particular motif or supermotif. A "subdominant epitope" is an epitope which evokes little or no response upon immunization with whole antigens which comprise the epitope, but for which a response can be obtained by immunization with an isolated peptide, and this response (unlike the case of cryptic epitopes) is detected when whole protein is used to recall the response in vitro or in vivo. A "supermotif is a peptide binding specificity shared by HLA molecules encoded by two or more HLA alleles. Preferably, a supermotif-bearing peptide is recognized with high or intermediate affinity (as defined herein) by two or more HLA antigens. "Synthetic peptide" refers to a peptide that is man-made using such methods as chemical synthesis or recombinant DNA technology. As used herein, a "vaccine" is a composition that contains one or more peptides of the invention. There are numerous embodiments of vaccines in accordance with the invention, such as by a cocktail of one or more peptides; one or more epitopes of the invention comprised by a polyepitopic peptide; or nucleic acids that encode such peptides or polypeptides, e.g., a minigene that encodes a polyepitopic peptide. The "one or more peptides" can include, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 , 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 or more peptides of the invention. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class I-binding peptides of the invention can be admixed with, or linked to, HLA class Il-binding peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. Vaccines can also comprise peptide-pulsed antigen presenting cells, e.g., dendritic cells. The nomenclature used to describe peptide compounds follows the conventional practice wherein the amino group is presented to the left (the N-terminus) and the carboxyl group to the right (the C-terminus) of each amino acid residue. When amino acid residue positions are referred to in a peptide epitope they are numbered in an amino to carboxyl direction with position one being the position closest to the amino terminal end of the epitope, or the peptide or protein of which it may be a part. In the formulae representing selected specific embodiments of the present invention, the amino- and carboxyl-terminal groups, although not specifically shown, are in the form they would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue is generally represented by standard three letter or single letter designations. The L-form of an amino acid residue is represented by a capital single letter or a capital first letter of a three-letter symbol, and the D-form for those amino acids having D-forms is represented by a lower case single letter or a lower case three letter symbol. Glycine has no asymmetric carbon atom and is simply referred to as "Gly" or G. Symbols for the amino acids are shown below. Single Letter Symbol Three Letter Symbol Amino Acids A Ala Alanine C Cys Cysteine D Asp Aspartic Acid E Glu Glutamic Acid F Phe Phenylalanine G Gly Glycine H His Histidine I He Isoleucine K Lys Lysine L Leu Leucine M Met Methionine N Asn Asparagine P Pro Proline Q Gin Glutamine R Arg Arginine S Ser Serine T Thr Threonine V Val Valine W Tip Tryptophan Y Tyr Tyrosine IV.B. Stimulation of CTL and HTL responses The mechanism by which T cells recognize antigens has been delineated during the past ten years. Based on our understanding of the immune system we have developed efficacious peptide epitope vaccine compositions that can induce a therapeutic or prophylactic immune response to HCV in a broad population. For an understanding of the value and efficacy of the claimed compositions, a brief review of immunology-related technology is provided. A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. et al, Cell 47:1071, 1986; Babbitt, B. P. et al, Nature 317:359, 1985; Townsend, A. and Bodmer, H., Annu. Rev. Immunol 7:601, 1989; Germain, R. N., Annu. Rev. Immunol 11 :403, 1993). Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified and are described herein and are set forth in Tables I, II, and III (see also, e.g., Southwood, et al, J. Immunol. 160:3363, 1998; Rammensee, et al, Immunogenetics 41:178, 1995; Rammensee et al, SYFPEITHI, access via web at : http://134.2.96.221/scripts.hlaserver.dll/home.htm; Sette, A. and Sidney, J. Curr. Opin. Immunol 10:478, 1998; Engelhard, V. H., Curr. Opin. Immunol 6:13, 1994; Sette, A. and Grey, H. M., Curr. Opin. Immunol. 4:79, 1992; Sinigaglia, F. and Hammer, J. Curr. Biol. 6:52, 1994; Ruppert et al, Cell 74:929-937, 1993; Kondo et al, J. Immunol. 155:4307-4312, 1995; Sidney et al, J. Immunol 157:3480-3490, 1996; Sidney et al, Human Immunol 45:79-93, 1996; Sette, A. and Sidney, J. Immunogenetics, in press, 1999). Furthermore, x-ray crystallographic analysis of HLA-peptide complexes has revealed pockets within the peptide binding cleft of HLA molecules which accommodate, in an allele-specific mode, residues borne by peptide ligands; these residues in turn determine the HLA binding capacity of the peptides in which they are present. (See, e.g., Madden, D.R. Annu. Rev. Immunol 13:587, 1995; Smith, et al, Immunity 4:203, 1996; Fremont et al, Immunity 8:305, 1998; Stern et al, Structure 2:245, 1994; Jones, E.Y. Curr. Opin. Immunol. 9:75, 1997; Brown, J. H. et al, Nature 364:33, 1993; Guo, H. C. et al, Proc. Natl Acad. Sci. USA 90:8053, 1993; Guo, H. C. et al, Nature 360:364, 1992; Silver, M. L. et al, Nature 360:367, 1992; Matsumura, M. et al, Science 257:927, 1992; Madden et al, Cell 70:1035, 1992; Fremont, D. H. et al, Science 257:919, 1992; Saper, M. A. , Bjorkman, P. J. and Wiley, D. C, J. Mol. Biol. 219:277, 1991.) Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I or class II supermotifs allows identification of regions within a protein that have the potential of binding particular HLA antigen(s). The present inventors have found that the correlation of binding affinity with immunogenicity, which is disclosed herein, is an important factor to be considered when evaluating candidate peptides. Thus, by a combination of motif searches and HLA- peptide binding assays, candidates for epitope-based vaccines have been identified. After determining their binding affinity, additional confirmatory work can be performed to select, amongst these vaccine candidates, epitopes with preferred characteristics in terms of population coverage, antigenicity, and immunogenicity. Various strategies can be utilized to evaluate immunogenicity, including: 1) Evaluation of primary T cell cultures from normal individuals (see, e.g., Wentworth, P. A. et al., Mol Immunol. 32:603, 1995; Celis, E. et al, Proc. Natl. Acad. Sci. USA 91 :2105, 1994; Tsai, V. et al., J. Immunol 158:1796, 1997; Kawashima, I. et al, Human Immunol. 59:1, 1998); This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide in the presence of antigen presenting cells in vitro over a period of several weeks. T cells specific for the peptide become activated during this time and are detected using, e.g., a ^^Cr-release assay involving peptide sensitized target cells. 2) Immunization of HLA transgenic mice (see, e.g., Wentworth, P. A. et al, J. Immunol 26:97, 1996; Wentworth, P. A. et al, Int. Immunol. 8:651, 1996; Alexander, J. et al, J. Immunol. 159:4753, 1997); In this method, peptides in incomplete Freund's adjuvant are administered subcutaneously to HLA transgenic mice. Several weeks following immunization, splenocytes are removed and cultured in vitro in the presence of test peptide for approximately one week. Peptide-specific T cells are detected using, e.g., a 51Cr-release assay involving peptide sensitized target cells and target cells expressing endogenously generated antigen. 3) Demonstration of recall T cell responses from immune individuals who have effectively been vaccinated, recovered from infection, and/or from chronically infected patients (see, e.g., Rehermann, B. et al, J. Exp. Med. 181:1047, 1995; Doolan, D. L. et al, Immunity 7:97, 1997; Bertoni, R. et al, J. Clin. Invest. 100:503, 1997; Threlkeld, S. C. et al, J. Immunol. 159:1648, 1997; Diepolder, H. M. et al, J. Virol. 71:6011, 1997). In applying this strategy, recall responses are detected by culturing PBL from subjects that have been naturally exposed to the antigen, for instance through infection, and thus have generated an immune response "naturally", or from patients who were vaccinated against the infection. PBL from subjects are cultured in vitro for 1-2 weeks in the presence of test peptide plus antigen presenting cells (APC) to allow activation of "memory" T cells, as compared to "naive" T cells. At the end of the culture period, T cell activity is detected using assays for T cell activity including 51Q- release involving peptide-sensitized targets, T cell proliferation, or lymphokine release. The following describes the peptide epitopes and corresponding nucleic acids of the invention. IV.C. Binding Affinity of Peptide Epitopes for HLA Molecules The large degree of HLA polymorphism is an important factor to consider with the epitope-based approach to vaccine development. To address this factor, epitope selection including identification of peptides capable of binding at high or intermediate affinity to multiple HLA molecules is often utilized, most preferably these epitopes bind at high or intermediate affinity to two or more allele specific HLA molecules. CTL-inducing peptides of interest for vaccine compositions preferably include those that have an IC 50 or binding affinity value for class I HLA molecules of 500 nM or better (i.e., the value is < 500 nM). HTL-inducing peptides preferably include those that have an IC 0 or binding affinity value for class II HLA molecules of 1000 nM or better, (i.e., the value is < 1,000 nM). For example, peptide binding is assessed by testing the capacity of a candidate peptide to bind to a purified HLA molecule in vitro. Peptides exhibiting high or intermediate affinity are then considered for further analysis. Selected peptides are tested on other members of the supertype family. In preferred embodiments, peptides that exhibit cross-reactive binding are then used in vaccines or in cellular screening analyses. Higher HLA binding affinity is typically correlated with greater immunogenicity. Greater immunogenicity can be manifested in several different ways. Immunogenicity corresponds to whether an immune response is elicited at all, and to the vigor of any particular response, as well as to the extent of a population in which a response is elicited. For example, a peptide might elicit an immune response in a diverse array of the population, yet in no instance produce a vigorous response. In accordance with these principles, close to 90% of high binding peptides have been found to be immunogenic, as contrasted with about 50% of the peptides which bind with intermediate affinity. Moreover, higher binding affinity peptides leads to more vigorous immunogenic responses. As a result, less peptide is required to elicit a similar biological effect if a high affinity binding peptide is used. Thus, in preferred embodiments of the invention, high affinity binding epitopes are particularly useful. The relationship between binding affinity for HLA class I molecules and immunogenicity of discrete peptide epitopes on bound antigens has been determined for the first time in the art by the present inventors. The correlation between binding affinity and immunogenicity was analyzed in two different experimental approaches (see, e.g., Sette, et al, J. Immunol. 153:5586-5592, 1994). In the first approach, the immunogenicity of potential epitopes ranging in HLA binding affinity over a 10,000-fold range was analyzed in HLA-A*0201 transgenic mice. In the second approach, the antigenicity of approximately 100 different hepatitis B virus (HBV)-derived potential epitopes, all carrying A*0201 binding motifs, was assessed by using PBL from acute hepatitis patients. Pursuant to these approaches, it was determined that an affinity threshold value of approximately 500 nM (preferably 50 nM or less) determines the capacity of a peptide epitope to elicit a CTL response. These data are true for class I binding affinity measurements for naturally processed peptides and for synthesized T cell epitopes. These data also indicate the important role of determinant selection in the shaping of T cell responses (see, e.g., Schaeffer et al. Proc. Natl. Acad. Sci. USA 86:4649-4653, 1989). An affinity threshold associated with immunogenicity in the context of HLA class II DR molecules has also been delineated (see, e.g., Southwood et al. J. Immunology 160:3363-3373,1998). In order to define a biologically significant threshold of DR binding affinity, a database of the binding affinities of 32 DR-restricted epitopes for their restricting element (i.e., the HLA molecule that binds the motif) was compiled. In approximately half of the cases (15 of 32 epitopes), DR restriction was associated with high binding affinities, i.e. binding affinity values of 100 nM or less. In the other half of the cases (16 of 32), DR restriction was associated with intermediate affinity (binding affinity values in the 100-1000 nM range). In only one of 32 cases was DR restriction associated with an IC 50 of 1000 nM or greater. Thus, 1000 nM can be defined as an affinity threshold associated with immunogenicity in the context of DR molecules. The binding affinity of peptides for HLA molecules can be determined as described in Example 1, below. IV.D. Peptide Epitope Binding Motifs and Supermotifs In the past few years evidence has accumulated to demonstrate that a large fraction of HLA class I and class II molecules can be classified into a relatively few supertypes, each characterized by largely overlapping peptide binding repertoires, and consensus structures of the main peptide binding pockets. For HLA molecule pocket analyses, the residues comprising the B and F pockets of HLA class I molecules as described in crystallographic studies were analyzed (see, e.g., Guo, H. C. et al, Nature 360:364, 1992; Saper, M. A. , Bjorkman, P. J. and Wiley, D. C, J. Mol Biol. 219:277, 1991; Madden, D. R., Garboczi, D. N. and Wiley, D. C, Cell 15:693, 1993; Parham, P., Adams, E. J., and Arnett, K. L., Immunol Rev. 143:141, 1995). In these analyses, residues 9, 45, 63, 66, 67, 70, and 99 were considered to make up the B pocket; and the B pocket was deemed to determine the specificity for the amino acid residue in the second position of peptide ligands. Similarly, residues 77, 80, 81, and 116 were considered to determine the specificity of the F pocket; the F pocket was deemed to determine the specificity for the C-terminal residue of a peptide ligand bound by the HLA class I molecule. Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues required for allele-specific binding to HLA molecules have been identified. The presence of these residues correlates with binding affinity for HLA molecules. The identification of motifs and/or supermotifs that correlate with high and intermediate affinity binding is an important issue with respect to the identification of immunogenic peptide epitopes for the inclusion in a vaccine. Kast et al. (J. Immunol. 152:3904-3912, 1994) have shown that motif-bearing peptides account for 90% of the epitopes that bind to allele-specific HLA class I molecules. In this study all possible peptides of 9 amino acids in length and overlapping by eight amino acids (240 peptides), which cover the entire sequence of the E6 and E7 proteins of human papillomavirus type 16, were evaluated for binding to five allele-specific HLA molecules that are expressed at high frequency among different ethnic groups. This unbiased set of peptides allowed an evaluation of the predictive value of HLA class I motifs. From the set of 240 peptides, 22 peptides were identified that bound to an allele-specific HLA molecule with high or intermediate affinity. Of these 22 peptides, 20 (i.e. 91%) were motif-bearing. Thus, this study demonstrates the value of motifs for the identification of peptide epitopes for inclusion in a vaccine: application of motif-based identification techniques eliminates screening of 90% of the potential epitopes in a target antigen protein sequence. Such peptide epitopes are identified in the Tables described below. Peptides of the present invention may also comprise epitopes that bind to MHC class II DR molecules. A greater degree of heterogeneity in both size and binding frame position of the motif, relative to the N and C termini of the peptide, exists for class II peptide ligands. This increased heterogeneity of HLA class II peptide ligands is due to the structure of the binding groove of the HLA class II molecule which, unlike its class I counterpart, is open at both ends. Crystallographic analysis of HLA class II DRB*0101- peptide complexes showed that the major energy of binding is contributed by peptide residues complexed with complementary pockets on the DRB*0101 molecules. An important anchor residue engages the deepest hydrophobic pocket (see, e.g., Madden, D.R. Ann. Rev. Immunol. 13:587, 1995) and is referred to as position 1 (PI). PI may represent the N-terminal residue of a class II binding peptide epitope, but more typically is flanked towards the N-terminus by one or more residues. Other studies have also pointed to an important role for the peptide residue in the 6 position towards the C- terminus, relative to PI, for binding to various DR molecules. Thus, peptides of the present invention are identified by any one of several HLA- specific amino acid motifs (see, e.g., Tables I-III). If the presence of the motif corresponds to the ability to bind several allele-specific HLA antigens, it is referred to as a supermotif. The HLA molecules that bind to peptides that possess a particular amino acid supermotif are collectively referred to as an HLA "supertype." The peptide motifs and supermotifs described below, and summarized in Tables I- III, provide guidance for the identification and use of peptide epitopes in accordance with the invention. Examples of peptide epitopes bearing a respective supermotif or motif are included in Tables as designated in the description of each motif or supermotif below. The Tables include a binding affinity ratio listing for some of the peptide epitopes. The ratio may be converted to IC 50 by using the following formula: IC 50 of the standard peptide/ratio = IC 5 o of the test peptide (i.e., the peptide epitope). The IC 50 values of standard peptides used to determine binding affinities for Class I peptides are shown in Table IV. The IC 50 values of standard peptides used to determine binding affinities for Class II peptides are shown in Table V. The peptides used as standards for the binding assays described herein are examples of standards; alternative standard peptides can also be used when performing such an analysis. To obtain the peptide epitope sequences listed in each Table, protein sequence data from fourteen HCV isolates were evaluated for the presence of the designated supermotif or motif. The fourteen strains include HPCCGAA, HPCPLYPRE, HCV-H- CMR, HCV-J1, HPCGENANTI, HPCGENOM, HPCHUMR, HPCJCG, HPCJTA, HCV- J483, HCV-JKl , HCV-N, HPCPOLP, and HCV-J8. Peptide epitopes were additionally evaluated on the basis of their conservancy among these fourteen strains. A criterion for conservancy requires that the entire sequence of an HLA class I binding peptide be totally- conserved in 79% of the sequences available for a specific protein. Similarly, a criterion for conservancy requires that the entire 9-mer core region of an HLA class II binding peptide be totally conserved in 79% of the sequences available for a specific protein. The percent conservancy of the selected peptide epitopes is indicated on the Tables. The frequency, i.e. the number of strains of the fourteen strains in which the totally conserved peptide sequence was identified, is also shown. The "position" column in the Tables designates the amino acid position of the HCV polyprotein that corresponds to the first amino acid residue of the epitope. The "number of amino acids" indicates the number of residues in the epitope sequence. HLA Class I Motifs Indicative of CTL Inducing Peptide Epitopes: The primary anchor residues of the HLA class I peptide epitope supermotifs and motifs delineated below are summarized in Table I. The HLA class I motifs set out in Table 1(a) are those most particularly relevant to the invention claimed here. Primary and secondary anchor positions are summarized in Table II. Allele-specific HLA molecules that comprise HLA class I supertype families are listed in Table VI. IV.D.1. HLA-A1 supermotif The HLA-A1 supermotif is characterized by the presence in peptide ligands of a small (T or S) or hydrophobic (L, I, V, or M) primary anchor residue in position 2, and an aromatic (Y, F, or W) primary anchor residue at the C-terminal position of the epitope. The corresponding family of HLA molecules that bind to the Al supermotif (i.e., the HLA-A1 supertype) includes at least A*0101, A*2601, A*2602, A*2501, and A*3201 (see, e.g., DiBrino, M. et al, J. Immunol. 151 :5930, 1993; DiBrino, M. et al, J. Immunol. 152:620, 1994; Kondo, A. et a , Immunogenetics 45:249, 1997). Other allele- specific HLA molecules predicted to be members of the Al superfamily are shown in Table VI. Peptides binding to each of the individual HLA proteins can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif. Peptide epitopes that comprise the Al supermotif are set forth in Table VII. IV.D.2. HLA-A2 supermotif Primary anchor specificities for allele-specific HLA-A2.1 molecules (Falk et al, Nature 351:290-296, 1991; Hunt et al, Science 255:1261-1263, 1992; Parker et al, J. Immunol. 149:3580-3587, 1992) and cross-reactive binding within the HLA A2 family (Fruci et al, Human Immunol. 38:187-192, 1993; Tanigaki et al, Human Immunol. 39:155-162, 1994) have been described. The present inventors have defined additional primary anchor residues that determine cross-reactive binding to multiple allele-specific HLA A2 molecules (Ruppert et al, Cell 74:929-937, 1993; Del Guercio et al, J. Immunol. 154:685-693, 1995; Kast et α/., J. Immunol. 152:3904-3912, 1994). The HLA- A2 supermotif comprises peptide ligands with L, I, V, M, A, T, or Q as a primary anchor residue at position 2 and L, I, V, M, A, or T as a primary anchor residue at the C-terminal position of the epitope. The corresponding family of HLA molecules (i.e., the HLA-A2 supertype that binds these peptides) is comprised of at least: A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*0209, A*0214, A*6802, and A*6901. Other allele- specific HLA molecules predicted to be members of the A2 superfamily are shown in Table VI. As explained in detail below, binding to each of the individual allele-specific HLA molecules can be modulated by substitutions at the primary anchor and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif. Peptide epitopes that comprise an A2 supermotif are set forth inTable VIII. The motifs comprising the primary anchor residues V, A, T, or Q at position 2 and L, I, V, A, or T at the C-terminal position are those most particularly relevant to the invention claimed herein. IV.D.3. HLA-A3 supermotif The HLA- A3 supermotif is characterized by the presence in peptide ligands of A, L, I, V, M, S, or, T as a primary anchor at position 2, and a positively charged residue, R or K, at the C-terminal position of the epitope (e.g., in position 9 of 9-mers). Exemplary members of the corresponding family of HLA molecules (the HLA- A3 supertype) that bind the A3 supermotif include at least A*0301, A*1101, A*3101, A*3301, and A*6801. Other allele-specific HLA molecules predicted to be members of the A3 superfamily are shown in Table VI. As explained in detail below, peptide binding to each of the individual allele-specific HLA proteins can be modulated by substitutions of amino acids at the primary and/or secondary anchor positions of the peptide, preferably choosing respective residues specified for the supermotif. Peptide epitopes that comprise the A3 supermotif are set forth in Table IX. O 01/21189 24 IV.D.4. HLA-A24 supermotif The HLA-A24 supermotif is characterized by the presence in peptide ligands of an aromatic (F, W, or Y) or hydrophobic aliphatic (L, I, V, M, or T) residue as a primary anchor in position 2, and Y, F, W, L, I, or M as primary anchor at the C-terminal position of the epitope. The corresponding family of HLA molecules that bind to the A24 supermotif (i.e., the A24 supertype) includes at least A*2402, A*3001, and A*2301. Other allele-specific HLA molecules predicted to be members of the A24 superfamily are shown in Table VI. Peptide binding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif. Peptide epitopes that comprise the A24 supermotif are set forth in Table X. IV.D.5. HLA-B7 supermotif The HLA-B7 supermotif is characterized by peptides bearing pro line in position 2 as a primary anchor, and a hydrophobic or aliphatic amino acid (L, I, V, M, A, F, W, or Y) as the primary anchor at the C-terminal position of the epitope. The corresponding family of HLA molecules that bind the B7 supermotif (i.e., the HLA-B7 supertype) is comprised of at least twenty six HLA-B proteins including: B*0702, B*0703, B*0704, B*0705, B*1508, B*3501, B*3502, B*3503, B*3504, B*3505, B*3506, B*3507, B*3508, B*5101, B*5102, B*5103, B*5104, B*5105, B*5301, B*5401, B*5501, B*5502, B*5601, B*5602, B*6701, and B*7801 (see, e.g., Sidney, et al, J. Immunol. 154:247, 1995; Barber, et al, Curr. Biol. 5:179, 1995; Hill, et al, Nature 360:434, 1992; Rammensee, et al, Immunogenetics 41 :178, 1995). Other allele-specific HLA molecules predicted to be members of the B7 superfamily are shown in Table VI. As explained in detail below, peptide binding to each of the individual allele-specific HLA proteins can be modulated by substitutions at the primary and/or secondary anchor positions of the peptide, preferably choosing respective residues specified for the supermotif. Peptide epitopes that comprise the B7 supermotif are set forth in Table XI. IV.D.6. HLA-B27 supermotif The HLA-B27 supermotif is characterized by the presence in peptide ligands of a positively charged (R, H, or K) residue as a primary anchor at position 2, and a hydrophobic (F, Y, L, W, M, I, A, or V) residue as a primary anchor at the C-terminal position of the epitope. Exemplary members of the corresponding family of HLA molecules that bind to the B27 supermotif (i.e., the B27 supertype) include at least B*1401, B*1402, B*1509, B*2702, B*2703, B*2704, B*2705, B*2706, B*3801, B*3901, B*3902, and B*7301. Other allele-specific HLA molecules predicted to be members of the B27 superfamily are shown in Table VI. Peptide binding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif. Peptide epitopes that comprise the B27 supermotif are set forth in Table XII. IV.D.7. HLA-B44 supermotif The HLA-B44 supermotif is characterized by the presence in peptide ligands of negatively charged (D or E) residues as a primary anchor in position 2, and hydrophobic residues (F, W, Y, L, I, M, V, or A) as a primary anchor at the C-terminal position of the epitope. Exemplary members of the corresponding family of HLA molecules that bind to the B44 supermotif (i.e., the B44 supertype) include at least: B*1801, B*1802, B*3701, B*4001, B*4002, B*4006, B*4402, B*4403, and B*4006. Peptide binding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions; preferably choosing respective residues specified for the supermotif. IV.D.8. HLA-B58 supermotif The HLA-B58 supermotif is characterized by the presence in peptide ligands of a small aliphatic residue (A, S, or T) as a primary anchor residue at position 2, and an aromatic or hydrophobic residue (F, W, Y, L, I, V, M, or A) as a primary anchor residue at the C-terminal position of the epitope. Exemplary members of the corresponding family of HLA molecules that bind to the B58 supermotif (i.e., the B58 supertype) include at least: B*1516, B*1517, B*5701, B*5702, and B*5801. Other allele-specific HLA molecules predicted to be members of the B58 superfamily are shown in Table VI. Peptide binding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif. Peptide epitopes that comprise the B58 supermotif are set forth in Table XIII. IV.D.9. HLA-B62 supermotif The HLA-B62 supermotif is characterized by the presence in peptide ligands of the polar aliphatic residue Q or a hydrophobic aliphatic residue (L, V, M, I, or P) as a primary anchor in position 2, and a hydrophobic residue (F, W, Y, M, I, V, L, or A) as a primary anchor at the C-terminal position of the epitope. Exemplary members of the corresponding family of HLA molecules that bind to the B62 supermotif (i.e., the B62 supertype) include at least: B*1501, B*1502, B*1513, and B5201. Other allele-specific HLA molecules predicted to be members of the B62 superfamily are shown in Table VI. Peptide binding to each of the allele-specific HLA molecules can be modulated by substitutions at primary and or secondary anchor positions, preferably choosing respective residues specified for the supermotif. Peptide epitopes that comprise the B62 supermotif are set forth in Table XIV. IV.D.10. HLA-A1 motif The HLA-A1 motif is characterized by the presence in peptide ligands of T, S, or M as a primary anchor residue at position 2 and the presence of Y as a primary anchor residue at the C-terminal position of the epitope. An alternative allele-specific Al motif is characterized by a primary anchor residue at position 3 rather than position 2. This motif is characterized by the presence of D, E, A, or S as a primary anchor residue in position 3, and a Y as a primary anchor residue at the C-terminal position of the epitope. Peptide binding to HLA Al can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif. Peptide epitopes that comprise either Al motif are set forth in Table XV. The epitopes comprising T, S, or M at position 2 and Y at the C-terminal position are also included in the listing of HLA- A 1 supermotif-bearing peptide epitopes listed in Table VII. IV.D.ll. HLA-A*0201 motif An HLA-A2*0201 motif was first determined to be characterized by the presence in peptide ligands of L or M as a primary anchor residue in position 2, and L or V as a primary anchor residue at the C-terminal position of a 9-residue peptide (Falk et al, Nature 351:290-296, 1991). The A*0201 motif was also determined to further comprise an I at position 2 and I or A at the C-terminal position of a nine amino acid peptide (Hunt et al, Science 255:1261-1263, March 6, 1992; Parker et al, J. Immunol. 149:3580-3587, 1992). Subsequently, the A*0201 allele-specific motif has been defined by the present inventors to additionally comprise V, A, T, or Q as a primary anchor residue at position 2, and M as a primary anchor residue at the C-terminal position of the epitope. Additionally, the A*0201 allele-specific motif has been found to comprise a T at the C- terminal position (Kast et al., J. Immunol. 152:3904-3912, 1994). Thus, the HLA- A*0201 motif comprises peptide ligands with L, I, V, M, A, T, or Q as primary anchor residues at position 2 and L, I, V, M, A, or T as a primary anchor residue at the C- terminal position of the epitope. The preferred and tolerated residues that characterize the primary anchor positions of the HLA-A*0201 motif are identical to the residues describing the A2 supermotif. (For reviews of relevant data, see, e.g., Del Guercio et al, J. Immunol. 154:685-693, 1995; Ruppert et al, Cell 74:929-937, 1993; Sidney et al, Immunol. Today 17:261-266, 1996; Sette and Sidney, Curr. Opin. in Immunol. 10:478- 482, 1998). Secondary anchor residues that characterize the A*0201 motif have additionally been defined as disclosed herein. These are disclosed in Table II. Peptide binding to HLA-A*0201 molecules can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif. Peptide epitopes that comprise an A*0201 motif are set forth in Table VIII. The A*0201 motifs comprising the primary anchor residues V, A, T, or Q at position 2 and L, I, V, A, or T at the C-terminal position are those most particularly relevant to the invention claimed herein. IV.D.12. HLA-A3 motif The HLA- A3 motif is characterized by the presence in peptide ligands of L, M, V, I, S, A, T, F, C, G, or D as a primary anchor residue at position 2, and the presence of K, Y, R, H, F, or A as a primary anchor residue at the C-terminal position of the epitope. Peptide binding to HLA- A3 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif. The A3 supermotif primary anchor residues comprise a subset of the A3- and Al 1-allele specific motif primary anchor residues. Peptide epitopes that comprise the A3 motif are set forth inTable XVI. Those peptide epitopes that also comprise the A3 supermotif are also listed in Table IX. IV.D.13. HLA-A11 motif The HLA-A11 motif is characterized by the presence in peptide ligands of V, T, M, L, I, S, A, G, N, C, D, or F as a primary anchor residue in position 2, and K, R, Y, or H as a primary anchor residue at the C-terminal position of the epitope. Peptide binding to HLA-A11 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif. Peptide epitopes that comprise the Al 1 motif are set forth in Table XVII; peptide epitopes comprising the A3 allele-specific motif are also present in this Table because of the overlap between the A3 and Al 1 motif primary anchor specificities. Further, those peptide epitopes that comprise the A3 supermotif are also listed in Table IX. IV.D.14. HLA-A24 motif The HLA-A24 motif is characterized by the presence in peptide ligands of Y, F, W, or M as a primary anchor residue in position 2, and F, L, I, or W as a primary anchor residue at the C-terminal position of the epitope. Peptide binding to HLA-A24 molecules can be modulated by substitutions at primary and/or secondary anchor positions; preferably choosing respective residues specified for the motif. Peptide epitopes that comprise the A24 motif are set forth inTable XVIII. These epitopes are also listed in Table X, which sets forth HLA-A24-supermotif-bearing peptide epitopes, as the primary anchor residues characterizing the A24 allele-specific motif comprise a subset of the A24 supermotif primary anchor residues. HLA Class II Binding Motifs The primary and secondary anchor residues of the HLA class II peptide epitope supermotifs and motifs delineated below are summarized in Table III. IV.D.15. HLA DR-1-4-7 supermotif Motifs have also been identified for peptides that bind to three common HLA class II allele-specific HLA molecules: HLA DRB1*0401, DRB1*0101, and DRB 1*0701. Collectively, the common residues from these motifs delineate the HLA DR-1-4-7 supermotif. Peptides that bind to these DR molecules carry a supermotif characterized by a large aromatic or hydrophobic residue (Y, F, W, L, I, V, or M) as a primary anchor residue in position 1, and a small, non-charged residue (S, T, C, A, P, V, I, L, or M) as a primary anchor residue in position 6 of a 9-mer core region. Allele- specific secondary effects and secondary anchors for each of these HLA types have also been identified. These are set forth in Table III. Peptide binding to HLA- DRB 1*0401, DRB1*0101, and/or DRB 1*0701 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the supermotif. Conserved peptide epitopes i.e., conserved in >79% (>11/14) of the HCV strains used for the present analysis, may be described as corresponding to epitopes containing a nine residue core comprising the DR-1-4-7 supermotif, and in which the 9 residue core is conserved in >79% (wherein position 1 of the motif is at position 1 of the nine residue core). Conserved 9-mer core regions are set forth in Table XlXa. Respective exemplary peptide epitopes of 15 amino acid residues in length, each of which comprise a conserved nine residue core, are also shown in section "a" of the Table. Cross-reactive binding data for exemplary 15-residue supermotif-bearing peptides are shown in Table XlXb. IV.D.16. HLA DR3 motifs Two alternative motifs (i.e., submotifs) characterize peptide epitopes that bind to HLA-DR3 molecules. In the first motif (submotif DR3 A) a large, hydrophobic residue (L, I, V, M, F, or Y) is present in anchor position 1 of a 9-mer core, and D is present as an anchor at position 4, towards the carboxyl terminus of the epitope. As in other class II motifs, core position 1 may or may not occupy the peptide N-terminal position. The alternative DR3 submotif provides for lack of the large, hydrophobic residue at anchor position 1, and or lack of the negatively charged or amide-like anchor residue at position 4, by the presence of a positive charge at position 6 towards the carboxyl terminus of the epitope. Thus, for the alternative allele-specific DR3 motif (submotif DR3B): L, I, V, M, F, Y, A, or Y is present at anchor position 1 ; D, N, Q, E, S, or T is present at anchor position 4; and K, R, or H is present at anchor position 6. Peptide binding to HLA-DR3 can be modulated by substitutions at primary and/or secondary anchor positions, preferably choosing respective residues specified for the motif. Conserved 9-mer core regions (i.e., those sequences that are conserved in at least 79% of the 14 HCV strains used for the analysis) corresponding to a nine residue sequence comprising the DR3A submotif (wherein position 1 of the motif is at position 1 of the nine residue core) are set forth in Table XXa. Respective exemplary peptide epitopes of 15 amino acid residues in length, each of which comprise a conserved nine residue core, are also shown in Table XXa. Table XXb shows binding data of exemplary DR3 submotif A-bearing peptides. Conserved 9-mer core regions (i.e., those that are at least 79% conserved in the 14 HCV strains used for the analysis) comprising the DR3B submotif and respective exemplary 15-mer peptides comprising the DR3 submotif-B epitope are set forth in Table XXc. Table XXd shows binding data of exemplary DR3 submotif B -bearing peptides. Each of the HLA class I or class II peptide epitopes set out in the Tables herein are deemed singly to be an inventive aspect of this application. Further, it is also an inventive aspect of this application that each peptide epitope may be used in combination with any other peptide epitope. IV.E. Enhancing Population Coverage of the Vaccine Vaccines that have broad population coverage are preferred because they are more commercially viable and generally applicable to the most people. Broad population coverage can be obtained using the peptides of the invention (and nucleic acid compositions that encode such peptides) through selecting peptide epitopes that bind to HLA alleles which, when considered in total, are present in most of the population. Table XXI lists the overall frequencies of the HLA class I supertypes in various ethnicities (Table XXIa) and the combined population coverage achieved by the A2-, A3-, and B7- supertypes (Table XXIb). The A2-, A3-, and B7 supertypes are each present on the average of over 40% in each of these five major ethnic groups. Coverage in excess of 80% is achieved with a combination of these supermotifs. These results suggest that effective and non-ethnically biased population coverage is achieved upon use of a limited number of cross-reactive peptides. Although the population coverage reached with these three main peptide specificities is high, coverage can be expanded to reach 95% population coverage and above, and more easily achieve truly multispecific responses upon use of additional supermotif or allele-specific motif bearing peptides. The B44-, A1-, and A24-supertypes are present, on average, in a range from 25% to 40% in these major ethnic populations (Table XXIa). While less prevalent overall, the B27-, B58-, and B62 supertypes are each present with a frequency >25% in at least one major ethnic group (Table XXIa). Table XXIb summarizes the estimated prevalence of combinations of HLA supertypes that have been identified in five major ethnic groups. The incremental coverage obtained by the inclusion of Al,- A24-, and B44-suρertypes to the A2, A3, and B7 coverage, or all of the supertypes described herein, is shown. The data presented herein, together with the previous definition of the A2-, A3-, and B7-supertypes, indicates that all antigens, with the possible exception of A29, B8, and B46, can be classified into a total of nine HLA supertypes. By including epitopes from the six most frequent supertypes, an average population coverage of 99% is obtained for five major ethnic groups.. IV.F. Immune Response-Stimulating Peptide Analogs In general, CTL and HTL responses are not directed against all possible epitopes. Rather, they are restricted to a few "immunodominant" determinants (Zinkernagel, et al, Adv. Immunol 27:5159, 1979; Bennink, et al, J. Exp. Med. 168:19351939, 1988; Rawle, et al, J. Immunol. 146:3977-3984, 1991). It has been recognized that immunodominance (Benacerraf, et al, Science 175:273-279, 1972) could be explained by either the ability of a given epitope to selectively bind a particular HLA protein (determinant selection theory) (Vitiello, et al., J. Immunol. 131:1635, 1983); Rosenthal, et al, Nature 267:156- 158, 1977), or to be selectively recognized by the existing TCR (T cell receptor) specificities (repertoire theory) (Klein, J., IMMUNOLOGY, THE SCIENCE OF SELFNONSELF DISCRIMINATION, John Wiley & Sons, New York, pp. 270-310, 1982). It has been demonstrated that additional factors, mostly linked to processing events, can also play a key role in dictating, beyond strict immunogenicity, which of the many potential determinants will be presented as immunodominant (Sercarz, et al, Annu. Rev. Immunol. 11:729-766, 1993). The concept of dominance and subdominance is relevant to immunotherapy of both infectious diseases and cancer. For example, in the course of chronic viral disease, recruitment of subdominant epitopes can be important for successful clearance of the infection, especially if dominant CTL or HTL specificities have been inactivated by functional tolerance, suppression, mutation of viruses and other mechanisms (Franco, et al, Curr. Opin. Immunol. 7:524-531, 1995). In the case of cancer and tumor antigens, CTLs recognizing at least some of the highest binding affinity peptides might be functionally inactivated. Lower binding affinity peptides are preferentially recognized at these times, and may therefore be preferred in therapeutic or prophylactic anti-cancer vaccines. In particular, it has been noted that a significant number of epitopes derived from known non-viral tumor associated antigens (TAA) bind HLA class I with intermediate affinity (IC 50 in the 50-500 nM range). For example, it has been found that 8 of 15 known TAA peptides recognized by tumor infiltrating lymphocytes (TIL) or CTL bound in the 50-500 nM range. (These data are in contrast with estimates that 90% of known viral antigens were bound by HLA class I molecules with IC 50 of 50 nM or less, while only approximately 10% bound in the 50-500 nM range (Sette, et al, J. Immunol, 153:558-5592, 1994). In the cancer setting this phenomenon is probably due to elimination or functional inhibition of the CTL recognizing several of the highest binding peptides, presumably because of T cell tolerization events. Without intending to be bound by theory, it is believed that because T cells to dominant epitopes may have been clonally deleted, selecting subdominant epitopes may allow existing T cells to be recruited, which will then lead to a therapeutic or prophylactic response. However, the binding of HLA molecules to subdominant epitopes is often less vigorous than to dominant ones. Accordingly, there is a need to be able to modulate the binding affinity of particular immunogenic epitopes for one or more HLA molecules, and thereby to modulate the immune response elicited by the peptide, for example to prepare analog peptides which elicit a more vigorous response. This ability would greatly enhance the usefulness of peptide-based vaccines and therapeutic agents. Although peptides with suitable cross-reactivity among all alleles of a superfamily are identified by the screening procedures described above, cross-reactivity is not always as complete as possible, and in certain cases procedures to increase cross-reactivity of peptides can be useful; moreover, such procedures can also be used to modify other properties of the peptides such as binding affinity or peptide stability. Having established the general rules that govern cross-reactivity of peptides for HLA alleles within a given motif or supermotif, modification (i.e., analoging) of the structure of peptides of particular interest in order to achieve broader (or otherwise modified) HLA binding capacity can be performed. More specifically, peptides which exhibit the broadest cross- reactivity patterns, can be produced in accordance with the teachings herein. The present concepts related to analog generation are set forth in greater detail in co-pending U.S.S.N. 09/226,775 filed 1/6/99. In brief, the strategy employed utilizes the motifs or supermotifs which correlate with binding to certain HLA molecules. The motifs or supermotifs are defined by having primary anchors, and in many cases secondary anchors. Analog peptides can be created by substituting amino acid residues at primary anchor, secondary anchor, or at primary and secondary anchor positions. Generally, analogs are made for peptides that already bear a motif or supermotif. Preferred secondary anchor residues of supermotifs and motifs that have been defined for HLA class I and class II binding peptides are shown in Tables II and III, respectively. For a number of the motifs or supermotifs in accordance with the invention, residues are defined which are deleterious to binding to allele-specific HLA molecules or members of HLA supertypes that bind the respective motif or supermotif (Tables II and III). Accordingly, removal of such residues that are detrimental to binding can be performed in accordance with the present invention. For example, in the case of the A3 supertype, when all peptides that have such deleterious residues are removed from the population of analyzed peptides, the incidence of cross-reactivity increases from 22% to 37% (see, e.g., Sidney, J. et al, Hu. Immunol. 45:79, 1996). Thus, one strategy to improve the cross-reactivity of peptides within a given supermotif is simply to delete one or more of the deleterious residues present within a peptide and substitute a small "neutral" residue such as Ala (that may not influence T cell recognition of the peptide). An enhanced likelihood of cross-reactivity is expected if, together with elimination of detrimental residues within a peptide, "preferred" residues associated with high affinity binding to an allele-specific HLA molecule or to multiple HLA molecules within a superfamily are inserted. To ensure that an analog peptide, when used as a vaccine, actually elicits a CTL response to the native epitope in vivo (or, in the case of class II epitopes, elicits helper T cells that cross-react with the wild type peptides), the analog peptide may be used to immunize T cells in vitro from individuals of the appropriate HLA allele. Thereafter, the immunized cells' capacity to induce lysis of wild type peptide sensitized target cells is evaluated. It will be desirable to use as antigen presenting cells, cells that have been either infected, or transfected with the appropriate genes, or, in the case of class II epitopes only, cells that have been pulsed with whole protein antigens, to establish whether endogenously produced antigen is also recognized by the relevant T cells. Another embodiment of the invention is to create analogs of weak binding peptides, to thereby ensure adequate numbers of cross-reactive cellular binders. Class I binding peptides exhibiting binding affinities of 500-5000 nM, and carrying an acceptable but suboptimal primary anchor residue at one or both positions can be "fixed" by substituting preferred anchor residues in accordance with the respective supertype. The analog peptides can then be tested for crossbinding activity. Another embodiment for generating effective peptide analogs involves the substitution of residues that have an adverse impact on peptide stability or solubility in, e.g., a liquid environment. This substitution may occur at any position of the peptide epitope. For example, a cysteine (C) can be substituted out in favor of α-amino butyric acid. Due to its chemical nature, cysteine has the propensity to form disulfide bridges and sufficiently alter the peptide structurally so as to reduce binding capacity. Substituting α- amino butyric acid for C not only alleviates this problem, but actually improves binding and crossbinding capability in certain instances (see, e.g., the review by Sette et al, In: Persistent Viral Infections. Eds. R. Ahmed and I. Chen, John Wiley & Sons, England, 1999). Substitution of cysteine with α-amino butyric acid may occur at any residue of a peptide epitope, i.e. at either anchor or non-anchor positions. Representative analog peptides are set forth in Table XXII. The Table indicates the length and sequence of the analog peptide as well as the motif or supermotif, if appropriate. The information in the "Fixed Nomenclature" column indicates the residues substituted at the indicated position numbers for the respective analog. IV.G. Computer Screening of Protein Sequences from Disease-Related Antigens for Supermotif- or Motif-Bearing Peptides In order to identify supermotif- or motif-bearing epitopes in a target antigen, a native protein sequence, e.g. , a tumor-associated antigen, or sequences from an infectious organism, or a donor tissue for transplantation, is screened using a means for computing, such as an intellectual calculation or a computer, to determine the presence of a supermotif or motif within the sequence. The information obtained from the analysis of native peptide can be used directly to evaluate the status of the native peptide or may be utilized subsequently to generate the peptide epitope. Computer programs that allow the rapid screening of protein sequences for the occurrence of the subject supermotifs or motifs are encompassed by the present invention; as are programs that permit the generation of analog peptides. These programs are implemented to analyze any identified amino acid sequence or operate on an unknown sequence and simultaneously determine the sequence and identify motif-bearing epitopes thereof; analogs can be simultaneously determined as well. Generally, the identified sequences will be from a pathogenic organism or a tumor-associated peptide. For example, the target molecules considered herein include, without limitation, the core, S, El, NS1/E2, NS2, NS3, NS4, and NS5 regions of HCV. In cases where the sequence of multiple variants of the same target protein are available, peptides may also be selected on the basis of their conservancy. A presently preferred criterion for conservancy defines that the entire sequence of an HLA class I binding peptide or the entire 9-mer core of a class II binding peptide, be totally (i.e., 100%) conserved in at least 79% of the sequences evaluated for a specific protein. This definition of conservancy has been employed herein; although, as appreciated by those in the art, lower or higher degrees of conservancy can be employed as appropriate for a given antigenic target. It is important that the selection criteria utilized for prediction of peptide binding are as accurate as possible, to correlate most efficiently with actual binding. Prediction of peptides that bind, for example, to HLA-A*0201, on the basis of the presence of the appropriate primary anchors, is positive at about a 30% rate (see, e.g., Ruppert, J. et al. Cell 74:929, 1993). However, by extensively analyzing peptide-HLA binding data disclosed herein, data in related patent applications, and data in the art, the present inventors have developed a number of allele-specific polynomial algorithms that dramatically increase the predictive value over identification on the basis of the presence of primary anchor residues alone. These algorithms take into account not only the presence or absence of primary anchors, but also consider the positive or deleterious presence of secondary anchor residues (to account for the impact of different amino acids at different positions). The algorithms are essentially based on the premise that the overall affinity (or ΔG) of peptide-HLA interactions can be approximated as a linear polynomial function of the type: ΔG = ai,- x a 2( x a 3l ...x a - where a y/ is a coefficient that represents the effect of the presence of a given amino acid (j) at a given position ( ) along the sequence of a peptide of n amino acids. An important assumption of this method is that the effects at each position are essentially independent of each other. This assumption is justified by studies that demonstrated that peptides are bound to HLA molecules and recognized by T cells in essentially an extended conformation. Derivation of specific algorithm coefficients has been described, for example, in Gulukota, K. et α/., J. Mol. Biol. 267:1258, 1997. Additional methods to identify preferred peptide sequences, which also make use of specific motifs, include the use of neural networks and molecular modeling programs (see, e.g., Milik et al, Nature Biotechnology 16:753, 1998; Altuvia et al, Hum. Immunol. 58:1, 1997; Altuvia et al, J. Mol Biol. 249:244, 1995; Buus, S. Curr. Opin. Immunol. 11 :209-213, 1999; Brusic, V. et al, Bioinformatics 14:121-130, 1998; Parker et al, J. Immunol. 152:163, 1993; Meister et al, Vaccine 13:581, 1995; Hammer et al, J. Exp. Med. 180:2353, 1994; Stumiolo et al, Nature Biotechnol 17:555 1999). For example, it has been shown that in sets of A*0201 motif-bearing peptides containing at least one preferred secondary anchor residue while avoiding the presence of any deleterious secondary anchor residues, 69% of the peptides will bind A*0201 with an IC 50 less than 500 nM (Ruppert, J. et al. Cell 74:929, 1993). These algorithms are also flexible in that cut-off scores may be adjusted to select sets of peptides with greater or lower predicted binding properties, as desired. In utilizing computer screening to identify peptide epitopes, a protein sequence or translated sequence may be analyzed using software developed to search for motifs, for example the "FINDPATTERNS' program (Devereux, et al. Nucl Acids Res. 12:387-395, 1984) or MotifSearch 1.4 software program (D. Brown, San Diego, CA) to identify potential peptide sequences containing appropriate HLA binding motifs. The identified peptides can be scored using customized polynomial algorithms to predict their capacity to bind specific HLA class I or class II alleles. As appreciated by one of ordinary skill in the art, a large array of computer programming software and hardware options are available in the relevant art which can be employed to implement the motifs of the invention in order to evaluate (e.g., without limitation, to identify epitopes, identify epitope concentration per peptide length, or to generate analogs) known or unknown peptide sequences. In accordance with the procedures described above, HCV peptide epitopes and analogs thereof that are able to bind HLA supertype groups or allele-specific HLA molecules have been identified (Tables VII-XX; Table XXII). IV.H. Preparation of Peptide Epitopes Peptides in accordance with the invention can be prepared synthetically, by recombinant DNA technology or chemical synthesis, or from natural sources such as native tumors or pathogenic organisms. Peptide epitopes may be synthesized individually or as polyepitopic peptides. Although the peptide will preferably be substantially free of other naturally occurring host cell proteins and fragments thereof, in some embodiments the peptides may be synthetically conjugated to native fragments or particles. The peptides in accordance with the invention can be a variety of lengths, and either in their neutral (uncharged) forms or in forms which are salts. The peptides in accordance with the invention are either free of modifications such as glycosylation, side chain oxidation, or phosphorylation; or they contain these modifications, subject to the condition that modifications do not destroy the biological activity of the peptides as described herein. The peptides of the invention can be prepared in a wide variety of ways. For the preferred relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. (See, for example, Stewart & Young, SOLID PHASE PEPTIDE SYNTHESIS, 2D. ED., Pierce Chemical Co., 1984). Further, individual peptide epitopes can be joined using chemical ligation to produce larger peptides that are still within the bounds of the invention. Alternatively, recombinant DNA technology can be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the art, as described generally in Sambrook et al, MOLECULAR CLONING, A LABORATORY MANUAL, Cold Spring Harbor Press, Cold Spring Harbor, New York (1989). Thus, recombinant polypeptides which comprise one or more peptide sequences of the invention can be used to present the appropriate T cell epitope. The nucleotide coding sequence for peptide epitopes of the preferred lengths contemplated herein can be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci, et al, J. Am. Chem. Soc. 103:3185 (1981). Peptide analogs can be made simply by substituting the appropriate and desired nucleic acid base(s) for those that encode the native peptide sequence; exemplary nucleic acid substitutions are those that encode an amino acid defined by the motifs/supermotifs herein. The coding sequence can then be provided with appropriate linkers and ligated into expression vectors commonly available in the art, and the vectors used to transform suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are now available. For expression of the fusion proteins, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression in the desired cellular host. For example, promoter sequences compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence. The resulting expression vectors are transformed into suitable bacterial hosts. Of course, yeast, insect or mammalian cell hosts may also be used, employing suitable vectors and control sequences. It is often preferable that the peptide epitope be as small as possible while still maintaining substantially all of the immunologic activity of the native protein. When possible, it may be desirable to optimize HLA class I binding peptide epitopes of the invention to a length of about 8 to about 13 amino acid residues, preferably 9 to 10. HLA class II binding peptide epitopes may be optimized to a length of about 6 to about 30 amino acids in length, preferably to between about 13 and about 20 residues. Preferably, the peptide epitopes are commensurate in size with endogenously processed pathogen- derived peptides or tumor cell peptides that are bound to the relevant HLA molecules, however, the identification and preparation of peptides of other lengths can also be carried out using the techniques described herein. In alternative embodiments, peptides of the invention can be linked as a polyepitopic peptide, or as a minigene that encodes a polyepitopic peptide. In another embodiment, it is preferred to identify native peptide regions that contain a high concentration of class I and/or class II epitopes. Such a sequence is generally selected on the basis that it contains the greatest number of epitopes per amino acid length. It is to be appreciated that epitopes can be present in a frame-shifted manner, e.g. a 10 amino acid long peptide could contain two 9 amino acid long epitopes and one 10 amino acid long epitope; upon intracellular processing, each epitope can be exposed and bound by an HLA molecule upon administration of such a peptide. This larger, preferably multi-epitopic, peptide can be generated synthetically, recombinantly, or via cleavage from the native source. IV.I. Assays to Detect T-Cell Responses Once HLA binding peptides are identified, they can be tested for the ability to elicit a T-cell response. The preparation and evaluation of motif-bearing peptides are described in PCT publications WO 94/20127 and WO 94/03205. Briefly, peptides comprising epitopes from a particular antigen are synthesized and tested for their ability to bind to the appropriate HLA proteins. These assays may involve evaluating the binding of a peptide of the invention to purified HLA class I molecules in relation to the binding of a radioiodinated reference peptide. Alternatively, cells expressing empty class I molecules (i.e. lacking peptide therein) may be evaluated for peptide binding by immunofluorescent staining and flow microfluorimetry. Other assays that may be used to evaluate peptide binding include peptide-dependent class I assembly assays and/or the inhibition of CTL recognition by peptide competition. Those peptides that bind to the class I molecule, typically with an affinity of 500 nM or less, are further evaluated for their ability to serve as targets for CTLs derived from infected or immunized individuals, as well as for their capacity to induce primary in vitro or in vivo CTL responses that can give rise to CTL populations capable of reacting with selected target cells associated with a disease. Corresponding assays are used for evaluation of HLA class II binding peptides. HLA class II motif-bearing peptides that are shown to bind, typically at an affinity of 1000 nM or less, are further evaluated for the ability to stimulate HTL responses. Conventional assays utilized to detect T cell responses include proliferation assays, lymphokine secretion assays, direct cytotoxicity assays, and limiting dilution assays. For example, antigen-presenting cells that have been incubated with a peptide can be assayed for the ability to induce CTL responses in responder cell populations. Antigen-presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells. Alternatively, mutant non-human mammalian cell lines that are deficient in their ability to load class I molecules with internally processed peptides and that have been transfected with the appropriate human class I gene, may be used to test for the capacity of the peptide to induce in vitro primary CTL responses. Peripheral blood mononuclear cells (PBMCs) may be used as the responder cell source of CTL precursors. The appropriate antigen-presenting cells are incubated with peptide, after which the peptide-loaded antigen-presenting cells are then incubated with the responder cell population under optimized culture conditions. Positive CTL activation can be determined by assaying the culture for the presence of CTLs that kill radio-labeled target cells, both specific peptide-pulsed targets as well as target cells expressing endogenously processed forms of the antigen from which the peptide sequence was derived. More recently, a method has been devised which allows direct quantification of antigen-specific T cells by staining with Fluorescein-labelled HLA tetrameric complexes (Airman, J. D. et al, Proc. Natl. Acad. Sci. USA 90:10330, 1993; Altaian, J. D. et al, Science 274:94, 1996). Other relatively recent technical developments include staining for intracellular lymphokines, and interferon release assays or ELISPOT assays. Tetramer staining, intracellular lymphokine staining and ELISPOT assays all appear to be at least 10-fold more sensitive than more conventional assays (Lalvani, A. et al, J. Exp. Med. 186:859, 1997; Dunbar, P. R. et al, Curr. Biol 8:413, 1998; Murali-Krishna, K. et al, Immunity 8:177, 1998). HTL activation may also be assessed using such techniques known to those in the art such as T cell proliferation and secretion of lymphokines, e.g. IL-2 (see, e.g. Alexander et al, Immunity 1:751-761, 1994). Alternatively, immunization of HLA transgenic mice can be used to determine immunogenicity of peptide epitopes. Several transgenic mouse models including mice with human A2.1, Al 1 (which can additionally be used to analyze HLA- A3 epitopes), and B7 alleles have been characterized and others (e.g., transgenic mice for HLA-A1 and A24) are being developed. HLA-DR1 and HLA-DR3 mouse models have also been developed. Additional transgenic mouse models with other HLA alleles may be generated as necessary. Mice may be immunized with peptides emulsified in Incomplete Freund's Adjuvant and the resulting T cells tested for their capacity to recognize peptide- pulsed target cells and target cells transfected with appropriate genes. CTL responses may be analyzed using cytotoxicity assays described above. Similarly, HTL responses may be analyzed using such assays as T cell proliferation or secretion of lymphokines. Exemplary immunogenic peptide epitopes are set out in Table XXIII. IV. J. Use of Peptide Epitopes as Diagnostic Agents and for Evaluating Immune Responses In one embodiment of the invention, HLA class I and class II binding peptides as described herein can be used as reagents to evaluate an immune response. The immune response to be evaluated can be induced by using as an immunogen any agent that may result in the production of antigen-specific CTLs or HTLs that recognize and bind to the peptide epitope(s) to be employed as the reagent. The peptide reagent need not be used as the immunogen. Assay systems that can be used for such an analysis include relatively recent technical developments such as tetramers, staining for intracellular lymphokines and interferon release assays, or ELISPOT assays. For example, a peptide of the invention may be used in a tetramer staining assay to assess peripheral blood mononuclear cells for the presence of antigen-specific CTLs following exposure to a tumor cell antigen or an immunogen. The HLA-tetrameric complex is used to directly visualize antigen-specific CTLs (see, e.g., Ogg et al, Science 279:2103-2106, 1998; and Altaian et al, Science 174:94-96, 1996) and determine the frequency of the antigen-specific CTL population in a sample of peripheral blood mononuclear cells. A tetramer reagent using a peptide of the invention may be generated as follows: A peptide that binds to an HLA molecule is refolded in the presence of the corresponding HLA heavy chain and β 2 -microglobulin to generate a trimolecular complex. The complex is biotinylated at the carboxyl terminal end of the heavy chain at a site that was previously engineered into the protein. Tetramer formation is then induced by the addition of streptavidin. By means of fluorescently labeled streptavidin, the tetramer can be used to stain antigen-specific cells. The cells may then be identified, for example, by flow cytometry. Such an analysis may be used for diagnostic or prognostic purposes. Cells identified by the procedure can also be used for therapeutic purposes. Peptides of the invention may also be used as reagents to evaluate immune recall responses, (see, e.g., Bertoni et al, J. Clin. Invest. 100:503-513, 1997 and Penna et al, J. Exp. Med. 174:1565-1570, 1991.) For example, patient PBMC samples from individuals with HCV infection may be analyzed for the presence of antigen-specific CTLs or HTLs using specific peptides. A blood sample containing mononuclear cells may be evaluated by cultivating the PBMCs and stimulating the cells with a peptide of the invention. After an appropriate cultivation period, the expanded cell population may be analyzed, for example, for cytotoxic activity (CTL) or for HTL activity. The peptides may also be used as reagents to evaluate the efficacy of a vaccine. PBMCs obtained from a patient vaccinated with an immunogen may be analyzed using, for example, either of the methods described above. The patient is HLA typed, and peptide epitope reagents that recognize the allele-specific molecules present in that patient are selected for the analysis. The immunogenicity of the vaccine is indicated by the presence of epitope-specific CTLs and/or HTLs in the PBMC sample. The peptides of the invention may also be used to make antibodies, using techniques well known in the art (see, e.g. CURRENT PROTOCOLS IN IMMUNOLOGY, Wiley/Greene, NY; and Antibodies A Laboratory Manual, Harlow and Lane, Cold Spring Harbor Laboratory Press, 1989), which may be useful as reagents to diagnose or monitor cancer. Such antibodies include those that recognize a peptide in the context of an HLA molecule, i.e., antibodies that bind to a peptide-MHC complex. IV.K. Vaccine Compositions Vaccines and methods of preparing vaccines that contain an immunogenically effective amount of one or more peptides as described herein are further embodiments of the invention. Once appropriately immunogenic epitopes have been defined, they can be sorted and delivered by various means, herein referred to as "vaccine" compositions. Such vaccine compositions can include, for example, lipopeptides (e.g.,Vitiello, A. et al, J. Clin. Invest. 95:341, 1995), peptide compositions encapsulated in poly(DL-lactide-co- glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al, Molec. Immunol 28:287-294, 1991: Alonso et al, Vaccine 12:299-306, 1994; Jones et al, Vaccine 13:675-681, 1995), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al, Nature 344:873-875, 1990; Hu et al, Clin Exp Immunol. 113:235-243, 1998), multiple antigen peptide systems (MAPs) (see e.g., Tarn, J. P., Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413, 1988; Tarn, J.P., J Immunol. Methods 196:17-32, 1996), viral delivery vectors (Perkus, M. E. et al, In: Concepts in vaccine development, Kaufmann, S. H. E., ed., p. 379, 1996; Chakrabarti, S. et al, Nature 320:535, 1986; Hu, S. L. et al, Nature 320:537, 1986; Kieny, M.-P. et al, AIDS Bio/Technology 4:790, 1986; Top, F. H. et al, J. Infect. Dis. 124:148, 1971; Chanda, P. K. et al, Virology 175:535, 1990), particles of viral or synthetic origin (e.g., Kofler, N. et al, J. Immunol. Methods. 192:25, 1996; Eldridge, . H. et al, Sem. Hematol 30:16, 1993; Falo, L. D., Jr. et al, Nature Med. 7:649, 1995), adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A. Annu. Rev. Immunol. 4:369, 1986; Gupta, R. K. et al, Vaccine 11:293, 1993), liposomes (Reddy, R. et al, J. Immunol 148:1585, 1992; Rock, K. L., Immunol. Today 17:131, 1996), or, naked or particle absorbed cDNA (Ulmer, J. B. et al, Science 259:1745, 1993; Robinson, H. L., Hunt, L. A., and Webster, R. G., Vaccine 11:957, 1993; Shiver, J. W. et al, In: Concepts in vaccine development, Kaufmann, S. H. E., ed., p. 423, 1996; Cease, K. B., and Berzofsky, J. A., Annu. Rev. Immunol. 12:923, 1994 and Eldridge, J. H. et al, Sem. Hematol. 30:16, 1993). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used. Vaccines of the invention include nucleic acid-mediated modalities. DNA or RNA encoding one or more of the peptides of the invention can also be administered to a patient. This approach is described, for instance, in Wolff et. al, Science 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide- mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687). For therapeutic or prophylactic immunization purposes, the peptides of the invention can also be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. As an example of this approach, vaccinea virus is used as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into a host bearing a tumor, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits a host CTL and/or HTL response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al, Nature 351:456- 460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g. adeno and adeno-associated virus vectors, retro viral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein. Furthermore, vaccines in accordance with the invention encompass compositions of one or more of the claimed peptide(s). A peptide can be present in a vaccine individually. Alternatively, the peptide can can exist as a homopolymer comprising multiple copies of the same peptide, or as a heteropolymer of various peptides. Polymers have the advantage of increased immuno logical reaction and, where different peptide epitopes are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different anti genie determinants of the pathogenic organism or tumor-related peptide targeted for an immune response. The composition can be a naturally occurring region of an antigen or can be prepared, e.g. , recombinantly or by chemical synthesis. Carriers that can be used with vaccines of the invention are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L-lysine, poly L-glutamic acid, influenza, hepatitis B virus core protein, and the like. The vaccines can contain a physiologically tolerable (i.e., acceptable) diluent such as water, or saline, preferably phosphate buffered saline. The vaccines also typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are examples of materials well known in the art. Additionally, as disclosed herein, CTL responses can be primed by O 01/21189 44 conjugating peptides of the invention to lipids, such as tripalmitoyl-S- glycerylcysteinlyseryl- serine (P 3 CSS). Upon immunization with a peptide composition in accordance with the invention, via injection, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal, or other suitable routes, the immune system of the host responds to the vaccine by producing large amounts of CTLs and/or HTLs specific for the desired antigen. Consequently, the host becomes at least partially immune to later infection, or at least partially resistant to developing an ongoing chronic infection, or derives at least some therapeutic benefit when the antigen was tumor-associated. In some embodiments it may be desirable to combine the class I peptide components with components that induce or facilitate neutralizing antibody responses to the target antigen of interest, particularly to viral envelope antigens. A preferred embodiment of such a composition comprises class I and class II epitopes in accordance with the invention. An alternative embodiment of such a composition comprises a class I and/or class II epitope in accordance with the invention, along with a PADRE™ (Epimmune, San Diego, CA) molecule (described, for example, in U.S. Patent Number 5,736,142). A vaccine of the invention can also include antigen-presenting cells, such as dendritic cells, as a vehicle to present peptides of the invention. Vaccine compositions can be created in vitro, following dendritic cell mobilization and harvesting, whereby loading of dendritic cells occurs in vitro. For example, dendritic cells are transfected, e.g., with a minigene in accordance with the invention. The dendritic cell can then be administered to a patient to elicit immune responses in vivo. Antigenic peptides are used to elicit a CTL and/or HTL response ex vivo, as well. The resulting CTL or HTL cells, can be used to treat tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a therapeutic vaccine peptide or nucleic acid in accordance with the invention. Ex vivo CTL or HTL responses to a particular tumor-associated antigen are induced by incubating in tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presenting cells (APC), such as dendritic cells, and the appropriate immunogenic peptide. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction O 01/21189 45 (HTL) of their specific target cell (an infected cell or a tumor cell). Transfected dendritic cells may also be used as antigen presenting cells. The vaccine compositions of the invention can also be used in combination with antiviral drugs such as interferon-α, or other treatments for viral infection. Preferably, the following principles are utilized when selecting an array of epitopes for inclusion in a polyepitopic composition for use in a vaccine, or for selecting discrete epitopes to be included in a vaccine and/or to be encoded by nucleic acids such as a minigene. It is preferred that each of the following principles are balanced in order to make the selection. The multiple epitopes to be incorporated in a given vaccine composition may be, but need not be, contiguous in sequence in the native antigen from which the epitopes are derived. Preferably, the following principles are utilized when selecting an array of epitopes for inclusion in a polyepitopic composition for use in a vaccine, or for selecting discrete epitopes to be included in a vaccine and/or to be encoded by nucleic acids such as a minigene. Exemplary epitopes that may be utilized in a vaccine to treat or prevent HCV infection are set out in Tables XXVI-XXIX, and Table XXXII. It is preferred that each of the following principles are balanced in order to make the selection. 1.) Epitopes are selected which, upon administration, mimic immune responses that have been observed to be correlated with HCV clearance. For HLA Class I this includes 3-4 epitopes that come from at least one antigen of HCV. For HLA Class II a similar rationale is employed; again 3-4 epitopes are selected from at least one HCV antigen (see e.g., Rosenberg et al, Science 278:1447-1450). 2.) Epitopes are selected that have the requisite binding affinity established to be correlated with immunogenicity: for HLA Class I an IC 50 of 500 nM or less, or for Class II an IC 50 of 1000 nM or less. 3.) Sufficient supermotif bearing-peptides, or a sufficient array of allele- specific motif-bearing peptides, are selected to give broad population coverage. For example, it is preferable to have at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess the breadth, or redundancy of, population coverage. 4.) When selecting epitopes from cancer-related antigens it is often preferred to select analogs because the patient may have developed tolerance to the native epitope. When selecting epitopes for infectious disease-related antigens it is preferable to select either native or analoged epitopes. 5.) Of particular relevance are epitopes referred to as "nested epitopes." Nested epitopes occur where at least two epitopes overlap in a given peptide sequence. A nested peptide sequence can comprise both HLA class I and HLA class II epitopes. When providing nested epitopes, it is preferable to provide a sequence that has the greatest number of epitopes per provided sequence. Preferably, one avoids providing a peptide that is any longer than the amino terminus of the amino terminal epitope and the carboxyl terminus of the carboxyl terminal epitope in the peptide. When providing a longer peptide sequence, such as a sequence comprising nested epitopes, it is important to screen the sequence in order to insure that it does not have pathological or other deleterious biological properties. 6.) If a polyepitopic protein is created, or when creating a minigene, an objective is to generate the smallest peptide that encompasses the epitopes of interest. This principle is similar, if not the same as that employed when selecting a peptide comprising nested epitopes. However, with an artificial polyepitopic peptide, the size minimization objective is balanced against the need to integrate any spacer sequences between epitopes in the polyepitopic protein. Spacer amino acid residues can be introduced to avoid junctional epitopes (an epitope recognized by the immune system, not present in the target antigen, and only created by the man-made juxtaposition of epitopes), or to facilitate cleavage between epitopes and thereby enhance epitope presentation. Junctional epitopes are generally to be avoided because the recipient may generate an immune response to that non-native epitope. Of particular concern is a junctional epitope that is a "dominant epitope." A dominant epitope may lead to such a zealous response that immune responses to other epitopes are diminished or suppressed. Examples of polyepitopic vaccine compositions designed based on the above criteria can include epitopes from the core, S, El, NS1/E2, NS2, NS3, NS4, and NS5 domains of the HCV polyprotein. These regions encompass the following amino acid sequences using numbering relative to the prototype HCV-1 strain (Genbank accession number M62321; see, e.g., US Patent Nos. 5,683,864 and 5,670,153): C domain (amino acids 1-120); S (amino acids 120-400); NS3 (amino acids 1050-1640); NS4 (amino acids 1640-2000); NS5 (amino acids 2000-3011); and envelop proteins, El and E2/NS1, encompassing amino acids 192-750. Amino acids 750 to 1050 are designated as domain X as applied to the present invention. As appreciated by one of ordinary skill in the art, the designation of the amino acid range for each domain may diverge to some extent from that of HCV-1 depending on the strain of HCV. One of ordinary skill in the art, when looking at an HCV polyprotein sequence, would readily be able to determine the domain boundaries. Specific embodiments of the polyepitopic compositions of the present invention include a pharmaceutical composition comprising a pharmaceutically acceptable carrier and combination of motif-bearing peptides that are immunologically cross-reactive with peptides of HCV-1, wherein at least one of the peptides bears a motif of Table la, and further wherein the combination of motif-bearing peptides consists of: a) one or more peptides comprising at least 8 amino acids from an HCV C domain; b) one or more peptides comprising at least 8 amino acids of a further domain selected from the group consisting of: an S domain, an NS3 domain, an NS4 domain, or an NS5 domain, and; c) optionally, one or more motif-bearing peptides from one or more additional HCV domains with a. proviso that an additional domain is not a further domain listed in "b". Preferably, such a pharmaceutical composition may additionally comprise one or more distinct HCV motif-bearing peptide(s) comprising at least 8 amino acids of an X domain or, alternatively, the composition may further comprise additional HCV motif-bearing peptide(s) that are from an envelope domain, the envelope domain peptide(s) consisting of one or more copies of a single HCV peptide comprising at least 8 amino acids of an envelope domain. In another embodiment, the polyepitopic pharmaceutical composition may comprise a pharmaceutically acceptable carrier and combination of motif-bearing peptides that are immunologically cross-reactive with HCV-1 peptides, the peptides from multiple domains of HCV, wherein at least one of the peptides bears a motif of Table la, and wherein the combination of motif-bearing peptides consists essentially of: a) one or more peptides comprising at least 8 amino acids from a C domain; and, b) one or more peptides comprising at least 8 amino acids from an S, NS3, NS4, or NS5 domain, and, one HCV peptide comprising at least 8 amino acids of an envelope domain. Such a composition may further comprise one or more HCV motif-bearing peptides comprising at least 8 amino acids of an X domain. Alternatively, a pharmaceutical composition of the invention may comprise: a) a pharmaceutically acceptable carrier; and, b) a combination of one or more motif-bearing peptides of at least 8 amino acids derived from one or more hepatitis C virus (HCV) domains, wherein said peptides are cross-reactive with peptides of HCV-1, with a proviso that the combination does not include a peptide of at least 8 amino acids from an HCV C domain, and wherein at least one of the peptides bears a motif of Table la, said domains selected from the group consisting of: an S domain; an NS3 domain; an NS4 domain; an NS5 domain; and, an X domain. Such a composition may additionally comprise motif- bearing HCV envelope peptide(s) consisting of one or more copies of a single HCV peptide comprising at least 8 amino acids of an envelope domain. Lastly, an embodiment of the invention may comprise a pharmaceutical composition comprising a pharmaceutically acceptable carrier and combination of two or more motif-bearing peptides from a single domain of an HCV-1 strain, said peptides immunologcially cross-reactive with peptides of an HCV-1 antigen, wherein at least one of the peptides bears a motif of Table la, and the peptides are derived from HCV, and the HCV domain is selected from the group consisting of: a C domain; an S domain; an NS3 domain; an NS4 domain; an NS5 domain; an X domain; or, an envelope domain from a single HCV strain, with a proviso that the envelope domain is other than a variable envelope domain. In the embodiments set forth, "peptides immunologically cross-reactive with HCV-1" refers to peptides that are bound by the same antibody; "derived from" refers to a fragment or subsequence and conservatively modifed variants thereof. IV.K.1. Minigene Vaccines A number of different approaches are available which allow simultaneous delivery of multiple epitopes. Nucleic acids encoding the peptides of the invention are a particularly useful embodiment of the invention. Epitopes for inclusion in a minigene are preferably selected according to the guidelines set forth in the previous section. A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding a peptide comprising one or multiple epitopes of the invention. The use of multi-epitope minigenes is described below and in, e.g., co-pending application U.S.S.N. 09/311,784; An, L. and Whitton, J. L., J. Virol. 71:2292, 1997; Thomson, S. A. et αl, J. Immunol. 157:822, 1996; Whitton, J. L. et αl, J. Virol 67:348, 1993; Hanke, R. et αl, Vaccine 16:426, 1998. For example, a multi-epitope DNA plasmid encoding supermotif- and/or motif-bearing HCV epitopes derived from multiple regions of the HCV polyprotein sequence, the PADRE™ universal helper T cell epitope (or multiple HTL epitopes from HCV), and an endoplasmic reticulum-translocating signal sequence can be engineered. The immunogenicity of a multi-epitopic minigene can be tested in transgenic mice to evaluate the magnitude of CTL induction responses against the epitopes tested. Further, the immunogenicity of DNA-encoded epitopes in vivo can be correlated with the in vitro responses of specific CTL lines against target cells transfected with the DNA plasmid. Thus, these experiments can show that the minigene serves to both: 1.) generate a CTL response and 2.) that the induced CTLs recognized cells expressing the encoded epitopes. For example, to create a DNA sequence encoding the selected epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes may be reverse translated. A human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences may be directly adjoined, so that when translated, a continuous polypeptide sequence is created. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequences that can be reverse translated and included in the minigene sequence include: HLA class I epitopes, HLA class II epitopes, a ubiquitination signal sequence, and/or an endoplasmic reticulum targeting signal. In addition, HLA presentation of CTL and HTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL or HTL epitopes; these larger peptides comprising the epitope(s) are within the scope of the invention. The minigene sequence may be converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) may be synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides can be joined, for example, using T4 DNA ligase. This synthetic minigene, encoding the epitope polypeptide, can then be cloned into a desired expression vector. Standard regulatory sequences well known to those of skill in the art are preferably included in the vector to ensure expression in the target cells. Several vector elements are desirable: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an E. coli origin of replication; and an E. coli selectable marker (e.g. ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, e.g., U.S. Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences. Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences and sequences for replication in mammalian cells may also be considered for increasing minigene expression. Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate E. coli strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis. Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank. In addition, immunostimulatory sequences (ISSs or CpGs) appear to play a role in the immunogenicity of DNA vaccines. These sequences may be included in the vector, outside the minigene coding sequence, if desired to enhance immunogenicity. In some embodiments, a bi-cistronic expression vector which allows production of both the minigene-encoded epitopes and a second protein (included to enhance or decrease immunogenicity) can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (e.g., IL-2, IL-12, GM-CSF), cytokine-inducing molecules (e.g., LeIF), costimulatory molecules, or for HTL responses, pan-DR binding proteins (PADRE™, Epimmune, San Diego, CA). Helper (HTL) epitopes can be joined to intracellular targeting signals and expressed separately from expressed CTL epitopes; this allows direction of the HTL epitopes to a cell compartment different than that of the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the HLA class II pathway, thereby improving HTL induction. In contrast to HTL or CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF-β) may be beneficial in certain diseases. Therapeutic quantities of plasmid DNA can be produced for example, by fermentation in E. coli, followed by purification. Aliquots from the working cell bank are used to inoculate growth medium, and grown to saturation in shaker flasks or a bioreactor according to well known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by QIAGEN, Inc. (Valencia, California). If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods. Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). This approach, known as "naked DNA," is currently being used for intramuscular (IM) administration in clinical trials. To maximize the immuno therapeutic effects of minigene DNA vaccines, an alternative method for formulating purified plasmid DNA may be desirable. A variety of methods have been described, and new techniques may become available. Cationic lipids can also be used in the formulation (see, e.g., as described by WO 93/24640; Mannino & Gould-Fogerite, BioTechniques 6(7): 682 (1988); U.S. Pat No. 5,279,833; WO 91/06309; and Feigner, et al, Proc. Nat 'I Acad. Sci. USA 84:7413 (1987). In addition, glycolipids, fusogenic liposomes, peptides and compounds referred to collectively as protective, interactive, non-condensing compounds (PINC) could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types. Target cell sensitization can be used as a functional assay for expression and HLA class I presentation of minigene-encoded CTL epitopes. For example, the plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for "naked" DNA, whereas cationic lipids allow direct in vitro transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 ( 51 Cr) labeled and used as target cells for epitope-specific CTL lines; cytolysis, detected by 51 Cr release, indicates both production of, and HLA presentation of, minigene-encoded CTL epitopes. Expression of HTL epitopes may be evaluated in an analogous manner using assays to assess HTL activity. In vivo immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human HLA proteins are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g., IM for DNA in PBS, intraperitoneal (IP) for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for 1 week in the presence of peptides encoding each epitope being tested. Thereafter, for CTL effector cells, assays are conducted for cytolysis of peptide-loaded, 51 Cr-labeled target cells using standard techniques. Lysis of target cells that were sensitized by HLA loaded with peptide epitopes, corresponding to minigene-encoded epitopes, demonstrates DNA vaccine function for in vivo induction of CTLs. Immunogenicity of HTL epitopes is evaluated in transgenic mice in an analogous manner. Alternatively, the nucleic acids can be administered using ballistic delivery as described, for instance, in U.S. Patent No. 5,204,253. Using this technique, particles comprised solely of DNA are administered. In a further alternative embodiment, DNA can be adhered to particles, such as gold particles. IV.K.2. Combinations of CTL Peptides with Helper Peptides Vaccine compositions comprising the peptides of the present invention, or analogs thereof, which have immunostimulatory activity may be modified to provide desired attributes, such as improved serum half life, or to enhance immunogenicity. For instance, the ability of the peptides to induce CTL activity can be enhanced by linking the peptide to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. The use of T helper epitopes in conjunction with CTL epitopes to enhance immunogenicity is illustrated, for example, in co-pending U.S.S.N. 08/820360, U.S.S.N. 08/197,484, and U.S.S.N. 08/464,234. Particularly preferred CTL epitope/HTL epitope conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues. Alternatively, the CTL peptide may be linked to the T helper peptide without a spacer. Although the CTL peptide epitope can be linked directly to the T helper peptide epitope, often CTL epitope/HTL epitope conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues. The CTL peptide epitope can be linked to the T helper peptide epitope either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated. HTL peptide epitopes can also be modified to alter their biological properties. For example, peptides comprising HTL epitopes can contain D-amino acids to increase their resistance to proteases and thus extend their serum half-life. Also, the epitope peptides of the invention can be conjugated to other molecules such as lipids, proteins or sugars, or any other synthetic compounds, to increase their biological activity. Specifically, the T helper peptide can be conjugated to one or more palmitic acid chains at either the amino or carboxyl termini. In certain embodiments, the T helper peptide is one that is recognized by T helper cells present in the majority of the population. This can be accomplished by selecting amino acid sequences that bind to many, most, or all of the HLA class II molecules. These are known as "loosely HLA-restricted" or "promiscuous" T helper sequences. Examples of amino acid sequences that are promiscuous include sequences from antigens such as tetanus toxoid at positions 830-843 (QYIKANSKFIGITE), Plasmodium falciparum CS protein at positions 378-398 (DIEKKIAKMEKASSVFNVVNS), and Streptococcus 18kD protein at positions 116 (GAVDSILGGVATYGAA). Other examples include peptides bearing a DR 1-4-7 supermotif, or either of the DR3 motifs. Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences not found in nature (see, e.g., PCT publication WO 95/07707). These synthetic compounds called Pan-DR-binding epitopes (e.g., PADRE™, Epimmune, Inc., San Diego, CA) are designed to most preferrably bind most HLA-DR (human HLA class II) molecules. For instance, a pan-DR-binding epitope peptide having the formula: aKXVWANTLKAAa, where "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and a is either D- alanine or L-alanine, has been found to bind to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless of their HLA type. An alternative of a pan-DR binding epitope comprises all "L" natural amino acids and can be provided in the form of nucleic acids that encode the epitope. In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes cytotoxic T lymphocytes. Lipids have been identified as agents capable of priming CTL in vivo against viral antigens. For example, palmitic acid residues can be attached to the ε-and α- amino groups of a lysine residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be administered either directly in a micelle or particle, incorporated into a liposome, or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant. In a preferred embodiment, a particularly effective immunogenic comprises palmitic acid attached to ε- and α- amino groups of Lys, which is attached via linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic peptide. As another example of lipid priming of CTL responses, E. coli lipoproteins, such as tripalmitoyl-S-glycerylcysteinlyseryl- serine (P 3 CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide. (See, e.g., Deres, et al, Nature 342:561, 1989). Peptides of the invention can be coupled to P CSS, for example, and the lipopeptide administered to an individual to specifically prime a CTL response to the target antigen. Moreover, because the induction of neutralizing antibodies can also be primed with P 3 CSS-conjugated epitopes, two such compositions can be combined to more effectively elicit both humoral and cell-mediated responses to infection. As noted herein, additional amino acids can be added to the termini of a peptide to provide for ease of linking peptides one to another, for coupling to a carrier support or larger peptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like. Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C- or N- terminus of the peptide or oligopeptide, particularly class I peptides. However, it is to be noted that modification at the carboxyl terminus of a CTL epitope may, in some cases, alter binding characteristics of the peptide. In addition, the peptide or oligopeptide sequences can differ from the natural sequence by being modified by terminal-NH 2 acylation, e.g., by alkanoyl (Cι-C 20 ) or thioglycolyl acetylation, terminal-carboxyl amidation, e.g., ammonia, methylamine, etc. In some instances these modifications may provide sites for linking to a support or other molecule. Vaccine Compositions Comprising Dendritic Cells Pulsed with CTL and/or HTL Peptides An embodiment of a vaccine composition in accordance with the invention comprises ex vivo administration of a cocktail of epitope-bearing peptides to PBMC, or isolated DC therefrom, from the patient's blood. A pharmaceutical to facilitate harvesting of DC can be used, such as GM-CSF/IL-4. After pulsing the DC with peptides and prior to reinfusion into patients, the DC are washed to remove unbound peptides. In this embodiment, a vaccine comprises peptide-pulsed DCs which present the pulsed peptide epitopes complexed with HLA molecules on their surfaces. The vaccine is then administered to the patient. IV.L. Administration of Vaccines for Therapeutic or Prophylactic Purposes The peptides of the present invention and pharmaceutical and vaccine compositions of the invention are useful for administration to mammals, particularly humans, to treat and/or prevent HCV infection. Vaccine compositions containing the peptides of the invention are administered to a patient infected with HCV or to an individual susceptible to, or otherwise at risk for, HCV infection to elicit an immune response against HCV antigens and thus enhance the patient's own immune response capabilities. In therapeutic applications, peptide and/or nucleic acid compositions are administered to a patient in an amount sufficient to elicit an effective CTL and/or HTL response to the virus antigen and to cure or at least partially arrest or slow symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on, e.g., the particular composition administered, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician. The vaccine compositions of the invention may also be used purely as prophylactic agents. Generally the dosage for an initial prophylactic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg. Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. This is followed by boosting dosages of between about 1.0 μg to about 50,000 μg of peptide administered at defined intervals from about four weeks to six months after the initial administration of vaccine. The immunogenicity of the vaccine may be assessed by measuring the specific activity of CTL and HTL obtained from a sample of the patient's blood. As noted above, peptides comprising CTL and or HTL epitopes of the invention induce immune responses when presented by HLA molecules and contacted with a CTL or HTL specific for an epitope comprised by the peptide. The manner in which the peptide is contacted with the CTL or HTL is not critical to the invention. For instance, the peptide can be contacted with the CTL or HTL either in vivo or in vitro. If the contacting occurs in vivo, the peptide itself can be administered to the patient, or other vehicles, e.g., DNA vectors encoding one or more peptides, viral vectors encoding the peptide(s), liposomes and the like, can be used, as described herein. When the peptide is contacted in vitro, the vaccinating agent can comprise a population of cells, e.g. , peptide- pulsed dendritic cells, or TAA-specific CTLs, which have been induced by pulsing antigen-presenting cells in vitro with the peptide. Such a cell population is subsequently administered to a patient in a therapeutically effective dose. The peptides or DNA encoding them can be administered individually or as fusions of one or more peptide sequences. For pharmaceutical compositions, the immunogenic peptides of the invention, or DNA encoding them, are generally administered to an individual already infected with HCV. The peptides or DNA encoding them can be administered individually or as fusions of one or more peptide sequences. Those in the incubation phase or the acute phase of infection can be treated with the immunogenic peptides separately or in conjunction with other treatments, as appropriate. For therapeutic use, administration should generally begin at the first diagnosis of HCV infection. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In chronic infection, loading doses followed by boosting doses may be required. Treatment of an infected individual with the compositions of the invention may hasten resolution of the infection in acutely infected individuals. For those individuals susceptible (or predisposed) to developing chronic infection, the compositions are particularly useful in methods for preventing the evolution from acute to chronic infection. Where susceptible individuals are identified prior to or during infection, the composition can be targeted to them, thus minimizing the need for administration to a larger population. The peptide or other compositions used for the treatment or prophylaxis of HCV infection can be used, e.g., in persons who have not manifested symptoms of disease but who act as a disease vector. In this context, it is generally important to provide an amount of the peptide epitope delivered by a mode of administration sufficient to effectively stimulate a cytotoxic T cell response; compositions which stimulate helper T cell responses can also be given in accordance with this embodiment of the invention. The dosage for an initial therapeutic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg. Dosage values for a human typically range from about 500 μg to about 50,000 μg per 70 kilogram patient. Boosting dosages of between about 1.0 μg to about 50000 μg of peptide pursuant to a boosting regimen over weeks to months may be administered depending upon the patient's response and condition as determined by measuring the specific activity of CTL and HTL obtained from the patient's blood. The peptides and compositions of the present invention may be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, as a result of the minimal amounts of extraneous substances and the relative nontoxic nature of the peptides in preferred compositions of the invention, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions relative to these stated dosage amounts. Thus, for treatment of chronic infection, a representative dose is in the range disclosed above, namely where the lower value is about 1, 5, 50, 500, or 1000 μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg, preferably from about 500 μg to about 50,000 μg per 70 kilogram patient. Initial doses followed by boosting doses at established intervals, e.g., from four weeks to six months, may be required, possibly for a prolonged period of time to effectively immunize an individual. In the case of chronic infection, administration should continue until at least clinical symptoms or laboratory tests indicate that the viral infection has been eliminated or substantially abated and for a period thereafter. The dosages, routes of administration, and dose schedules are adjusted in accordance with methodologies known in the art. The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, intrathecal, or local administration. Preferably, the pharmaceutical compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc. The concentration of peptides of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected. A human unit dose form of the peptide composition is typically included in a pharmaceutical composition that comprises a human unit dose of an acceptable carrier, preferably an aqueous carrier, and is administered in a volume of fluid that is known by those of skill in the art to be used for administration of such compositions to humans (see, e.g., Remington's Pharmaceutical Sciences. 17 th Edition, A. Gennaro, Editor, Mack Publising Co., Easton, Pennsylvania, 1985). The peptides of the invention may also be administered via liposomes, which serve to target the peptides to a particular tissue, such as lymphoid tissue, or to target selectively to infected cells, as well as to increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the peptide compositions. Liposomes for use in accordance with the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospho lipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al, Ann. Rev. Biophys. Bioeng. 9:467 (1980), and U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369. For targeting cells of the immune system, a ligand to be incorporated into the liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, mter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated. For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%. For aerosol administration, the immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are 0.01%-20% by weight, preferably 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery. IV.M. Kits The peptide and nucleic acid compositions of this invention can be provided in kit form together with instructions for vaccine administration. Typically the kit would include desired peptide compositions in a container, preferably in unit dosage form and instructions for administration. An alternative kit would include a minigene construct with desired nucleic acids of the invention in a container, preferably in unit dosage form together with instructions for administration. Lymphokines such as IL-2 or IL-12 may also be included in the kit. Other kit components that may also be desirable include, for example, a sterile syringe, booster dosages, and other desired excipients. The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters that can be changed or modified to yield alternative embodiments in accordance with the invention. V. EXAMPLES As in many viral diseases, there is evidence that clearance of HCV is mediated by CTL. In a study of primary HCV infection in six chimpanzees, four progressed to chronic infection (Cooper et al, abstract, 19 th US- Japan Hepatitis Joint Panel Meeting, January 27-29, 1998). It was found that these four animals showed either no CTL response or a very narrowly focused response during early infection. In contrast, in the remaining two animals that resolved the infection, a broad CTL response was observed against multiple HCV proteins, some of which were conserved. Weiner et al (Proc. Natl. Acad. Sci. USA 92:2755-2759, 1995) demonstrated that viral escape, in which the epitopes presented to PATR class I molecules mutated, was linked with a progression toward chronic infection. These data show a role for the CTL in directing the course of HCV disease, and in shaping the genetic composition of HCV species in the persistently infected host. In work in humans, Koziel and co-workers have established the presence of HCV- specific CTL in liver infiltrates from patients with chronic HCV infection (Koziel et al, J. Immunol. 149:3339, 1992; and Koziel et al, J. Virol. 67:7522, 1993), and have also identified a number of CTL epitopes recognized in the context of several different HLA class I molecules. Other investigators have shown that HCV-specific CTL can be detected in the peripheral blood of patients with chronic hepatitis C (Cerny et al, J. Clin. Invest. 95:521, 1995; Cerny et al, Curr. Topics in Micro, and Immunol 189:169, 1994; Cerny et al, Abst. 2 nd International Meeting on Hepatitis C and Related Viruses; La Jolla, CA, 1994; Battegay et al, Abst. 2 nd International Meeting on Hepatitis C and Related Viruses; La Jolla, CA, 1994; Shirai et al, J. Virol. 68:3334, 1994; Shirai et al, J. Immunol. 154:2733, 1995; Battegay et al, J. Virol. 69:2462, 1995). In addition, escape variants have been demonstrated in patients chronically infected with HCV (Chang et al. , J. Clin. Invest. 100:2376-2385, 1997; Tsai et al, Gastroenterology 115:954-966, 1998). The magnitude of the CTL responses observed in HCV-infected patients is, in general, higher than those observed in the case of chronic hepatitis B infection, suggesting that there is less impairment of specific T cell immunity than with HB V infection. The magnitude of CTL responses in HCV patients is, however, lower than those observed in HBV infected individuals who successfully cleared HBV infection. These results support the understanding that HCV infected patients are capable of responding to active immunotherapy, and suggest that potentiation and increasing of T cell responses to HCV may be of use in therapy and prevention of chronic HCV infection (Prince, A. M. F EMS Micro. Rev. 14:273, 1994). Several groups have analyzed the potential role of HCV-specific CTL responses in disease resistance and pathogenesis. In some studies no correlation was found between CTL viremia and CTL precursor frequency for individual HCV epitopes (Rehermann et al, J. Clin. Invest. 98:1432-1440, 1996; Wong et α/., J. Immunol. 160:1479-1488, 1998). In other studies, however, it was shown that a clear correlation existed between levels of HCV infection and CTL responses, provided that the global response against multiple CTL epitopes was considered (Rehermann et al, J. Virol. 70:7092-7102, 1996). These data represent a strong rationale for development of vaccine constructs capable of inducing vigorous CTL responses directed against a multiplicity of conserved HCV- derived epitopes. Koziel and colleagues have demonstrated the presence of HCV-specific CTLs, as well as T helper cell responses, in exposed but seronegative individuals (Koziel et al, J. Infect. Diseases 176:859-866, 1997). In addition, HCV-specific CTLs have been detected in healthy, seronegative family members of chronically HCV-infected patents, indicating that a protective immunity is established in absence of a detectable infection (Bronowicki et al, J. Infect. Dis. 176:518-522, 1997; Scognamiglio et al, in preparation). Experimental evidence also indicates that HTL epitopes play an important role in immune reactivity and defenses against HCV infection (Missale et al, J. Clin. Invest. 98:706-714, 1996). Diepolder et al (in Lancet 346:1006, 1995) have shown that a region of the NS3 gene (NS3 1007-1534) is recognized by patients who clear acute HCV infection, but is not seen by patients who develop chronic infection. Subsequent studies showed that this particular region contain a highly cross-reactive HTL epitope (NS3 1248-1261), which binds with good affinity to 10 of 13 DR molecules tested, and is highly conserved in 30/33 different HCV isolates considered (Diepolder et al, J. Virol. 71:6011-6019, 1997). These data suggested that directing HTL responses to this type of epitope (rather than to less cross-reactive and/or highly variable ones) will be of therapeutic and prophylactic benefit and strongly argue for inclusion of this and other epitopes with similar characteristics in HCV vaccine constructs. The following examples illustrate identification, selection, and use of immunogenic Class I and Class II peptide epitopes for inclusion in vaccine compositions. Example 1 : HLA Class I and Class II Binding Assays The following example of peptide binding to HLA molecules demonstrates quantification of binding affinities of HLA class I and class II peptides. Binding assays can be performed with peptides that are either motif-bearing or not motif-bearing. Epstein-Barr virus (EBV)-transformed homozygous cell lines, fibroblasts, CIR, or 721.22 transfectants were used as sources of HLA class I molecules. The specific cell lines routinely used for purification of MHC class I and class II molecules are listed in Table XXIV. Cell lysates were prepared and HLA molecules purified in accordance with disclosed protocols (Sidney et al, Current Protocols in Immunology 18.3.1 (1998); Sidney, et al, J. Immunol. 154:247 (1995); Sette, et al, Mol. Immunol 31 :813 (1994)). HLA molecules were purified from lysates by affinity chromatography. The lysate was passed over a column of Sepharose CL-4B beads coupled to an appropriate antibody. The antibodies used for the extraction of HLA from cell lysates are listed in Table XXV. The anti-HLA column was then washed with lOmM Tris-HCL, pH 8.0, in 1% NP-40, PBS, and PBS containing 0.4% n-octylglucoside and HLA molecules were eluted with 50mM diethylamine in 0.15M NaCl containing 0.4% n-octylglucoside, pH 11.5. A 1/25 volume of 2.0M Tris, pH 6.8, was added to the eluate to reduce the pH to ~8.0. Eluates were then be concentrated by centrifugation in Centriprep 30 concentrators (Amicon, Beverly, MA). Protein content was evaluated by a BCA protein assay (Pierce Chemical Co., Rockford, IL) and confirmed by SDS-PAGE. A detailed description of the protocol utilized to measure the binding of peptides to Class I and Class II MHC has been published (Sette et al, Mol. Immunol. 31:813, 1994; Sidney et al, in Current Protocols in Immunology, Margulies, Ed., John Wiley & Sons, New York, Section 18.3, 1998). Briefly, purified MHC molecules (5 to 500nM) were incubated with various unlabeled peptide inhibitors and 1-lOnM 125 I-radiolabeled probe peptides for 48h in PBS containing 0.05% Nonidet P-40 (NP40) (or 20% w/v digitonin for H-2 IA assays) in the presence of a protease inhibitor cocktail. All assays were at pH 7.0 with the exception of DRB1*0301, which was performed at pH 4.5, and DRB1*1601 (DR2w21βι) and DRB4*0101 (DRw53), which were performed at pH 5.0. Following incubation, MHC-peptide complexes were separated from free peptide by gel filtration on 7.8 mm x 15 cm TSK200 columns (TosoHaas 16215, Montgomeryville, PA). Because the large size of the radiolabeled peptide used for the DRB1*1501 (DR2w2βι) assay makes separation of bound from unbound peaks more difficult under these conditions, all DRB1*1501 (DR2w2βι) assays were performed using a 7.8mm x 30cm TSK2000 column eluted at 0.6 mls/min. The eluate from the TSK columns was passed through a Beckman 170 radioisotope detector, and radioactivity was plotted and integrated using a Hewlett-Packard 3396A integrator, and the fraction of peptide bound was determined. Radiolabeled peptides were iodinated using the chloramine-T method. Representative radiolabeled probe peptides utilized in each assay, and its assay specific IC 50 nM, are summarized in Tables IV and V. Typically, in preliminary experiments, each MHC preparation was titered in the presence of fixed amounts of radiolabeled peptides to determine the concentration of HLA molecules necessary to bind 10-20% of the total radioactivity. All subsequent inhibition and direct binding assays were performed using these HLA concentrations. Since under these conditions [label]<[HLA] and IC50>[HLA], the measured IC 50 values are reasonable approximations of the true K D values. Peptide inhibitors are typically tested at concentrations ranging from 120 μg/ml to 1.2 ng/ml, and are tested in two to four completely independent experiments. To allow comparison of the data obtained in different experiments, a relative binding figure is calculated for each peptide by dividing the IC 50 of a positive control for inhibition by the IC 0 for each tested peptide (typically unlabeled versions of the radiolabeled probe peptide). For database purposes, and inter-experiment comparisons, relative binding values are compiled. These values can subsequently be converted back into IC 50 nM values by dividing the IC 50 nM of the positive controls for inhibition by the relative binding of the peptide of interest. This method of data compilation has proven to be the most accurate and consistent for comparing peptides that have been tested on different days, or with different lots of purified MHC. Because the antibody used for HLA-DR purification (LB3.1) is α-chain specific, βi molecules are not separated from β 3 (and/or β 4 and β 5 ) molecules. The βi specificity of the binding assay is obvious in the cases of DRB1*0101 (DRl), DRB1*0802 (DR8w2), and DRB 1*0803 (DR8w3), where no β 3 is expressed. It has also been demonstrated for DRB1*0301 (DR3) and DRB3*0101 (DR52a), DRB1*0401 (DR4w4), DRB1*0404 (DR4wl4), DRB1*0405 (DR4wl5), DRB1*1101 (DR5), DRB1*1201 (DR5wl2), DRB1*1302 (DR6wl9) and DRB1*0701 (DR7). The problem of β chain specificity for DRB1*1501 (DR2w2β , DRB5*0101 (DR2w2β 2 ), DRB1*1601 (DR2w21βι), DRB5*0201 (DR51Dw21), and DRB4*0101 (DRw53) assays is circumvented by the use of fibroblasts. Development and validation of assays with regard to DRβ molecule specificity have been described previously (see, e.g., Southwood et al, J. Immunol. 160:3363-3373, 1998). Binding assays as outlined above may be used to analyze supermotif and/or motif- bearing epitopes as, for example, described in Example 2. Example 2. Identification of Conserved HLA Supermotif- and Motif-Bearing CTL Candidate Epitopes Vaccine compositions of the invention may include multiple epitopes that comprise multiple HLA supermotifs or motifs to achieve broad population coverage. This example illustrates the identification of supermotif- and motif-bearing epitopes for the inclusion in such a vaccine composition. Calculation of population coverage was performed using the strategy described below. Computer searches and algorthims for identification of supermotif and/or motif-bearing epitopes Computer searches for epitopes bearing HLA Class I or Class II supermotifs or motifs were performed as follows. All translated HCV isolate sequences were analyzed using a text string search software program, e.g., MotifSearch 1.4 (D. Brown, San Diego) to identify potential peptide sequences containing appropriate HLA binding motifs; alternative programs are readily produced in accordance with information in the art in view of the motif/supermotif disclosure herein. Furthermore, such calculations can be made mentally. Identified A2-, A3-, and DR-supermotif sequences were scored using polynomial algorithms to predict their capacity to bind to specific HLA-Class I or Class II molecules. These polynomial algorithms take into account both extended and refined motifs (that is, to account for the impact of different amino acids at different positions), and are essentially based on the premise that the overall affinity (or ΔG) of peptide-HLA molecule interactions can be approximated as a linear polynomial function of the type: "ΔG" = a u x a 2i x a 3 , x a m where a is a coefficient which represents the effect of the presence of a given amino acid (j) at a given position (i) along the sequence of a peptide of n amino acids. The crucial assumption of this method is that the effects at each position are essentially independent of each other (i.e., independent binding of individual side-chains). When residue y occurs at position i in the peptide, it is assumed to contribute a constant amount j, to the free energy of binding of the peptide irrespective of the sequence of the rest of the peptide. This assumption is justified by studies from our laboratories that demonstrated that peptides are bound to MHC and recognized by T cells in essentially an extended conformation (data omitted herein). The method of derivation of specific algorithm coefficients has been described in Gulukota et αl., J. Mol. Biol. 267:1258-126, 1997; (see also Sidney et αl, Human Immunol. 45:79-93, 1996; and Southwood et al, J. Immunol 160:3363-3373, 1998). Briefly, for all i positions, anchor and non-anchor alike, the geometric mean of the average relative binding (ARB) of all peptides carrying^ is calculated relative to the remainder of the group, and used as the estimate of ,. For Class II peptides, if multiple alignments are possible, only the highest scoring alignment is utilized, following an iterative procedure. To calculate an algorithm score of a given peptide in a test set, the ARB values corresponding to the sequence of the peptide are multiplied. If this product exceeds a chosen threshold, the peptide is predicted to bind. Appropriate thresholds are chosen as a function of the degree of stringency of prediction desired. Selection ofHLA-A2 supertype cross-reactive peptides Complete polyprotein sequences from fourteen HCV isolates were aligned, then scanned, utilizing motif identification software, to identify conserved 9- and 10-mer sequences containing the HLA- A2-supermotif main anchor specificity. A total of 231 conserved, HLA-A2 supermotif-positive sequences were identified. These peptides were then evaluated for the presence of A*0201 preferred secondary anchor residues using A*0201 -specific polynomial algorithms. A total of 67 conserved, motif-bearing and algorithm-positive sequences were identified. Fifty of these conserved, motif-containing 9- and 10-mer peptides were tested for their capacity to bind to purified HLA-A*0201 molecules in vitro (HLA-A*0201 is considered a prototype A2 supertype molecule). Sixteen peptides bound A*0201 with IC 50 values <500 nM; 4 with high binding affinities (IC 50 values <50 nM) and 12 with intermediate binding affinities, in the 50-500 nM range (Table XXVI). These 16 peptides were then tested for binding to additional A2-supertype molecules (A*0202, A*0203, A*0206, and A*6802). As shown in Table XXVI, most of these peptides were found to be A2-supertype cross-reactive binders. More specifically, 12/16 (75%) peptides bound at least three of the five A2-supertype molecules tested. Selection ofHLA-A3 supermotif-bearing epitopes The sequences from the same fourteen known HCV isolates scanned above were also examined for the presence of conserved peptides with the HLA- A3 -supermotif primary anchors. A total of 71 conserved 9- or 10-mer motif containing sequences were identified. Further analysis using the A03 and Al 1 algorithms (see, e.g., Gulukota et al, J. Mol. Biol. 267:1258-1267, 1997 and Sidney et al, Human Immunol. 45:79-93, 1996) identified 39 sequences that scored high in either or both algorithms. Twenty seven of the 39 peptides were synthesized and tested for binding to HLA-A*03 and HLA-A*11, the two most prevalent A3-supertype molecules. Fifteen peptides were identified which bound A3 and/or Al 1 with binding affinities of <500 nM (Table XXVII). These peptides were then tested for binding cross-reactivity to the other common A3-supertype alleles (A*3101, A*3301, and A*6801). Seven of the 15 peptides bound at least three of the five HLA- A3 -supertype molecules tested. In the course of an independent series of experiments (Kubo et al, J. Immunol. 152:3913-3924, 1994), one peptide, HCV NS3 1262, not identified by the selection criteria utilized above because it does not have the A3 -supermotif main anchor specificity, was determined to be cross-reactive in the A3-supertype, binding A*03, A*l 1, and A*6801. It is also shown in Table XXVII. Interestingly, this peptide represents a single residue N- terminal truncation of peptide 1073.14, which is also shown in Table XXVII. In summary, 8 peptides that bind 3 or more A3 -supertype molecules derived from conserved regions of the HCV genome were identified. Selection ofHLA-B7 supermotif bearing epitopes When the same fourteen HCV isolates were also analyzed for the presence of conserved 9- or 10-mer peptides with the HLA-B7-supermotif, 35 sequences were identified. The corresponding peptides were synthesized and tested for binding to HLA- B*0702, the most common B7-supertype allele (i.e., the prototype B7 supertype allele). Thirteen peptides bound B*0702 with IC 50 of <500 nM (Table XXVIIIa). These 13 peptides were then tested for binding to other common B7-supertype molecules (B*3501, B*51, B*5301, and B*5401). As shown in Table XXVIIIa, only 1 peptide (Core 169) was capable of binding to three or more of the five B7-supertype alleles tested. To identify additional B7-supertype epitopes, further studies were undertaken. The protein sequences from the fourteen HCV isolates utilized above were again examined to identify conserved, motif-containing 8- and 11-mers. The isolates were also examined for 9- and 10-mer sequences allowing for lower conservancy (51%-78%). Twenty-five 8-mers, sixteen 11-mers, and thirty-five 9- and 10-mers were identified, synthesized, and tested for binding to B*0702. Thirteen peptides bound with high or intermediate affinity (IC 50 <500 nM) (Table XXVIIIb). These peptides were additionally screened for binding to other B7-supertype molecules. Only one cross-reactive binder, the NS3 1378 8-mer (peptide 29.0035/1260.04), was identified (Table XXVIIIb). In summary, a total of two cross-reactive B7-supertype binders were identified (Core 169 and NS3 1378). Selection of Al and A24 motif-bearing epitopes To further increase population coverage, HLA-A1 and -A24 epitopes can also be incorporated into potential vaccine constructs. In a previous analysis, two Al and three A24 binders, 100% conserved among four strains of HCV, were identified (Wentworth et al, Int. Immunol. 8:651-659, 1996). An analysis of the protein sequence data from the fourteen HCV strains utilized above demonstrated that these peptides were >79% conserved, and also identified an additional eleven Al- and twenty five A24-motif-containing conserved sequences (see Table XXIXA and B). Eight of the additional eleven Al peptides and seven of the additional twenty five A24 peptides were tested for binding to the appropriate HLA molecule (i.e., Al or A24). Overall, as shown in Table XXIX, four A 1 -motif peptides (A) and three A24-motif peptides (B) have been found with binding capacities of 500 nM or less for the appropriate allele-specific HLA molecule. Analysis of the HLA-A2 and A3 supermotif-bearing epitopes identified above revealed that in 13/14 cases, peptides binding the supertype prototype HLA molecule (i.e. A*0201 for the A2 supertype, and A*0301 for the A3 supertype) with an IC 50 of less than lOOnM were cross-reactive and recognized by HCV-infected patients as described in Example 3, which follows. Based on these observations, two Al peptides and one A24 peptide epitopes were also selected as candidates for inclusion in vaccine compositions; these peptides bind the appropriate HLA molecule with an IC 50 of less than lOOnM. Example 3: Confirmation of Immunogenicity Evaluation of A *0201 immunogenicity It has been shown that CTL induced in A*0201/K b transgenic mice exhibit specificity similar to CTL induced in the human system (see, e.g., Vitiello et al, J. Exp. Med. 173:1007-1015, 1991; Wentworth et al, Eur. J. Immunol. 26:97-101, 1996). Accordingly, these mice were used to evaluate the immunogenicity of the twelve conserved A2-supertype cross-reactive peptides identified in Example 2 above. CTL induction in transgenic mice following peptide immmunization has been described (Vitiello et al, J. Exp. Med. 173:1007-1015, 1991; Alexander et al; J. Immunol. 159:4753-4761, 1997). In these studies, mice were injected subcutaneously at the base of the tail with each peptide (50 μg/mouse) emulsified in IF A in the presence of an excess of an IA b -restricted helper peptide (140 μg/mouse) (HBV core 128-140, Sette et al, J. Immunol. 153:5586-5592, 1994). Eleven days after injection, splenocytes were incubated in the presence of peptide-loaded syngenic LPS blasts. After six days, cultures were assayed for cytotoxic activity using peptide-pulsed targets. The data, summarized in Table XXX, indicate that 7 of the 12 peptides (58%) were capable of inducing primary CTL responses in A*0201/K transgenic mice. (For these studies, a peptide was considered positive if it induced CTL (L.U. 30/10 6 cells >2 in at least two transgenic animals (Wentworth et al, Eur. J. Immunol. 26:97-101, 1996). The conserved, cross reactive candidate CTL epitopes were also tested for recognition in vitro by PBMCs obtained from HCV-infected patients. Briefly, PBMC from patients infected with HCV were cultured in the presence of 10 μg/ml of synthetic peptide. After 7 and 14 days, the cultures were restimulated with peptide. The cultures were assayed for cytolytic activity on day 21 using target cells pulsed with the specific peptide in a standard four hour 51 Cr release assay. The data are summarized in Table XXX. As shown, all 12 peptides are CTL epitopes recognized by PBMC from HCV- infected patients. From the data in Table XXX, it is interesting to note that HLA transgenics did not fully reveal the immunogenicity of some peptides that were positive in recall responses. This apparent discrepancy may reflect differences in the route of immunization utilized (e.g. , natural infection versus peptide immunization), or CTL repertoire. Evaluation ofA*03/All immunogenicity The immunogenicity of six of the eight A3-supertype cross-reactive peptides identified in Example 2 above was evaluated in HLA-A11/K b transgenic mice, using the protocol described above for HLA-A2 transgenic mice (Alexander et al, J. Immunol. 159:4753-4761, 1997). Five of these six peptides were able to induce primary CTL responses (Table XXXI). All eight peptides were also studied by collaborators using PBMC cultures from HCV infected patients and contacts of such patients. This data is also summarized in Table XXXI. Briefly, all eight peptides were recognized by HCV infected individuals. Evaluation ofB7 immunogenicity One of the two B7-supertype cross-reactive peptides (1145.12, Core 169) has been evaluated for immunogenicity in HCV-infected patients. Two independent collaborators have shown that this peptide is indeed immunogenic, and is recognized by T cells from HCV-infected patients (Chang et al, J. Immunol 162: 1156-1164, 1999) Example 4: Implementation of the Extended Supermotif to Improve the Binding Capacity of Native Epitopes by Creating Analogs HLA motifs and supermotifs (comprising primary and/or secondary residues) are useful in the identification and preparation of highly cross-reactive native peptides, as demonstrated herein. Moreover, the definition of HLA motifs and supermotifs also allows one to engineer highly cross-reactive epitopes by identifying residues within a native peptide sequence which can be analogued, or "fixed" to confer upon the peptide certain characteristics, e.g. greater cross-reactivity within the group of HLA molecules that comprise a supertype, and/or greater binding affinity for some or all of those HLA molecules. Examples of analog peptides that exhibit modulated binding affinity are set forth in this example. Analoging at Primary Anchor Residues As shown in Example 2, more than ten different HCV-derived, A2-supertype- restricted epitopes were identified. Peptide engineering strategies are implemented to further increase the cross-reactivity of the candidate epitopes identified above which bind 3/5 of the A2 supertype alleles tested. On the basis of the data disclosed, e.g., in related and co-pending U.S.S.N 09/226,775, the main anchors of A2-supermotif-bearing peptides are altered, for example, to introduce a preferred L, I, V, or M at position 2, and I or V at the C-terminus. To analyze the cross-reactivity of the analog peptides, each engineered analog is initially tested for binding to the prototype A2 supertype allele A*0201, then, if A*0201 binding capacity is maintained, for A2-supertype cross-reactivity. Similarly, analogs of HLA- A3 supermotif-bearing epitopes may also be generated. For example, peptides binding to 3/5 of the A3-supertype molecules may be engineered at primary anchor residues to possess a preferred residue (V, S, M, or A) at position 2. The analog peptides are then tested for the ability to bind A*03 and A*l 1 (prototype A3 supertype alleles). Those peptides that demonstrate < 500 nM binding capacity are then tested for A3-supertype cross-reactivity. Similarly to the A2- and A3- motif bearing peptides, peptides binding 3 or more B7-supertype alleles may be improved, where possible, to achieve increased cross- reactive binding. B7 supermotif-bearing peptides may, for example, be engineered to possess a preferred residue (V, I, L, or F) at the C-terminal primary anchor position, as demonstrated by Sidney et al. (J. Immunol 157:3480-3490, 1996). Analoging at Secondary Anchor Residues Moreover, HLA supermotifs are of value in engineering highly cross-reactive peptides and/or peptides that bind HLA molecules with increased affinity by identifying particular residues at secondary anchor positions that are associated with such properties. Demonstrating this, the binding capacity of a peptide representing a discreet single amino acid substitution at position one was analyzed. Peptide 1145.13 (Table XXVIIIc), which represents the substitution of L to F at position 1 of the core 169 sequence, binds all five B7-supertype molecules with a good affinity (all IC 50 values < 132 nM), and in 3 instances has higher affinity over that of the parent peptide by >35-fold. Because so few B7-supertype cross-reactive epitopes were identified, our results from previous binding evaluations were analyzed to identify conserved (8-, 9-, 10-, or 11- mer) peptides which bind, minimally, 3/5 B7 supertype molecules with weak affinity (IC 50 of 500nM-5μM). This analysis identified 9 peptides, 6 of which are analogued (including core 169 which had been previously analogued). These peptides are tested for enhanced binding affinity and B7-supertype cross-reactivity. Engineered analogs with sufficiently improved binding capacity or cross- reactivity are tested for immunogenicity in HLA-B7-transgenic mice, following for example, IFA immunization or lipopeptide immunization. In conclusion, these data demonstrate that by the use of even single amino acid substitutions, it is possible to increase the binding affinity and/or cross-reactivity of peptide ligands for HLA supertype molecules. Example 5: Identification of conserved HCV-derived sequences with HLA-DR binding motifs Peptide epitopes bearing an HLA class II supermotif or motif may also be identified as outlined below using methodology similar to that described in Examples 1-3. Selection of HLA-DR-supermotif-bearing epitopes To identify HCV-derived, HLA class II HTL epitopes, the same fourteen HCV polyprotein sequences used for the identification of HLA Class I supermotif/motif sequences were analyzed for the presence of sequences bearing an HLA-DR-motif or supermotif. Specifically, 15-mer sequences were selected comprising a DR-supermotif, further comprising a 9-mer core, and three-residue N- and C-terminal flanking regions (15 amino acids total). It was also required that the 15-mer sequence be conserved in at least 79% (11/14) of the HCV strains analyzed. These criteria identified a total of 49 non-redundant sequences, which are shown in Table XXXIIA. (In the context of Class II epitopes, a sequence is considered operationally redundant if more than 80% of it's sequence overlaps with another peptide.) Protocols for predicting peptide binding to DR molecules have been developed (Southwood et al., J. Immunol. 160:3363-3373, 1998). These protocols, specific for individual DR molecules, allow the scoring, and ranking, of 9-mer core regions. Each protocol not only scores peptide sequences for the presence of DR-supermotif primary anchors (i.e., at position 1 and position 6) within a 9-mer core, but additionally evaluates sequences for the presence of secondary anchors. Using allele specific selection tables (see, e.g., Southwood et al, ibid.), it has been found that these protocols efficiently select peptide sequences with a high probability of binding a particular DR molecule. Additionally, it has been found that performing these protocols in tandem, specifically those for DRl, DR4w4, and DR7, can efficiently select DR cross-reactive peptides. To see if these protocols serve to identify additional epitopes, the same HCV polyproteins used above were re-scanned for the presence of 15-mer peptides with 9-mer core regions that were >79% (11/14 strains) conserved. This identified 152 sequences; 49 of which were identified previously, as described above. Next, the 9-mer core region of each of these peptides was scored using the DRl, DR4w4, and DR7 algorithms. Twenty- two peptides, including 12 new sequences (10 peptides were from the original set of 49) were found to have 9-mer cores with protocol-derived scores predictive of cross-reactive DR binders. The 12 additional sequences are shown in Table XXXIIB. The conserved, HCV-derived peptides identified above were tested for their binding capacity for various common HLA-DR molecules. All peptides were initially tested for binding to the DR molecules in the primary panel: DRl, DR4w4, and DR7. Peptides binding at least 2 of these 3 DR molecules were then tested for binding to DR2w2 βl, DR2w2 β2, DR6wl9, and DR9 molecules in secondary assays. Finally, peptides binding at least 2 of the 4 secondary panel DR molecules, and thus cumulatively at least 4 of 7 different DR molecules, were screened for binding to DR4wl5, DR5wl 1, and DR8w2 molecules in tertiary assays. Peptides binding at least 7 of the 10 DR molecules comprising the primary, secondary, and tertiary screening assays were considered cross-reactive DR binders. The composition of these screening panels, and the phenotypic frequency of associated antigens, are shown in Table XXXIII. Upon testing, it was found that 29 of the original 75 peptides (39%) bound two or more of the primary HLA molecules. Twenty-six of these cross-reactive binders were then tested in the secondary assays, and nineteen were found to bind at least four of the seven HLA DR molecules in the primary and secondary panels. Finally, the nineteen peptides passing the secondary screening phase were tested for binding in the tertiary assays. As a result, nine peptides were identified which bound at least seven often common HLA-DR molecules. Table XXXIV shows these nine peptides and their binding capacity for each allele-specific HLA-DR molecule in the primary through tertiary panels. Also shown in Table XXXIV are two peptides (F 134.05 and F 134.08) for which a complete binding analysis was not performed. However, both of these peptides bound six of the seven HLA DR molecules tested. F 134.08 nests peptide 1283.44, which bound eight of 10 allele-specific HLA molecules. In conclusion, eleven cross-reactive DR-binding peptides, derived from six discrete (i.e. non-redundant) regions of the HCV genome, have been identified. Two of the six regions from which these epitopes were derived are covered by multiple, overlapping epitopes. Selection of conserved DR3 motif peptides Because HLA-DR3 is an allele that is prevalent in Caucasian, Black, and Hispanic populations, DR3 binding capacity is an important criterion in the selection of HTL epitopes. However, data generated previously indicated that DR3 only rarely cross-reacts with other DR alleles (Sidney et al, J. Immunol. 149:2634-2640, 1992; Geluk et al, J. Immunol 152:5742-5748, 1994; Southwood et al, J. Immunol 160:3363-3373, 1998). This is not entirely surprising in that the DR3 peptide-binding motif appears to be distinct from the specificity of most other DR alleles. To efficiently identify peptides that bind DR3, target proteins were analyzed for conserved sequences carrying one of the two DR3 specific binding motifs reported by Geluk et al. (J. Immunol. 152:5742-5748, 1994). Fifteen sequences, including a peptide nested within a DR-supermotif sequence identified above (peptide Pape 22), were identified (Table XXXIId). Preferably, DR3 motifs will be found clustered in proximity with DR supermotif regions. Fourteen of the fifteen peptides containing a DR3 motif were tested for their DR3 binding capacity. Two peptides (CH35.0106 and CH35.0107) were found to bind DR3 with an affinity of lμM or less (Table XXXV), and thereby qualify as HLA class II high affinity binders. DR3 binding epitopes identified in this manner may then be included in vaccine compositions with DR supermotif-bearing peptide epitopes. Example 6: Immunogenicity of candidate HCV-derived HTL epitopes and known dominant HCV HTL epitope In the course of collaborative studies with G. Pape and C. Ferrari, eight conserved, HCV-derived peptides have been identified which are recognized by HCV-infected individuals. One of these studies (Diepolder et al, J. Virol. 71 :6011-6019, 1997), identified peptide F98.05, which spans residues 1248-1261 of the NS3 protein, as an immunodominant CD4+ T-cell epitope that was recognized by 14/23 NS3-specific CD4+ T-cell clones from 4/5 patients with acute hepatitis C infection. This epitope, shown above to be an HLA-DR cross-reactive binder (see Table XXXIV), was capable of being presented to helper CD4+ T cells by multiple HLA molecules (DR4, DRl 1, DR12, DR13, and DRl 6). Two other peptides, Pape 22 and Pape 29, were also recognized by CD4+ T cell clones, although, in a more limited context; correspondingly, neither of these peptides are DR-cross-reactive binders. By direct peripheral blood T cell stimulation and by fine specificity analysis of HCV-specific T-cell lines and clones, studies done in collaboration with Ferrari's group identified 6 immunodominant epitopes, including one also identified in the Pape collaboration, that are derived from conserved regions of the core, NS3, and NS4 proteins. These epitopes were also found to be cross-reactive, being presented to T cells in the context of different Class II molecules. Three of the 6 epitopes, F98.04 (FI 34.03), F 134.05 and F 134.08, are cross-reactive HLA-DR binders (see Table XXXIV). In conclusion, the immunogenicity of 8 epitopes derived from conserved regions of the HCV genome has been demonstrated. Three of these epitopes (F98.05, F134.05, and F134.08; see Table XXXIV) are broadly cross-reactive HLA-DR binding peptides. Example 7. Calculation of phenotypic frequencies of HLA-supertypes in various ethnic backgrounds to determine breadth of population coverage This example illustrates the assessment of the breadth of population coverage of a vaccine composition comprised of multiple epitopes comprising multiple supermotifs and/or motifs. In order to analyze population coverage, gene frequencies of HLA alleles were determined. Gene frequencies for each HLA allele were calculated from antigen or allele frequencies utilizing the binomial distribution formulae gf=l-(SQRT(l-af)) (see, e.g., Sidney et al, Human Immunol. 45:79-93, 1996). To obtain overall phenotypic frequencies, cumulative gene frequencies were calculated, and the cumulative antigen frequencies derived by the use of the inverse formula [af=l-(l-Cgf) ]. Where frequency data was not available at the level of DNA typing, correspondence to the serologically defined antigen frequencies was assumed. To obtain total potential supertype population coverage no linkage disequilibrium was assumed, and only alleles confirmed to belong to each of the supertypes were included (minimal estimates). Estimates of total potential coverage achieved by inter- loci combinations were made by adding to the A coverage the proportion of the non-A covered population that could be expected to be covered by the B alleles considered (e.g., total= : A+B*(l-A)). Confirmed members of the A3-like supertype are A3, Al 1, A31, A*3301, and A*6801. Although the A3-like supertype may also include A34, A66, and A*7401, these alleles were not included in overall frequency calculations. Likewise, confirmed members of the A2-like supertype family are A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*6802, and A*6901. Finally, the B7-like supertype-confirmed alleles are: B7, B*3501-03, B51, B*5301, B*5401, B*5501-2, B*5601, B*6701, and B*7801 (potentially also B*1401, B*3504-06, B*4201, and B*5602). Population coverage achieved by combining the A2-, A3- and B7-supertypes is approximately 86% in five major ethnic groups (see Table XXI). Coverage may be extended by including peptides bearing the Al and A24 motifs. On average, Al is present in 12% and A24 in 29% of the population across five different major ethnic groups (Caucasian, North American Black, Chinese, Japanese, and Hispanic). Together, these alleles are represented with an average frequency of 39% in these same ethnic populations. The total coverage across the major ethnicities when Al and A24 are combined with the coverage of the A2-, A3- and B7-supertype alleles is >95%. An analagous approach can be used to estimate population coverage achieved with combinations of class II motif-bearing epitopes. Summary of candidate HLA class I and class II epitopes In summary, on the basis of the data presented in the above examples, 26 CTL candidate peptide epitopes derived from conserved regions of the HCV virus have been identified (Table XXXVIa). These include twelve HLA-A2 supermotif-bearing epitopes, eight HLA- A3 supermotif-bearing epitopes, and one HLA-B7 supermotif-bearing epitope, each capable of binding to multiple A2-, A3-, or B7-supertype molecules, and immunogenic in HLA transgenic mice or antigenic for human PBL (with the exception of peptide 29.0035/1260.04). Additional epitopes not evaluated for immunogenicity are also included. They are an additional B7-supermotif-bearing epitope and two HLA-A1 and one HLA-A24 high-affinity binding peptides. A known HLA- A31 restricted epitope (VGIYLLPNR), which also binds HLA-A33, is also set out in Table XXXVIa and is useful in combination with other Class I or Class II epitopes. With these 26 CTL epitopes (as disclosed herein and from the art), average population coverage, (i.e., recognition of at least one HCV epitope), is predicted to be greater than 95% in each of five major ethnic populations. The potential redundancy of coverage afforded by 25 of these epitopes (the peptide 24.0086 was not included) was estimated using the game theory Monte Carlo simulation analysis, which is known in the art (see e.g., Osborne, M.J. and Rubinstein, A. "A course in game theory" MIT Press, 1994). As shown in Figure 1, it is estimated that 90% of the individuals in a population comprised of the Caucasian, North American Black, Japanese, Chinese, and Hispanic ethnic groups would recognize 2 or more of the candidate epitopes described herein. A list of HCV-derived HTL epitopes that would be preferred for use in the design of minigene constructs or other vaccine formulations is summarized in Table XXXVIb. As shown, 9 different peptide-binding regions have been identified which bind multiple HLA-DR molecules or bind HLA-DR3. (In the case of the NS4 1914-1935 region, the longer peptide, F 134.08, recognized by patients, was chosen over the shorter peptide, 1283.44. The longer peptide essentially incorporates the shorter peptide, and also binds additional DR molecules that the shorter peptide does not bind.) Three of these peptides have been recognized as dominant epitopes in HCV infected patients. It is estimated that each of 10 common DR molecules recognizing the DR supermotif, and DR3, are covered by a minimum of 2 epitopes. Correspondingly, the total estimated population coverage represented by this panel of epitopes is in excess of 91% in each of the 5 major ethnic populations (Table XXXVII). Example 8: Recognition Of Generation Of Endogenous Processed Antigens After Priming This example determines that CTL induced by native or analogued peptide epitopes identified and selected as described in Examples 1-6 recognize endogenously synthesized, i.e., native antigens. Effector cells isolated from transgenic mice that are immunized with peptide epitopes as in Example 3, for example HLA-A2 supermotif-bearing epitopes, are re- stimulated in vitro using peptide-coated stimulator cells. Six days later, effector cells are assayed for cytotoxicity and the cell lines that contain peptide-specific cytotoxic activity are further re-stimulated. An additional six days later, these cell lines are tested for cytotoxic activity on 51 Cr labeled Jurkat-A2.1/K b target cells in the absence or presence of peptide, and also tested on 51 Cr labeled target cells bearing the endogenously synthesized antigen, i.e. cells that are stably transfected with HCV expression vectors. The result will demonstrate that CTL lines obtained from animals primed with peptide epitope recognize endogenously synthesized HCV antigen. The choice of transgenic mouse model to be used for such an analysis depends upon the epitope(s) that is being evaluated. In addition to HLA-A*0201/K b transgenic mice, several other transgenic mouse models including mice with human Al 1, which may also be used to evaluate A3 epitopes, and B7 alleles have been characterized and others (e.g., transgenic mice for HLA-A1 and A24) are being developed. HLA-DR1 and HLA-DR3 mouse models have also been developed, which may be used to evaluate HTL epitopes. Example 9: Activity Of CTL-HTL Conjugated Epitopes In Transgenic Mice This example illustrates the induction of CTLs and HTLs in transgenic mice by use of an HCV CTL/HTL peptide conjugate whereby the vaccine composition comprises peptides administered to an HCV-infected patient or an individual at risk for HCV. The peptide composition can comprise multiple CTL and/or HTL epitopes. This analysis demonstrates enhanced immunogenicity that can be achieved by inclusion of one or more HTL epitopes in a vaccine composition. Such a peptide composition can comprise a lipidated HTL epitope conjugated to a preferred CTL epitope containing, for example, at least one CTL epitope selected from Table XXVI-XXIX, or an analog of that epitope. The HTL epitope is, for example, selected from Table XXXII. Lipopeptide preparation: Lipopeptides are prepared by coupling the appropriate fatty acid to the amino terminus of the resin bound peptide. A typical procedure is as follows: A dichloromethane solution of a four- fold excess of a pre-formed symmetrical anhydride of the appropriate fatty acid is added to the resin and the mixture is allowed to react for two hours. The resin is washed with dichloromethane and dried. The resin is then treated with trifluoroacetic acid in the presence of appropriate scavengers [e.g. 5% (v/v) water] for 60 minutes at 20°C. After evaporation of excess trifluoroacetic acid, the crude peptide is washed with diethyl ether, dissolved in methanol and precipitated by the addition of water. The peptide is collected by filtration and dried. Immunization procedures: Immunization of transgenic mice is performed as described (Alexander et al, J. Immunol. 159:4753-4761, 1997). For example, A2/K b mice, which are transgenic for the human HLA A2.1 allele and are useful for the assessment of the immunogenicity of HLA-A*0201 motif- or HLA-A2 supermotif- bearing epitopes, are primed subcutaneously (base of the tail) with 0.1 ml of peptide conjugate formulated in saline, or DMSO/saline. Seven days after priming, splenocytes obtained from these animals are restimulated with syngenic irradiated LPS -activated lymphoblasts coated with peptide. Cell lines: Target cells for peptide-specific cytotoxicity assays are Jurkat cells transfected with the HLA-A2.1/K b chimeric gene (e.g., Vitiello et al, J. Exp. Med. 173:1007, 1991) In vitro CTL activation: One week after priming, spleen cells (30xl0 6 cells/flask) are co-cultured at 37°C with syngeneic, irradiated (3000 rads), peptide coated lymphoblasts (10x10° cells/flask) in 10 ml of culture medium/T25 flask. After six days, effector cells are harvested and assayed for cytotoxic activity. Assay for cytotoxic activity: Target cells (1.0 to 1.5x10°) are incubated at 37°C in the presence of 200 μl of 51 Cr. After 60 minutes, cells are washed three times and resuspended in R10 medium. Peptide is added where required at a concentration of 1 μg/ml. For the assay, 10 4 51 Cr-labeled target cells are added to different concentrations of effector cells (final volume of 200 μl) in U-bottom 96-well plates. After a 6 hour incubation period at 37°C, a 0.1 ml aliquot of supernatant is removed from each well and radioactivity is determined in a Micromedic automatic gamma counter. The percent specific lysis is determined by the formula: percent specific release = 100 x (experimental release - spontaneous release)/(maximum release - spontaneous release). To facilitate comparison between separate CTL assays run under the same conditions, % 51 Cr release data is expressed as lytic units/10 6 cells. One lytic unit is arbitrarily defined as the number of effector cells required to achieve 30% lysis of 10,000 target cells in a 6 hour 51 Cr release assay. To obtain specific lytic units/10 6 , the lytic units/10 6 obtained in the absence of peptide is subtracted from the lytic units/10 6 obtained in the presence of peptide. For example, if 30% 51 Cr release is obtained at the effector (E): target (T) ratio of 50:1 (i.e., 5xl0 5 effector cells for 10,000 targets) in the absence of peptide and 5:1 (i.e., 5x10 4 effector cells for 10,000 targets) in the presence of peptide, the specific lytic units would be: [(l/50,000)-(l/500,000)] x 10 6 = 18 LU. The results are analyzed to assess the magnitude of the CTL responses of animals injected with the immunogenic CTL/HTL conjugate vaccine preparation and are compared to the magnitude of the CTL response achieved using the CTL epitope as outlined in Example 3. Analyses similar to this may be performed to evaluate the immunogenicity of peptide conjugates containing multiple CTL epitopes and/or multiple HTL epitopes. In accordance with these procedures it is found that a CTL response is induced, and concomitantly that an HTL response is induced upon administration of such compositions. Example 10. Selection of CTL and HTL epitopes for inclusion in an HCV-specific vaccine. This example illustrates the procedure for the selection of peptide epitopes for vaccine compositions of the invention. The peptides in the composition can be in the form of a nucleic acid sequence, either single or one or more sequences (i.e., minigene) that encodes peptide(s), or may be single and/or polyepitopic peptides. Epitopes are selected which, upon administration, mimic immune responses that have been observed to be correlated with tumor clearance. For example, vaccine can include 3-4 epitopes that come from at least one HCV antigen region. Epitopes from one region can be used in combination with epitopes from one or more additional HCV antigen regions. Analogs of epitopes can also be selected for inclusion in the vaccine. Epitopes are often selected that have a binding affinity of an IC 50 of 500 nM or less for an HLA class I molecule, or for class II, an IC 50 of 1000 nM or less. Sufficient supermotif bearing peptides, or a sufficient array of allele-specific motif bearing peptides, are selected to give broad population coverage. For example, epitopes are selected to provide at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess breadth, or redundancy, of population coverage. When creating a polyepitopic compositions, e.g. a minigene, it is typically desirable to generate the smallest peptide possible that encompasses the epitopes of interest. The principles employed are similar, if not the same, as those employed when selecting a peptide comprising nested epitopes. Additionally, however, upon determination of the nucleic acid sequence to be provided as a minigene, the peptide sequence encoded thereby is analyzed to determine whether any "junctional epitopes" have been created. A junctional epitope is a potential HLA binding epitope, as predicted, e.g., by motif analysis. Junctional epitopes are generally to be avoided because the recipient may bind to an HLA molecule and generate an immune response to that epitope, which is not present in a native protein sequence. Peptide epitopes for inclusion in vaccine compositions are, for example, selected from those listed in Tables XXVI-XXIX and Table XXXII. A vaccine composition comprised of selected peptides, when administered, is safe, efficacious, and elicits an immune response similar in magnitude of an immune response that clears an acute HCV infection. Example 11: Construction of Mini gene Multi-Epitope DNA Plasmids This example provides guidance for the construction of a minigene expression plasmid. Minigene plasmids may, of course, contain various configurations of CTL and/or HTL epitopes or epitope analogs as described herein. Examples of the construction and evaluation of expression plasmids are described, for example, in co- pending U.S.S.N. 09/311,784 filed 5/13/99. An example of such a plasmid for the expression of HCV epitopes is shown in Figure 2, which illustrates the orientation of HCV peptide epitopes in a minigene construct. A minigene expression plasmid may include multiple CTL and HTL peptide epitopes. In the present example, HLA-A2, -A3, -B7 supermotif-bearing peptide epitopes and HLA-A1 and -A24 motif-bearing peptide epitopes are used in conjunction with DR supermotif-bearing epitopes and/or DR3 epitopes (Figure 2). Preferred epitopes are identified, for example, in Tables XXVI-XXIX and XXXII. HLA class I supermotif or motif-bearing peptide epitopes derived from multiple HCV antigens, e.g., the core, NS4, NS3, NS5, NS1/E2, are selected such that multiple supermotifs/motifs are represented to ensure broad population coverage. Similarly, HLA class II epitopes are selected from multiple HCV antigens to provide broad population coverage, i.e. both HLA DR-1-4-7 supermotif-bearing epitopes and HLA DR-3 motif-bearing epitopes are selected for inclusion in the minigene construct. The selected CTL and HTL epitopes are then incorporated into a minigene for expression in an expression vector. This example illustrates the methods to be used for construction of such a minigene-bearing expression plasmid. Other expression vectors that may be used for minigene compositions are available and known to those of skill in the art. The minigene DNA plasmid contains a consensus Kozak sequence and a consensus murine kappa Ig-light chain signal sequence followed by CTL and/or HTL epitopes selected in accordance with principles disclosed herein. The sequence encodes an open reading frame fused to the Myc and His antibody epitope tag coded for by the pcDNA 3.1 Myc-His vector. Overlapping oligonucleotides, for example eight oligonucleotides, averaging approximately 70 nucleotides in length with 15 nucleotide overlaps, are synthesized and HPLC-purified. The oligonucleotides encode the selected peptide epitopes as well as appropriate linker nucleotides, Kozak sequence, and signal sequence. The final multiepitope minigene is assembled by extending the overlapping oligonucleotides in three sets of reactions using PCR. A Perkin/Elmer 9600 PCR machine is used and a total of 30 cycles are performed using the following conditions: 95°C for 15 sec, annealing temperature (5° below the lowest calculated Tm of each primer pair) for 30 sec, and 72°C for 1 min. For the first PCR reaction, 5 μg of each of two oligonucleotides, i.e., an amplification primer pair, are annealed and extended: Oligonucleotides 1+2, 3+4, 5+6, and 7+8 are combined in 100 μl reactions containing Pfu polymerase buffer (lx= 10 mM KCL, 10 mM (NH 4 ) 2 SO 4 , 20 mM Tris-chloride, pH 8.75, 2 mM MgSO 4 , 0.1% Triton X- 100, 100 μg/ml BSA), 0.25 mM each dNTP, and 2.5 U of Pfu polymerase. The full- length dimer products are gel-purified, and two reactions containing the product of 1+2 and 3+4, and the product of 5+6 and 7+8 are mixed, annealed, and extended for 10 cycles. Half of the two reactions are then mixed, and 5 cycles of annealing and extension carried out before flanking primers are added to amplify the full length product for 25 additional cycles. The full-length product is gel-purified and cloned into pCR-blunt (Invitrogen) and individual clones are screened by sequencing. Example 12. The plasmid construct and the degree to which it induces immunogenicity. The degree to which the plasmid construct prepared using the methodology outlined in Example 11 is able to induce immunogenicity is evaluated through in vivo injections into mice and subsequent in vitro assessment of CTL and HTL activity, which are analysed using cytotoxicity and proliferation assays, respectively, as detailed e.g., in U.S.S.N. 09/311,784 filed 5/13/99 and Alexander et al, Immunity 1:751-761, 1994. For example, to assess the capacity of a pMin minigene construct that contains HLA-A2 supermotif epitopes to induce CTLs in vivo, HLA-A2.1/K b transgenic mice are immunized intramuscularly with 100 μg of naked cDNA. As a means of comparing the level of CTLs induced by cDNA immunization, a control group of animals is also immunized with an actual peptide composition that comprises multiple epitopes synthesized as a single polypeptide as they would be encoded by the minigene. Splenocytes from immunized animals are stimulated twice with each of the respective compositions (peptide epitopes encoded in the minigene or the polyepitopic peptide), then assayed for peptide-specific cytotoxic activity in a 5 Cr release assay. The results indicate the magnitude of the CTL response directed against the A3 -restricted epitope, thus indicating the in vivo immunogenicity of the minigene vaccine and polyepitopic vaccine. It is, therefore, found that the minigene elicits immune responses directed toward the HLA-A2 supermotif peptide epitopes as does the polyepitopic peptide vaccine. A similar analysis is also performed using other HLA-A3 and HLA-B7 transgenic mouse models to assess CTL induction by HLA- A3 and HLA-B7 motif or supermotif epitopes. To assess the capacity of a class II epitope encoding minigene to induce HTLs in vivo, I-A b restricted mice, for example, are immunized intramuscularly with 100 μg of plasmid DNA. As a means of comparing the level of HTLs induced by DNA immunization, a group of control animals is also immunized with an actual peptide composition emulsified in complete Freund's adjuvant. CD4+ T cells, i.e. HTLs, are purified from splenocytes of immunized animals and stimulated with each of the respective compositions (peptides encoded in the minigene). The HTL response is measured using a 3 H-thymidine incorporation proliferation assay, (see, e.g., Alexander et al. Immunity 1:751-761, 1994). the results indicate the magnitude of the HTL response , thus demonstrating the in vivo immunogenicity of the minigene. Alternatively, plasmid constructs can be evaluated in vitro by testing for epitope presentation by APC following transduction or transfection of the APC with an epitope- expressing nucleic acid construct. Such a study determines "antigenicity" and allows the use of human APC. The assay determines the ability of the epitope to be presented by the APC in a context that is recognized by a T cell by quantifying the density of epitope-HLA class I complexes on the cell surface. Quantitation can be performed by directly measuring the amount of peptide eluted from the APC (see, e.g., Sijts et al, J. Immunol. 156:683-692, 1996; Demotz et al, Nature 342:682-684, 1989); or the number of peptide- HLA class I complexes can be estimated by measuring the amount of lysis or lymphokine release induced by infected or transfected target cells, and then determining the concentration of peptide necessary to obtained equivalent levels of lysis or lymphokine release (see, e.g., Kageyama et al, J. Immunol. 154:567-576, 1995). Example 13: Peptide Composition for Prophylactic Uses Vaccine compositions of the present invention are used to prevent HCV infection in persons who are at risk for such infection. For example, a polyepitopic peptide epitope composition (or a nucleic acid comprising the same) containing multiple CTL and HTL epitopes such as those selected in Examples 9 and/or 10, which are also selected to target greater than 80% of the population, is administered to individuals at risk for HCV infection. The composition is provided as a single lipidated polypeptide that encompasses multiple epitopes. The vaccine is administered in an aqueous carrier comprised of Freunds Incomplete Adjuvant. The dose of peptide for the initial immunization is from about 1 to about 50,000 μg, generally 100-5,000 μg, for a 70 kg patient. The initial administration of vaccine is followed by booster dosages at 4 weeks followed by evaluation of the magnitude of the immune response in the patient, by techniques that determine the presence of epitope-specific CTL populations in a PBMC sample. Additional booster doses are administered as required. The composition is found to be both safe and efficacious as a prophylaxis against HCV infection. Alternatively, the polyepitopic peptide composition can be administered as a nucleic acid in accordance with methodologies known in the art and disclosed herein. Example 14: Polyepitopic Vaccine Compositions Derived from Native HCV Sequences A native HCV polyprotein sequence is screened, preferably using computer algorithms defined for each class I and/or class II supermotif or motif, to identify "relatively short" regions of the polyprotein that comprise multiple epitopes and is preferably less in length than an entire native antigen. This relatively short sequence that contains multiple distinct, even overlapping, epitopes is selected and used to generate a minigene construct. The construct is engineered to express the peptide, which corresponds to the native protein sequence. The "relatively short" peptide is generally less than 250 amino acids in length, often less than 100 amino acids in length, preferably less than 75 amino acids in length, and more preferably less than 50 amino acids in length. The protein sequence of the vaccine composition is selected because it has maximal number of epitopes contained within the sequence, i.e., it has a high concentration of epitopes. As noted herein, epitope motifs may be nested or overlapping (i.e., frame shifted relative to one another). For example, with frame shifted overlapping epitopes, two 9-mer epitopes and one 10-mer epitope can be present in a 10 amino acid peptide. Such a vaccine composition is administered for therapeutic or prophylactic purposes. The vaccine composition will preferably include, for example, three CTL epitopes and at least one HTL epitope from an HCV antigen. This polyepitopic native sequence is administered either as a peptide or as a nucleic acid sequence which encodes the peptide. Alternatively, an analog can be made of this native sequence, whereby one or more of the epitopes comprise substitutions that alter the cross-reactivity and/or binding affinity properties of the polyepitopic peptide. The embodiment of this example provides for the possibility that an as yet undiscovered aspect of immune system processing will apply to the native nested sequence and thereby facilitate the production of therapeutic or prophylactic immune response-inducing vaccine compositions. Additionally such an embodiment provides for the possibility of motif-bearing epitopes for an HLA makeup that is presently unknown. Furthermore, this embodiment (absent analogs) directs the immune response to multiple peptide sequences that are actually present in native HCV antigens thus avoiding the need to evaluate any junctional epitopes. Lastly, the embodiment provides an economy of scale when producing nucleic acid vaccine compositions. Related to this embodiment, computer programs can be derived in accordance with principles in the art, which identify in a target sequence, the greatest number of epitopes per sequence length. Example 15. Polyepitopic Vaccine Compositions Directed To Multiple Diseases The HCV peptide epitopes of the present invention are used in conjunction with peptide epitopes from target antigens related to one or more other diseases, to create a vaccine composition that is useful for the prevention or treatment of HCV as well as the one or more other disease(s). Examples of the other diseases include, but are not limited to, HIV, and HBV. For example, a polyepitopic peptide composition comprising multiple CTL and HTL epitopes that target greater than 98% of the population may be created for administration to individuals at risk for both HCV and HIV infection. The composition can be provided as a single polypeptide that incorporates the multiple epitopes from the various disease-associated sources, or can be administered as a composition comprising one or more discrete epitopes. Example 16. Use of peptides to evaluate an immune response Peptides of the invention may be used to analyze an immune response for the presence of specific CTL or HTL populations directed to a prostate cancer-associated antigen. Such an analysis may be performed using multimeric complexes as described, e.g., by Ogg et al, Science 279:2103-2106, 1998 and Greten et al, Proc. Natl. Acad. Sci. USA 95:7568-7573, 1998. In the following example, peptides in accordance with the invention are used as a reagent for diagnostic or prognostic purposes, not as an immunogen. In this example, highly sensitive human leukocyte antigen tetrameric complexes ("tetramers") are used for a cross-sectional analysis of, for example, HCV HLA-A*0201- specific CTL frequencies from HLA A*0201 -positive individuals at different stages of disease or following immunization using an HCV peptide containing an A*0201 motif. Tetrameric complexes are synthesized as described (Musey et al, N. Engl J. Med. 337:1267, 1997). Briefly, purified HLA heavy chain (A*0201 in this example) and β2- microglobulin are synthesized by means of a prokaryotic expression system. The heavy chain is modified by deletion of the transmembrane-cytosolic tail and COOH-terminal addition of a sequence containing a BirA enzymatic biotinylation site. The heavy chain, β2-microglobulin, and peptide are refolded by dilution. The 45-kD refolded product is isolated by fast protein liquid chromatography and then biotinylated by BirA in the presence of biotin (Sigma, St. Louis, Missouri), adenosine 5'triphosphate and magnesium. Streptavidin-phycoerythrin conjugate is added in a 1 :4 molar ratio, and the tetrameric product is concentrated to 1 mg/ml. The resulting product is referred to as tetramer-phycoerythrin. For the analysis of patient blood samples, approximately one million PBMCs are centrifuged at 300g for 5 minutes and resuspended in 50 μl of cold phosphate-buffered saline. Tri-color analysis is performed with the tetramer- phycoerythrin, along with anti-CD8-Tricolor, and anti-CD38. The PBMCs are incubated with tetramer and antibodies on ice for 30 to 60 min and then washed twice before formaldehyde fixation. Gates are applied to contain >99.98% of control samples. Controls for the tetramers include both A*0201 -negative individuals and A* 0201 -positive uninfected donors. The percentage of cells stained with the tetramer is then determined by flow cytometry. The results indicate the number of cells in the PBMC sample that contain epitope-restricted CTLs, thereby readily indicating the extent of immune response to the HCV epitope, and thus the stage of HCV infection or exposure to a vaccine that elicits a protective or therapeutic response. Example 17: Use of Peptide Epitopes to Evaluate Recall Responses The peptide epitopes of the invention are used as reagents to evaluate T cell responses, such as acute or recall responses, in patients. Such an analysis may be performed on patients who have recovered from infection, who are chronically infected with HCV, or who have been vaccinated with an HCV vaccine. For example, the class I restricted CTL response of persons who have been vaccinated may be analyzed. The vaccine may be any HCV vaccine. PBMC are collected from vaccinated individuals and HLA typed. Appropriate peptide epitopes of the invention that are preferably highly conserved and, optimally, bear supermotifs to provide cross-reactivity with multiple HLA supertype family members, are then used for analysis of samples derived from individuals who bear that HLA type. PBMC from vaccinated individuals are separated on Ficoll-Histopaque density gradients (Sigma Chemical Co., St. Louis, MO), washed three times in HBSS (GIBCO Laboratories), resuspended in RPMI-1640 (GIBCO Laboratories) supplemented with L- glutamine (2mM), penicillin (50U/ml), streptomycin (50 μg/ml), and Hepes (lOmM) containing 10% heat-inactivated human AB serum (complete RPMI) and plated using microculture formats. A synthetic peptide comprising an epitope of the invention is added at 10 μg/ml to each well and HBV core 128-140 epitope is added at 1 μg/ml to each well as a source of T cell help during the first week of stimulation. In the microculture format, 4 x 10 5 PBMC are stimulated with peptide in 8 replicate cultures in 96-well round bottom plate in 100 μl/well of complete RPMI. On days 3 and 10, 100 ml of complete RPMI and 20 U/ml final concentration of rIL-2 are added to each well. On day 7 the cultures are transferred into a 96-well flat-bottom plate and restimulated with peptide, rIL-2 and 10 5 irradiated (3,000 rad) autologous feeder cells. The cultures are tested for cytotoxic activity on day 14. A positive CTL response requires two or more of the eight replicate cultures to display greater than 10% specific 51 Cr release, based on comparison with uninfected control subjects as previously described (Rehermann, et al, Nature Med. 2:1104,1108, 1996; Rehermann et al, J. Clin. Invest. 97:1655-1665, 1996; and Rehermann et al. J. Clin. Invest. 98:1432-1440, 1996). Target cell lines are autologous and allogeneic EBV-transformed B-LCL that are either purchased from the American Society for Histocompatibility and Immunogenetics (ASHI, Boston, MA) or established from the pool of patients as described (Guilhot, et al. J. Virol. 66:2610-2618, 1992). Cytotoxicity assays are performed in the following manner. Target cells consist of either allogeneic HLA-matched or autologous EBV-transformed B lymphoblastoid cell line that are incubated overnight with the synthetic peptide epitope of the invention at 10 μM, and labeled with 100 μCi of 51 Cr (Amersham Corp., Arlington Heights, IL) for 1 hour after which they are washed four times with HBSS. Cytolytic activity is determined in a standard 4-h, split well 51 Cr release assay using U-bottomed 96 well plates containing 3,000 targets/well. Stimulated PBMC are tested at effector/target (E/T) ratios of 20-50:1 on day 14. Percent cytotoxicity is determined from the formula: 100 x [(experimental release-spontaneous release)/maximum release-spontaneous release)]. Maximum release is determined by lysis of targets by detergent (2% Triton X-100; Sigma Chemical Co., St. Louis, MO). Spontaneous release is <25% of maximum release for all experiments. The results of such an analysis indicate the extent to which HLA-restricted CTL populations have been stimulated by previous exposure to HCV or an HCV vaccine. The class II restricted HTL responses may also be analyzed. Purified PBMC are cultured in a 96-well flat bottom plate at a density of 1.5x10 5 cells/well and are stimulated with 10 μg/ml synthetic peptide, whole antigen, or PHA. Cells are routinely plated in replicates of 4-6 wells for each condition. After seven days of culture, the medium is removed and replaced with fresh medium containing lOU/ml IL-2. Two days later, 1 μCi 3 H-thymidine is added to each well and incubation is continued for an additional 18 hours. Cellular DNA is then harvested on glass fiber mats and analyzed for 3 H-thymidine incorporation. Antigen-specific T cell proliferation is calculated as the ratio of J H- thymidine incorporation in the presence of antigen divided by the 3 H-thymidine incorporation in the absence of antigen. Example 18: Induction Of Specific CTL Response In Humans A human clinical trial for an immunogenic composition comprising CTL and HTL epitopes of the invention is set up as an IND Phase I, dose escalation study and carried out as a randomized, double-blind, placebo-controlled trial. Such a trial is designed, for example, as follows: A total of about 27 subjects are enrolled and divided into 3 groups: Group I: 3 subjects are injected with placebo and 6 subjects are injected with 5 μg of peptide composition; Group II: 3 subjects are injected with placebo and 6 subjects are injected with 50 μg peptide composition; Group III: 3 subjects are injected with placebo and 6 subjects are injected with 500 μg of peptide composition. After 4 weeks following the first injection, all subjects receive a booster inoculation at the same dosage. The endpoints measured in this study relate to the safety and tolerability of the peptide composition as well as its immunogenicity. Cellular immune responses to the peptide composition are an index of the intrinsic activity of this the peptide composition, and can therefore be viewed as a measure of biological efficacy. The following summarize the clinical and laboratory data that relate to safety and efficacy endpoints. Safety: The incidence of adverse events is monitored in the placebo and drug treatment group and assessed in terms of degree and reversibility. Evaluation of Vaccine Efficacy: For evaluation of vaccine efficacy, subjects are bled before and after injection. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity. The vaccine is found to be both safe and efficacious. Example 19: Phase II Trials In Patients Infected With HCV Phase II trials are performed to study the effect of administering the CTL-HTL peptide compositions to patients having chronic HCV infection. The main objectives of the trials are to determine an effective dose and regimen for inducing CTLs in chronically infected HCV patients, to establish the safety of inducing a CTL and HTL response in these patients, and to see to what extent activation of CTLs improves the clinical picture of chronically infected CTL patients, as manifested by a transient flare in alanine aminotransferase (ALT), normalization of ALT, and reduction in HCV DNA. Such a study is designed, for example, as follows: The studies are performed in multiple centers. The trial design is an open-label, uncontrolled, dose escalation protocol wherein the peptide composition is administered as a single dose followed six weeks later by a single booster shot of the same dose. The dosages are 50, 500 and 5,000 micrograms per injection. Drug-associated adverse effects (severity and reversibility) are recorded. There are three patient groupings. The first group is injected with 50 micrograms of the peptide composition and the second and third groups with 500 and 5,000 micrograms of peptide composition, respectively. The patients within each group range in age from 21-65, include both males and females, and represent diverse ethnic backgrounds. All of them are infected with HCV for over five years and are HIV, HBV and delta hepatitis virus (HDV) negative, but have positive levels of HCV antigen. The magnitude and incidence of ALT flares and the levels of HCV DNA in the blood are monitored to assess the effects of administering the peptide compositions. The levels of HCV DNA in the blood are an indirect indication of the progress of treatment. The vaccine composition is found to be both safe and efficacious in the treatment of chronic HCV infection. Example 20. Induction of CTL Responses Using a Prime Boost Protocol A prime boost protocol can also be used for the administration of the vaccine to humans. Such a vaccine regimen may include an initial administration of, for example, naked DNA followed by a boost using recombinant virus encoding the vaccine, or recombinant protein/polypeptide or a peptide mixture administered in an adjuvant. For example, the initial immunization may be performed using an expression vector, such as that constructed in Example 11, in the form of naked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to 1000 μg) can also be administered using a gene gun. Following an incubation period of 3-4 weeks, a booster dose is administered. The booster can, e.g., be recombinant fowlpox virus administered at a dose of 5-10 7 to 5xl0 9 pfu. An alternative recombinant virus, such as an MVA, canarypox, adenovirus, or adeno-associated virus, can also be used for the booster, or the polyepitopic protein or a mixture of the peptides can be administered. For evaluation of vaccine efficacy, patient blood samples will be obtained before immunization as well as at intervals following administration of the initial vaccine and booster doses of the vaccine. Peripheral blood mononuclear cells are isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples are assayed for CTL and HTL activity. Analysis of the results will indicate that a magnitude of response sufficient to achieve protective immunity or to treat HCV infection infection is generated. Example 21. Administration of Vaccine Compositions Using Dendritic Cells Vaccines comprising peptide epitopes of the invention may be administered using dendritic cells. In this example, the peptide-pulsed dendritic cells can be administered to a patient to stimulate a CTL response in vivo. In this method dendritic cells are isolated, expanded, and pulsed with a vaccine comprising peptide CTL and HTL epitopes of the invention. The dendritic cells are infused back into the patient to elicit CTL and HTL responses in vivo. The induced CTL and HTL then destroy (CTL) or facilitate destruction (HTL) of the specific target HCV-infected cells that bear the proteins from which the epitopes in the vaccine are derived. Alternatively, Ex vivo CTL or HTL responses to a particular tumor-associated antigen can be induced by incubating in tissue culture the patient's, or genetically compatible, CTL or HTL precursor cells together with a source of antigen-presenting cells, such as dendritic cells, and the appropriate immunogenic peptides. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cells, i.e., tumor cells. Example 22: Alternative Method of Identifying Motif-Bearing Peptides Another way of identifying motif-bearing peptides is to elute them from cells bearing defined MHC molecules. For example, EBV transformed B cell lines used for tissue typing, have been extensively characterized to determine which HLA molecules they express. In certain cases these cells express only a single type of HLA molecule. These cells can then be infected with a pathogenic organism, e.g., HCV, or transfected with nucleic acids that express the antigen of interest. Thereafter, peptides produced by endogenous antigen processing of peptides produced consequent to infection (or as a result of transfection) will bind be displayed on the cell surface. The peptides are then eluted from the HLA molecules by exposure to mild acid conditions and their amino acid sequence determined, e.g., by mass spectral analysis (e.g., Kubo et al, J. Immunol. 152:3913, 1994). Because, as disclosed herein, the majority of peptides that bind a particular HLA molecule are motif-bearing, this is an alternative modality for obtaining the motif-bearing peptides correlated with the particular HLA molecule expressed on the cell. Alternatively, cell lines that do not express any endogenous HLA molecules can be transfected with an expression construct encoding a single HLA allele. These cells may then be used as described, i.e., they may be infected with a pathogenic organism or transfected with nucleic acid encoding an antigen of interest to isolate peptides corresponding to the pathogen or antigen of interest that have been presented on the cell surface. Peptides obtained from such an analysis will bear motif(s) that correspond to binding to the single HLA allele that is expressed in the cell. As appreciated by one in the art, one can perform a similar analysis on a cell bearing more than one HLA allele and subsequently determine peptides specific for each HLA allele expressed. Moreover, one of skill would also recognize that means other than infection or transfection, such as loading with a protein antigen, can be used to provide a source of antigen to the cell. The above examples are provided to illustrate the invention but not to limit its scope. For example, the human terminology for the Major Histocompatibility Complex, namely HLA, is used throughout this document. It is to be appreciated that these principles can be extended to other species as well. Thus, other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent application cited herein are hereby incorporated by reference for all purposes. TABLE I Bolded residues are preferred, italicized residues are less preferred: A peptide is considered motif-bearing if it has primary anchors at each primary anchor position for a motif or supermotif as specified in the above table. TABLE II POSITION E Θ a 0 0 0 • Θ C-terminus SUPERMOTIFS A l 1° Anchor 1° Anchor T.IΛ V.M.S F,W,Y A2 1° Anchor 1° Anchor L,I,VAM, L,I,V,M,A,T T.Q A3 preferred 1° Anchor Y,F,W (4/5) Y.F.W Y,F,W (4/5) P (4/5) 1 "Anchor CΛ C V,S,M,AJ, (3/5) R,K CO ι,ι CΛ deleterious D,E (3/5); P (5/5) D,E (4/5) m 1° Anchor 1° Anchor CΛ A24 Y.F.WJ. F,I,y, ff.L.A m L.M. T m B7 preferred F,W,Y (5/5) 1 "Anchor F,W,Y (4/5) F.W.Y 1 "Anchor L,I,V,M (3/5) P (3/5) V,l,L,V,M, WXA deleterious D,E (3/5); P(5/5); D,E (3/5) G (4/5) Q,N (4/5) D,E (4/5) m G(4/5); A(3/5); Q,N (3/5) 1° Anchor 1° Anchor B27 R,H,K F,Y, L,WM, A 1" Anchor 1° Anchor B44 E,D F.W.Y.L^M.V.A 1" Anchor 1° Anchor B58 A.T.S F,W,Y,LJ, V.M.A 1° Anchor 1° Anchor B62 Q,L,/, V,M, F.W.Y.Λ/J, V.L.A P POSITION E 0 0 0 C-terminus MOTIFS Al preferred G,F,Y,W 1 "Anchor D.E.A Y,F,W D,E,Q,N Y.F.W 1 "Anchor 9-mer S,T,M Y deleterious D.E R,H,K,L,I,V M.P CΛ C 00 CΛ Al preferred G,R,H,K A.S.T.C.L.I 1 "Anchor G,S,T,C A,S,T,C L,I,V, D,E 1 "Anchor 9-mer V,M, O,E ,S Y m deleterious R,H,K,D,E, D,E P.Q.N R,H,K P.G G.P CΛ P,Y,F,W m m TJ c m POSITION 0 0 0 0 0 19] C-terminus or C-terminus Al peferred Y,F,W 1 "Anchor D,E,A,Q,N A Y.F.W.Q.N P,A,S,T,C G,D,E 1 "Anchor 10-mer S,T,M Y deleterious G,P R,H,K,G,L,I D,E R,H,K Q,N,A ,H,K,Y,F, R,H,K V,M W CΛ C DO CΛ Al preferred Y,F,W S.T.CL.I.V 1 "Anchor Y.F.W P,G Y.F.W 1 "Anchor 10-mer M D,E,Λ,S Y m CΛ deleterious R,H,K R,H,K ) D,E, P,R,H,K Q,N m P,Y,F,W m TJ C m A2.1 preferred Y,F,W 1 "Anchor Y.F.W s,τ,c Y,F,W 1 "Anchor 9-mer M . y.Q, V,L,I,MΛ T A, T deleterious D,E,P D.E.R.K.H R,K,H D.E.R.K.H A2.1 preferred A.Y.F.W 1 "Anchor L,V,I,M F,Y,W, 1 "Anchor 10-mer LMJ. Q, L.V.I.M V,L,J,M.A, T A. T deleterious D,E,P D,E R,K,H,A R,K,H D,E,R, R,K,H K,H POSITION 0 0 0 0 C- or terminus C-terminus A3 preferred R,H,K 1 "Anchor Y,F,W P,R,H,K,Y, Y.F.W 1 "Anchor L.M.V.I.S, F,W K,Y,R,/ , ,Λ A,T,F,C,G D CΛ C deleterious D,E,P D,E DO CΛ A 1 1 preferred 1 "Anchor Y.F.W Y,FW Y.F. Y,FW 1 "Anchor V,T,L,M,I, K„RY,H m S,A,G,N,C, CΛ D,F m m deleterious D,E,P TJ A24 preferred Y,F,W,R,H,K 1 "Anchor S,T,C Y,F,W Y,F,W 1 "Anchor c 9-mer Y,F,W,M F.L.I.W m deleterious D,E,G D,E Q,N,P D,E,R,H ( K G A,Q,N A24 preferred 1 "Anchor Y.F.W.P 1 "Ancho 10-mer Y,F,W,Λ F.L.I.W deleterious G,D,E Q,N R,H,K D,E Q,N D,E,A A3101 preferred R,H,K 1 "Anchor Y,F,W Y,F,W Y.F.W A,P 1 "Anchor M,V/I> , R,K I,S deleterious D,E,P D,E A,D,E D,E D,E D,E POSITION E 0 0 0 0 0 C- or terminus C-terminus A3301 preferred 1 "Anchor Y,F,W A,Y,F,W 1 "Anchor M,V,A,L,F, R,K I.S.T deleterious G,P D,E CΛ C DO A6801 preferred Y,F,W,S,T,C 1 "Anchor Y,F,W,L,I, Y.F.W 1 "Anchor CΛ A,V,T,M,5, V,M R, L.I m deleterious G,P D,E,G R,H,K CΛ m m B0702 preferred R.H.K.F.W.Y 1 "Anchor R,H,K R,H,K R,H,K R,H,K P,A 1 "Anchor TJ P c L,M,F,W, Y I V m deleterious D,E,Q,N,P D.E.P D,E D.E G.D.E Q,N D,E B3501 preferred F,W,Y,L,I,V,M 1 "Anchor F,W,Y F.W.Y 1 "Anchor P L.M.F.W.YJ, V,A deleterious A,G,P POSITION E 0 0 0 0 0 C- or terminus Xterminus B51 preferred L.I.V.M.F.W.Y 1 "Anchor F,W,Y s,τ,c F,W,Y F.W.Y 1 "Anchor P L,I,V,F,W, Y.A.M deleterious A,G,P,D,E,R ) H,K ) D,E D,E,Q,N G,D,E S,T,C CΛ C DO CΛ B5301 preferred L.I.V.M.F.W.Y 1 "Anchor F,W,Y S.T.C F,W,Y L,I,V,M,F, F.W.Y 1 "Anchor P W,Y I,M,F,W,Y, A.L. V m CΛ deleterious A,G,P,Q,N R,H,K,Q,N D,E X m m 50 B5401 preferred F,W,Y 1° Anchor F,W,Y,L,I,V L,I,V, A,L,I,V,M F,W,Y,A,P 1 "Anchor P M A,T,I,V,A m M,F. W, Y deleterious G.P.Q.N.D.E G,D,E,S,T,C R,H,K,D,E D,E Q,N,D,G,E D,E Italicized residues indicate less preferred or "tolerated" residues. The information in Table II is specific for 9-mers unless otherwise specified. Table III POSITION MOTIFS l υ anchor 1 Θ 0 I" anchor 61 0 DR4 preferred F, M, Y,L, I, M T I V, S, T, C, P, A, M,H, M,H V, W L,I,M deleterious w. R, W,D,E DRl preferred M, F, L, I, V, P, A, M, Q V, M, A, T, S, P, M, A, V,M W, Y L. C CΛ C deleterious C C,H F,D C, W,D G, D, E, D DO CΛ DR7 preferred M, F, L, I, V, M W A I, V, M, S, A, C, M ι,v W, Y T.P.L m deleterious c, G, G, R,D N G CΛ m m DR Supermotif M, F, L, I, V, V, M, S, T, A, C, W, Y P.L.I TJ c m DR3 MOTIFS 1 ° anchor 1 a 1° anchor 4| g |1" anchor 6 motif a L, I, V, M, F, preferred Y D motif b L, I, V, M, F, D.N.Q.E, preferred A,Y S, T K,R,H Italicized residues indicate less preferred or "tolerated" residues. Table IV: HLA Class I Standard Peptide Binding Affinity. Table V. HLA Class II Standard Peptide Binding Affinity. Table VI Allelle-specific HLA-supertype members HLA-supertype Verified" Predicted 0 Al A*0101, A*2501, A*2601, A*2602, A*3201 A*0102, A*2604, A*3601, A*4301, A*8001 A2 A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*0208, A*0210, A*021 1, A*0212, A*0213 A*0209, A*0214, A*6802, A*6901 A3 A*0301, A*1101, A*3101, A*3301, A*6801 A*0302, A*1102, A*2603, A*3302, A*3303, A*3401, A*3402, A*6601, A*6602, A*7401 A24 A*2301, A*2402, A*3001 A*2403, A*2404, A*3002, A*3003 B7 B*0702, B*0703, B*0704, B*0705, B*1508, B*3501, B*3502, B*3503, B* 1511, B*4201, B*5901 B*3503, B*3504, B*3505, B*3506, B*3507, B*3508, B*5101, B*5102, CΛ c B*5103, B*5104, B*5105, B*5301, B*5401, B*5501, B*5502, B*5601, DO 8*5602, B*6701, B*7801 CΛ B27 B* 1401, B*1402, B*1509, B*2702, B*2703, 8*2704, B*2705, B*2706, 6*2701, B*2707, B*2708, B*3802, B*3903, B*3904, B*3801, 8*3901, B*3902, B*7301 B*3905, B*4801, B*4802, 6* 1510, B* 1518, 8* 1503 B44 B*1801, B* 1802, B*3701, B*4402, B*4403, B*4404, B*4001, B*4002, B*4101, B*4501, B*4701 , B*4901, B*5001 m B*4006 CΛ B58 B*5701, B*5702, B*5801, 8*5802, B*1516, B* 1517 m B62 B*1501, 8*1502, B* 1513, B*5201 8*1301, 6*1302, 6* 1504, 6*1505, 6* 1506, 6* 1507, m 6*1515, 6*1520, B* 1521, B* 1512, B*1514, B* 1510 TJ c Verified alleles include alleles whose specificity has been determined by pool sequencing analysis, peptide binding assays, or by analysis m of the sequences of CTL epitopes. b. Predicted alleles are alleles whose specificity is predicted on the basis of B and F pocket structure to overlap with the supertype specificity. §o- » cθ Q π <o oι π o ) α> ( θ o> ( D * to o) n ) (θ tt) (D (ø ια o) r (θ cn o> cn (o n cn (D (θ C) io α *» ^ o> β r*» OS r^ eD φ r * > σι 05 co co co co r- " co r * - r- r-. co cn r-. co e cn ro r» N o ■ 3 a « O TM C0s —- ~ ffi. — ^ oi fla oi ffi o πi ^ ^ ^ a co a a o V B 3 a ιn iθ α3 θ 1 . Λ N N θ W N W - ffl - n n π o o ) _ . n o> o - β — w , S β " C M C j " to w o N σ> ( θ 'Λ N <o ^ <θ tti eD N ^ J « l D T . oι o r ι r; n ^ N 0> ι - - " ffl N β M0 in σ> Λ 0 O t0 ^ ffl [D l0 S N 0l Λ N p N N w ' σ » HCV ADZ Super Motif with Binding Information Conservancy Ffβq. Position Scquencα A'0201 A'0202 A'0203 A'0206 A*6B02 93 13 2673 DTRCFDSTV 93 13 2673 DTΠCFDSTVI 66 12 21 DVKFPGGGQI 0.0001 B6 12 21 DVKFPGGGQW 79 11 750 EΛALENLV 100 14 2794 EΛ TΠYSΛ CO c 86 12 2237 EANLLWDOE CO 93 13 1377 EIPFYGKA CO 93 13 1377 E1PFYGKAI 0.0001 too 14 281 ELΓΓSCSS V 00002 79 11 666 ELSPLLLST 79 11 666 ELSPLLLSTT m B6 12 2245 EMGGNrm 0.0003 co ββ 12 1731 EQFKOKΛL B6 12 1731 EQFKOKALGL m m 86 12 1731 EQFKOKALGLL 66 12 1342 ETΛGA LV 86 12 1342 ETAGAΠLW 86 12 1342 ETAGAΠLWL 86 12 1342 ETΛGARLWLΛ m 66 12 1207 ETTMHSPV 66 12 1207 Eπ RSPVFT 8β 12 1659 E TSTWV 86 IZ 1S59 EWTSTWVL 0.0001 86 12 1659 EWTSTWVLV 0.0004 93 13 130 FΛDLMGYI 79 11 130 FADLMGYIPL 79 11 130 FADLMGYIPLV 100 14 1927 FASRGN1W 86 12 1927 FASRGNI tVSHT 100 14 1773 FISGIQYL 100 14 1773 FISGIQYLA 0.1000 too 14 1773 FISGIQYLAGL 79 11 1304 FLΛDGQCSGGA 86 12 177 FLLALLSCLT 93 13 72B FLLLΛDAΠV 0.2800 0.0460 0.0670 0.0150 0.3600 86 12 1228 FQVAHLHA 86 12 1228 FQVAHUIAPT 79 11 2646 FQYSPGQFW 100 14 2792 FTEAMTRYSA 93 13 15Θ7 FTGLTHIDA o © ε o p=ϋ c o o o D o a — O o o o en o o o o o o o o en o o α o o o σ o b i 1 eH 11CV API Super Motif with Binding Inrprmation Conservancy Fieq. Position Sequence A'0201 A'0202 A'0203 A * 0206 A'6β02 79 11 2918 RIHGLSAFSL 0.0280 0.0055 0.0160 0.0002 0.0032 79 11 2611 RLIVFPDL 79 11 2611 RUVFPD GV 0.0890 0.0110 1.0000 0.0100 0.0050 79 t 1 1618 RLKPUHGPT 86 12 1029 BLLΛP1TA 86 12 1347 RLVVLATA C/> 86 c 12 1347 RL VLΛTAT 100 14 619 RL HYPCT CO CΛ 66 12 317 R AWDMMM H 93 13 635 Π YVGGVEHΠL H B6 12 2243 nOCMGGNI C 88 12 2243 RQEMGGNΠ " — 1 m 86 12 2243 ROE GGNftRV c/> 79 11 I2B4 RTGVRTIT 79 11 1284 RTGVRTΠT m 100 14 2621 RVCEKMAL m 66 12 2621 RVCEKMALYDV — 1 B6 12 2252 RVESENKV D 86 12 2252 RVESE KW 0.0001 c 79 11 2100 ΠVGOFHYV I- B6 12 156 RV EDGVNYA m 86 12 156 . RVLEDGVNYAT 86 12 2833 RVYYLTRDPT 79 11 1655 SADLEWT 79 11 1655 SADLEWTST 79 11 2212 SAPSLKAT 79 11 2212 SAPSLKΛTCT 93 13 2207 SASQLSΛPSL 100 14 175 SIFLLALL 86 12 175 SIFLLALLSCL 100 14 1470 SLDPTFTI 86 12 1470 SLDPTFTIET 79 11 1470 SLDPTFTIEΠ 79 11 2926 SLHSYSPGEI D.000B 86 1 -ά i OS i o TunDf ' iQV n nno? 100 14 2178 SMLTDPSHI 0.0053 100 14 2178 SMLTOPSIIIT 100 14 2178 SMLTDPSHITA 66 12 2163 SQLPCEPEPDV 93 13 2209 SQLSAPSL 79 11 2209 SQLSAPSL Λ 79 11 2209 SQLSAPSLKΛT o cn « ■ o o σ o o o o o o d o S a o σ> o o o en o en o o o O o «— o o o o o o o o en o cn o «n — o o — a tβ β ιo n βj ιθ "" * - ffc tϊ ^ co cD co σ o to n s o ui in in in n σ oi cn m in O O CO CO ^ α o ) θ3 to co to o r^ θ3 C cc & o ifi 't v T v i o iø 'i Pi o oi Φ n n oi Φ oι σι ιr — * - to ιo » cn β α α iø iβ S MB iv Q) tO CD CD C O CM C M CM CM " r^ *— — ιn oD in wι iΛ -- »- ιΛ ^ ■ CM — -<- CM CM .- »- — - — — CM CM CM CM C M — T -- C M C M C M CM » - » - — ■ » - '- ^ , C e '.n »- C\J C>j e C y- cn o o o ° to oi α io to o α o n o α iα io iD io ifl ca C) O) to to cθ co o) θ) θi σι θ) to cn n cσ to co ,_ » o_ _ o_ _ CO I _ N o to ιo o N r» ι*. p. _. 10 Ol IS O IB UCV AOZ Super Motif with Biπdinp Informntign Conservancy Freq Position Sequence A'0201 A'0202 A'0203 A*02D6 A*6802 79 11 I5S4 YQATVCARAQA 79 11 1106 YTNVDQDL 79 11 1106 YTNVDQDI.V 86 12 276 YVGOLCGSV 0.0018 86 12 276 YVGDLCGSVFL 93 13 637 YVGGVEHT. 0.0008 O B6 12 1939 YVPESDAA c ββ 12 1939 YVPESDAAA 00 B6 12 1939 YVPESDAΛΛRV CO 555 m co m m c ι- m o o — o o o o o ^ O o o o 1- o o •- m o o *- o © o - v tr w w ifl tn ifl β o © n ■ »» © n tt β- O M , ιn e> ^ o o^r o o *~ ^ cM to in ui o w ^ ID N * - « - N t - ^ N - ^ *- ^ « ^ N W - ^ " ^ W W --- - πn«- ^ ^ V n ^ N ^ ^ V ^ ^ N N ^ 0 π W N ft ' p > ft ' w o w tj o) φ σι θ) (D m σ) m ^ n Λ θ θ * n ^ o σ. (θ iD α o) ft > nπ a ff i C5 0 o 2 ' β ? ^ Λ θ> t D tβ α n cn o □ IICV A24 Super Motif With Binding Information Sequence Position No. ol Sequence Conservancy A'2401 Ammo Acids Frequency <%) F1SGIQYL 1773 8 14 100 RSGIQYIAGL 1773 11 14 100 FLLALLSCL 177 9 12 86 FTEA TRY 2792 8 τ'4 100 FTGLTHIDAHF 1567 11 13 93 FTTLPALSTGL but 11 11 79 FWAKHMWNF 1765 9 12 86 69000 FWAKHMWNH 1765 10 12 86 GFADUJIGY 129 8 13 93 GFADLMGYI 129 9 13 93 GFADLMGYIPL 129 11 11 79 GFSYDTRCF 2669 9 11 79 O c GIQYLAGL 1776 8 14 100 GIQYLAGLSTL 1776 11 14 CO too CO GLPVCQDHL 1652 0 13 93 GLFVDQOHLEF 1552 11 12 06 GLSAFSLHSY 2921 10 11 79 00001 GLSTLPGNPAI 1782 1 I 11 79 GLIHIDAHF 1569 9 13 93 m GLTHIDAHFL 1569 10 13 93 co GTFPINAY 2063 8 11 79 GVAGALVAF 1863 9 12 86 m GVAKAVOF 1193 8 11 79 m GVLAΛLAAY 1670 9 12 88 GVLAALAAYCL 1670 11 12 86 GVNYATGNL 161 9 11 79 GVRVCcKM 2619 a 14 100 2619 10 14 m GVRVCEKMΛL 100 GVRVCEK ALY 2619 11 14 100 GVRVLHX.VNY 154 11 12 86 GWCAAIL 1900 8 11 79 GWRLLAPI 1027 8 11 79 GWRLLAPITAY 1027 11 11 79 GYGAGVAGAL 1859 10 12 86 0.0003 GYIPLVGAPL 135 10 11 79 0.0057 GYRRCRASGVL 2728 11 12 86 HLHQNiVDVQY 696 11 .11 79 HLPYIEQG 1719 9. 11 79 HMWNFISGI 1769 9 13 93 HMWNF1SGDY 1769 11 13 93 HTPVNSWL 2855 8 12 86 HTPVNSWLG I 2855 11 12 86 HVGPGBGAVOW 1910 11 11 79 IFLLALLSCL 176 10 12 86 ILGGWVAAQL 1816 10 12 86 00026 HCV Λ24 Super Motif With Binding Information TΎSTYGKF 1297 θ 13 93 TΥSTΥGKR 1297 9 12 86 0.0230 VFTGLTH1 1S66 8 13 93 VIOTLTCGF 122 9 i> 2 86 VLAALAAY 1671 8 12 86 VLAALAAYCL 107 i m 12 86 0.0070 VLEDGV Y 157 β 12 86 VLNPSVAATL 1258 10 14 100 V ΓTSCGNΠ. 2737 10 11 79 VLVDILAGY 1ΘS2 9 11 79 VLVGGVLAAL 1666 10 12 • 86 VMGSSYGF 2639 8 11 79 V GSSYGΓOY 2639 10 It 79 O VTQTVDFSL 1463 9 12 86 c VTBHADVI 1138 a 11 79 CO VATDAL 1439 8 11 79 CO WGWCAAI 1898 9 11 79 G CAAIL 1898 10 11 79 TST VL 1660 8 12 86 VYUPRRGPRL 34 11 13 93 0.0016 m WMNRLIAF 1920 8 14 100 co WVLVGGVL 1665 8 12 86 WVLVGGVLAAL 1665 11 12 86 m YIPLVGAPL 136 9 11 79 m YLAGLSTL 1779 8 14 100 YLKGSSGGPL 1165 10 12 86 YLKGSSGGPU. 1165 11 12 06 Yii nRGPn 35 10 13 93 00001 YLVTRHΛDVI 1136 10 11 79 m YT VDQDL 1106 8 11 78 YINVOQOLVGW 1106 11 11 79 YVGtXOGSVF 276 10 12 86 YVGDLCGSVFL 276 11 12 86 YVGGvBHFL 637 9 13 93 YYBGLDVSVI 1422 10 14 100 260 3 821 tXZ.6ϊ/00Sfl/I3d 68ΪU/Ϊ0 OΛV 621 X_.6ϊ/00Sfl/I3d 68ΪU/Ϊ0 OΛV 9CI ϊLL6l/00SΛ/lDd 68ΪU/Ϊ0 OΛV o o α o o o o o o o o o o σ o o o o o o o o σ o o o o σ o o o σ o o σ o o o o o o o o o o « β iD i o ιn v o <D ifl '- Λ βt [fl N 7-CV B(S2 Si Mpiif Sequence Position No. ol Sequence Conservancy Amino Acids Frequency (%) SPTHWPESDA 1935 12 86 SQLTCEPEPOV 2163 12 86 SVAATIGFGAY 12.2 14 100 TLGFGAYMSKA 1266 12 86 TU-F ILGGWV 1B11 12 86 TPCTCGSSOLY 1126 11 79 TPGLPVCQDHL 1550 13 93 TPVNSWLGNII 2856 12 ββ TVLDQAETAGA 1336 12 66 VLCECYDAGCA 1521 11 79 CO c VLVDILAGYGA 1B52 11 79 VLVGGVLAALA 1666 12 86 CO VQPEKGGRKPA 2600 CO 11 79 VQWMNRUAFA 1318 14 100 WCAAILRRHV 1801 11 7B WVLVGGVLAAL 1665 12 66 YLKGSSGGPLL 1165 12 D6 m YLVAYQATVCA 1590 12 86 co YOATVCAHAQA 1594 11 79 YVGDLCX3SVFL 276 12 66 m YVPESDAAARV 1939 12 86 m 426 m IICV Λ03 Motif with Uiiuling Information Sequence Position No ol Sequence Conservancy A'0301 Amino Acids Frequency (%) WGPTOPRH 107 0 12 OB WGPTDPRRR 107 9 12 Θ6 WGPTDPRR SR 107 11 12 66 WLLSPRGSR 96 9 12 86 0000Θ W NRUΛF 1920 B 14 100 WMNRLIAFA 1920 9 14 too 00003 W NRUAFASR 1920 11 14 100 W NSTGFTK 557 9 11 79 00530 VWLVGGVLA 16G5 9 12 66 WVLVGGVLΛA 1665 10 12 06 CO YΛTGNIPGCSF 164 11 12 06 c YDAGCAWY 1526 0 11 79 CO YDIHCDECH 1315 10 12 06 CΛ YGΛGVAGA 1060 0 12 06 YGΛGVAGALVA 1060 II 12 06 YGFQYSPGQR 2644 to 11 79 Yl±PRRGPR 35 9 13 93 00054 m YLVAYQATVCA 1590 11 12 86 YSPGEINR 2930 β 11 79 YSPGEINRVA 2930 10 11 79 m YSPGQRVEF 2648 9 11 79 m YSTYGKFLA 1298 9 12 06 YVGDLCGSVF 27G 10 12 86 YVGGVEHR 637 0 14 100 YVPESDΛA 1939 0 12 86 YVPESDΛΛΛ 1939 9 12 06 m YVPESDAΛAR 1939 10 12 06 00003 567 3 o o b o 0 © o cn oi en ø _ _ ø Ξ H _ * O N i. N ^ ca S to Table XVIII IICV Λ24 Motif With Binding Information Sequence PosKion No. ol Sequence Conservancy A * 2401 Amino Acids Frequency (%) AWDMMMNW 319 0 12 06 AYAAQGYKVL 1248 10 11 79 00009 AYYHGLDVSVI 1421 11 14 too CYDAGCAW 1525 0 11 79 CYDAGCAWYEL 1525 11 11 79 OFSLDPTF I46Θ 0 14 100 DFSLDPTFTI 1468 10 14 100 FWAKHMWNF 1765 9 12 86 69000 FWAKHMWNFI 1765 10 12 86 GFADLWGYI 129 9 13 93 GFΛDLMGYIPL 129 11 11 79 GFSYDTRCF _6C9 9 11 79 GWRLLAPI 1027 0 11 79 CΛ GYGAGVΛGAL 1059 10 12 06 00003 C GYIPLVGAPL 135 10 11 79 00057 CD GYRRCRASGVL 2720 11 12 06 CΛ HMWNFISG1 1769 9 13 93 IFLLALLSCL 1 6 10 12 86 IMAKNEVF 2591 8 12 66 KFPGGGO 23 β 13 93 m LFN1LGGW 1813 8 12 06 CΛ LWARMILMTHF 2872 11 12 86 LWFOEMGGM 2241 10 12 86 m LYLVTRHADVI 11 11 79 m 1135 MWNRSGI 1770 0 14 too MWNFISGIQYL 1770 11 14 too MYVGGVEHRL 636 10 13 93 00270 NFISGIQYL 1772 9 14 too 00170 PMGFSYDTRCF 11 11 79 m 2667 QFKQKALGL 1732 9 12 86 QFKQKALGLL 1732 10 12 86 QWMNRUAF 1919 9 14 100 QYLAGLSTL 1778 9 14 100 00480 QYSPGQRVEF 2647 10 11 79 o.otao QYSPGQRVEFL 2647 11 11 79 flMAWDMMMNW 317 to 12 86 RMILMTHF 2075 a 12 86 RMILMTHFF 2075 9 12 86 RMYVGGVEHHL 635 11 13 93 SFSIFLLAL 173 9 14 100 SFSIFLLALL 173 10 14 too 00041 SMLTDPSHI 2178 9 14 100 SWDQMWKCL 160B 9 11 79 SYLKGSSGGPL 1164 11 12 86 TWMNSTGF 556 8 11 79 IICV Λ24 Motif With Binding Infonnatioii Sequence Position No. ol S Seeqquueennccee C Coonnsseerrvvaannccyy A'2401 Amino Acids Frequency (%) TWVLVGGVL 1664 9 12 OG TYSTYGKF 1297 8 13 93 TYSTYGKFL 1297 1 122 8866 00230 VFTGLTHI 1566 8 13 93 VMGSSYGF 2639 8 11 79 VYLLPRRGPRL 34 11 1 133 9 933 0.0016 WMNR IAF 1920 8 14 100 YYRGLDVSVI 1422 10 14 100 CΛ 5 533 2 C O CΛ m CΛ X m m 3J c ι- m g 3e n i fl ffι f) - r oι ι t o B n - - 'J θι — en 5 n w σ> o ■ > σ) r ϊ i-. «' h- ; c\] lD t , l ι , '» en ' , *- ''* r - '*" c o o- > o n w π ■ W ' « - ' - r>ι tM n ' - ιM π cv - - ' Table XXb HCV DK 3Λ Molil Wil Uiiulinμ lufoi million Core Sequence Exemplniy Sequence OTO on i DR4w4 DFMvolS On5v»l l DπSw12 DR6 l9 OR7 DΠBW2 ore Df FLΛOGGCSO YGKFIΛOGGCSGGΛY FSLOPTFTI TVOFSIDPTFTIETT 0. 1600 IEGEPGDPO PPLEGEPGOPOLSO ■0.0017 LPCEPEPDV GSQLPCEPEPDVAVL -0.0017 MΛWD M N GHΠMΛVVD MMIMWSPT 00200 00015 0.0044 0.1600 d.0(j79 0.0080 0.0017 0.0230 MLTOPSHIT LTSMLTDPSHITAET 0.0004 0.0740 -0.0003 SADLE r MΛCMSΛOLEVVTSTW VATOALMTO VWVATDALMTGYTG 1.1000 0.0040 0.0047 0.0014 0.0006 0.0029 0.0400 0.0029 VCQDHIEFW GLPVCQDHLEFWESV 0.0063 VFPDLGV lV RLIVFPDIGVRVCEK VFTDNSSPP RSPVFTDNSSPPAVP CΛ VIXECYDΛG DSSVLCECYDΛGCΛW ■ 0.0017 C CO VIEDGVNYA GVnvLEOGVNYΛTGN 0.0007 0 0000 • 0.0002 CΛ VLVOILΛGY VOPEKGGFK VFCVOPEKGGΠKPΛΠ YDLELITSC QPEYDLELirsCSSN 0.0003 -0.0002 YSIEPLDLP. GΛCYSIEI'LDLPQII YVGOLCGSV SΛMYVGLXCGSVFLV •0.0017 m YVPESDΛAA PTHYVPESDΛAΛ VT 0.0220 CΛ 19 m m m Table XXd HCV 3B Motif Bindin g Data raexKKCo VRATHΠSE nLGvrwTfKTsεnso SDLYLVTRHAOVIPV 00022 CΛ C 00 CΛ m CΛ m m m TABLE XXI. Population coverage with combined HLA Supertypes PHENOTYPIC FREQUENCY Caucasian North Japanese Chinese Hispanic Average HLA-SUPERTYPES American Black a. Individual Supertypes A2 45.8 39.0 42.4 45.9 43.0 43.2 A3 37.5 42.1 45.8 52.7 43.1 44.2 B7 38.6 52.7 48.8 35.5 47.1 44.7 Al 47.1 16.1 21.8 14.7 26.3 25.2 A24 23.9 38.9 58.6 40.1 38.3 40.0 B44 43.0 21.2 42.9 39.1 39.0 37.0 B27 28.4 26.1 13.3 13.9 35.3 23.4 B62 12.6 4.8 36.5 25.4 11.1 18.1 B58 10.0 25.1 1.6 9.0 5.9 10.3 b. Combined Supertypes A2, A3, B7 83.0 86.1 87.5 88.4 86.3 86.2 A2, A3, B7, A24, B44, Al 99.5 98.1 100.0 99.5 99.4 99.3 A2, A3, B7, A24, B44, Al, 99.9 99.6 100.0 99.8 99.9 99.8 B27, B62, B58 }\CV ANALOGS B7 Fixed Al A2 A3 A24 AA Sequence lil Super Anchor Nomen. Molil Super Super Mo Molil Molil Molil Fixer CΛ C DD CΛ m CΛ m m m Table XXIII. Immunogenicity of identified supermotif-bearing peptides Immunogenicity Human Transgenic mice Bamaba; Barnaba; Supermotif Peptide Sequence Protein Position patients contacts Chisari Pape overall Frequency Response A2 1073 05 LLFNILGGWV NS4 1812 1/6 7/17 2/21 0/6 10/50 6/6 6.4 (1 7) 1090 18 FLLLADARV NS1/E2 728 2/6 7/17 1/21 0/6 10/50 5/6 9.5 (3.0) 1013 02 YLVAYQATV NS4 1590 1/6 4/17 1/21 0/6 6/50 5/6 8.5 (3.7) c 2 1090 22 RLIVFPDLGV NS5 2578 2/6 5/17 0/21 0/6 7/50 0/6 - 1013 1002 DLMGYIPLV Core 132 2/6 7/17 1/21 1/6 11/50 5/6 8.8 (2.6) 24 0073 WMNRLIAFA NS4 1920 1/6 3/17 2/21 1/6 7/50 0/6 - CΛ 24 0075 VLVGGVLAA NS4 1666 1/6 6/17 3/21 1/6 1 1/50 0/6 - C 1 174 08 DO HMWNFISGI NS4 1769 3/6 3/17 2/21 0/6 8/50 6/6 6.4 (1.7) CΛ 1073 06 ILAGYGAGV NS4 1851 2/6 3/17 0/21 0/6 5/50 3/6 54.7 (3 3) H 1073 07 YLLPRRGPRL CORE 35 2/6 5/17 7/21 1/6 17/50 4/6 59.1 (7.2) C 24 0071 LLFLLLADA NS1/E2 726 2/6 9/17 0/21 0/6 1 1/50 0/6 - m 1 0119 YLVTRHADV NS3 1131 6/6 10/17 0/21 1/6 17/50 0/6 - CΛ A3 1 0952 KTSERSQPR CORE 51 2/16 1/4 3/12 0/6 6/38 3/6 23 4 (1.3) m 1073 1 1 RLGVRATRK CORE 43 4/16 1/4 7/12 1/6 13/38 3/6 42.2 (1.2) m 1 0955 QLFTFSPRR ENV 290 1/16 0/4 6/12 1/6 8/38 1073 13 RMYVGGVEHR NS1/E2 632 5/16 1/4 4/12 1/6 11/38 2/6 2.8 (1.1) TJ 1 0123 LIFCHSKKK NS3 1396 6/16 1/4 4/12 2/6 13/38 3/6 4.4 ( 1.1) I- 1073 10 GVAGALVAFK NS4 1863 3/16 0/4 6/12 2/6 1 1/38 6/6 56.5 (1.7) m 24 0090 Is) VAGALVAFK NS4 1864 4/16 1/4 6/12 0/4 1 1/38 1/6 7.1 σ> 24 0086 TLGFGAYMS NS3 1262 6/16 2/12 2/5 10/33 B7 1145 12 LPGCSFSIF CORE 169 2 3/10 5 Table XXIV. Human and murine IMHC-peptide binding assays established using purified MHC molecules and gel filtration chromatography A. Class I binding assays Radiolabeled peptide Species Antigen Allele Cell line Source Sequence Notes Human Al A*0101 Steinlin Hu. J chain 102-110 YTAWPLVY no NEN in PI cocktail A2 A*0201 JY HBVc 18-27 F6->Y FLPSDYFPSV " A2 A*0202 P815 (transfected) HBVc 18-27 F6->Y FLPSDYFPSV " A2 A*0203 FUN HBVc 18-27 F6->Y FLPSDYFPSV " A2 A*0206 CLA HBVc 18-27 F6->Y FLPSDYFPSV A2 A*0207 721.221 (transfected) HBVc 18-27 F6->Y FLPSDYFPSV A3 GM3107 non-natural (A3CON1) KVFPYALINK " Al l BVR non-natural (A3CON1) KVFPYALINK " CΛ C A24 A*2402 AS1 16 non-natural (A24CON1) AYIDNYNKF " DO A31 A*3I0I SPACH non-natural (A3CON1) KVFPYALINK ' CΛ A33 A 4 3301 LWAGS non-natural (A3CON1) KVFPYALINK A28/68 A*6801 C1R HBVc 141-151 T7->Y STLPETYVVRR ' A28/68 A*6802 AMAI HBV pol 646-654 C4->A FTQAGYPAL B7 B*0702 GM3107 A2 sigal seq. 5-13 (L7->Y) APRTLVYLL m B8 B*0801 Steinlin HVgp 586-593 Yl->F, Q5-> FLKDYQLL CΛ B27 B*2705 LG2 R 60s FRYNGLIHR m B35 B*3501 C1R. BVR non-natural (B35CON2) FPFKYAAAF m B35 B*3502 TISI non-natural (B35CON2) FPFKYAAAF B35 B*3503 EHM non-natural (B35CON2) FPFKYAAAF B44 B*4403 PITOUT EF-1 G6->Y AEMGKYSFY B51 AS116 non-natural (B35CON2) FPFKYAAAF m B53 B*5301 AMAI non-natural (B35CON2) FPFKYAAAF Isi B54 B*5401 KT3 non-natural (B35CON2) FPFKYAAAF Cw4 Cw*0401 C1R non-natural (C4CON1) QYDDAVYKL C 6 Cw*0602 721.221 transfected non-natural (C6CON I) YRHDGGNVL Cw7 Cw*0702 721.221 transfected non-natural (C6CON I) YRHDGGNVL Mouse D EL4 Adenovirus ElA P7->Y SGPSNTYPEI b EL4 VSV NP 52-59 RGYVFQGL D d P815 HIV-IIIB ENV G4->Y RGPYRAFVT1 κ d P815 non-natural (KdCONl) KFNPMKTYI L d P815 HBVs 28-39 IPQSLDSYWTSL Table XXIV. Human and murine MHC-peptide binding assays established using purified MHC molecules and gel filtration chromatography B. Clas! 5 II bindin g assays Radiolabeled peptide Species Antigen Allele Cell line Source Sequence Notes Human DRl DRB1*0101 LG2 HA Y307-319 YPKYVKQNTLKLAT DR2 DRB1 *1501 L466.1 MBP 88-102Y VVHFFKNIVTPRTPPY DR2 DRBl' 1601 L242.5 non-natural (760.16) YAAFAAAKTAAAFA DR3 DRB1*0301 MAT MT 65kD Y3-13 YKTIAFDEEARR optimal assay pH is 4.5 DR4 4 DRB 1*0401 Preiss non-natural (717.01) YARFQSQTTLKQKT DR4wl0 DRB 1 *0402 YAR non-natural (717.10) YARFQRQTTLKAAA DR4wl4 DRB 1*0404 BIN 40 non-natural (717.01) YARFQSQTTLKQKT DR4wl5 DRB 1*0405 KT3 non-natural (717.01) YARFQSQTTLKQKT DR7 DRB 1*0701 Pitout Tet. tox. 830-843 QYIKANSKFIGITE CΛ C DR8 DRB 1 *0802 OLL Tet. tox. 830-843 QYIKANSKFIGITE CO DR8 DRB 1*0803 LUY Tet. tox. 830-843 QYIKANSKFIGITE CΛ DR9 DRB 1 *0901 HID Tet. tox. 830-843 QYIKANSKFIGITE DR1 1 DRB1*1101 Sweig Tet. tox. 830-843 QYIKANSKFIGITE DR12 DRB1* 1201 Herluf unknown eluted peptide EALIHQLKINPYVLS DRB DRB1*1302 H0301 Tet. tox. 830-843 S->A QYIKANAKFIGΠΈ m DR51 DRB5*0101 GM3107 or L416.3 Tet. tox. 830-843 QYIKANAKFIGITE CΛ DR51 DRB5*0201 L255.1 HA 307-319 PKYVKQNTLKLAT m DR52 DRB3*0101 MAT Tet. tox. 1272-1284 NGQIGNDPNRDIL m DR53 DRB4*0101 L257.6 non-natural (717.01) YARFQSQTTLKQKT no NEM in PI mix DQ3.1 DQA1*0301/DQB1*0301 PF non-natural (ROIV) YAHAAHAAHAAHAAHAA Mouse IA" DB27.4 non-natural (ROIV) YAHAAHAAHAAHAAHAA optimal assay pH is 5.5 IA d A20 non-natural (ROIV) YAHAAHAAHAAHAAHAA m IA k CH-12 HEL 46-61 YNTDGSTDYGILQINSR optimal assay pH is 5.0 IA S LSI 02.9 non-natural (ROIV) YAHAAHAAHAAHAAHAA IA U 91.7 non-natural (ROIV) YAHAAHAAHAAHAAHAA IE d A20 Lambda repressor 12-26 YLEDARRKKAIYEKKK optimal assay pH is 5.0 IE k CH-12 Lambda repressor 12-26 YLEDARRKKAIYEKKK optimal assay pH is 5.0 Table XXV. Monoclonal antibodies used in MHC purification. Monoclonal antibody Specificity W6/32 HLA-class I B123.2 HLA-B and C IVD12 HLA-DQ LB3.1 HLA-DR CΛ <=■ Ml/42 H-2 class I 00 ^ 28-14-8S H-2 D b and L d c 34-5-8S H-2 D d H-2 K b C ™Λ B8-24-3 m SFl-1.1.1 H-2 K d m H Y-3 H-2 K b 6 c 10.3.6 H-2 IA k E 14.4.4 H-2 IE d , IE K MKD6 H-2 IA d Y3JP [-2 IA b , IA S , IA U Table XXVI: HCV-derived conserved high algorithm A*0201-binding peptides A2- supertype binding capacity (IC50 nM) Peptide Molecule 1st Position Sequence Consv. A*0201 A*0202 A*0203 A*0206 A*6802 A2 XRN 1073.05 NS4 1812 LLFNILGGWV 85 4.2 1 13 3.2 19 33 5 1090.18 NS1/E2 728 FLLLADARV 92 18 90 149 247 1 1 1 5 1013.02 NS4 1590 YLVAYQATV 85 20 39 16 82 33 5 1090.22 NS5 261 1 RLIVFPDLGV 79 56 391 10 370 8000 4 CΛ 1013.1002 CORE 132 DLMGYIPLV 79 80 4778 204 481 12 4 C 24.0073 NS4 1920 WMNRLIAFA 100 122 130 3.3 1609 400 4 DD CΛ 24.0075 NS4 1666 VLVGGVLAA 85 185 331 32 308 3077 4 1 174.08 NS4 1769 HMWNFISGI 92 15 10750 77 132 7547 3 1073.06 NS4 1851 ILAGYGAGV 79 116 143 5.0 755 889 3 1073.07 CORE 35 YLLPRRGPRL 92 125 6143 455 416 10256 3 m 24.0071 NS1/E2 726 LLFLLLADA 100 217 287 455 3364 3077 3 CΛ 1.01 19 LORF 1 131 YLVTRHADV 85 455 2048 3.6 71 3077 3 m m 24.0065 NS4 1891 ILSPGALVV 92 238 10750 27 1028 3077 2 1013.12 NS1/E2 686 ALSTGLIHL 85 313 7167 45 18500 10256 2 939.14 NS1/E2 696 HLHQNIVDV 85 500 3071 19 1370 1081 1 2 1090.21 NS5 2918 RLHGLSAFSL 79 179 782 625 18500 12500 1 m Table XXVII: HCV-derived conserved high algorithm A*03 and/or A*ll binding peptides A3-supertype binding capacity (IC50 nM) Peptide Molecule 1st Position Sequence Consv. A*03 A*l l A*3101 A*3301 A*6801 A3 XRN 1.0952 CORE 51 KTSERSQPR 92 69 94 67 1813 145 4 1073.1 1 CORE 43 RLGVRATRK 79 12 207 429 - - 3 1.0955 EN VI 290 QLFTFSPRR 79 15 182 621 3766 3 3 1073.13 NS1/E2 632 RMYVGGVEHR 100 15 300 95 9667 1778 3 1.0123 NS3 1396 LIFCHSKKK 100 20 32 2535 24167 333 3 CΛ C 1073.10 NS4 1863 GVAGALVAFK 85 28 4 3273 26364 1 18 3 DO 24.0090 NS4 1864 VAGALVAFK 85 46 7 3750 1 1600 258 3 CΛ 24.0086 NS3 1262 LGFGAYMSK 85 136 21 2950 22308 222 3 1 174.16 NS1/E2 557 WMNSTGFTK 79 208 74 12857 690 1429 2 1073.14 NS3 1261 TLGFGAYMSK 85 136 98 - 22308 8889 2 m 1090.23 LORF 1 183 AVCTRGVAK 79 423 240 16364 - - 2 CΛ 1090.24 NS5 2596 EVFCVQPEK 85 13750 222 - - 18 2 m 24.0103 NS1/E2 647 AACNWTRGER 85 36667 429 400 5273 4444 2 m 1073.16 NS3 1232 HLHAPTGSGK 85 19 2500 - - 2857 1 1073.12 NS3 1395 HLIFCHSKKK 100 423 - 20000 - - 1 1090.26 NS3 1395 HLIFCHSKK 100 440 10000 - - 8000 1 m A dash indicates IC50nM >30,000 Table XXVIII: HCV derived conserved B*0702 binding peptides A. High conservancy 9- and 10-mer peptides. B7-supertype binding capacity (IC50 nM) Peptide Molecule 1st Position Sequence Consv. B*0702 B*3501 B*51 B*5301 B*5401 B7 XRN 1 145.12 Core 169 LPGCSFSIF 92 28 90 100 114 6667 4 15.0048 E2 681 LPALSTGLI 85 157 2.8 1500 20000 2 15.0234 NS3 1620 KPTLHGPTPL 79 3.9 27500 - - 15.0247 NS5 2835 APTLWARMIL 79 6.3 5500 - - CΛ C 15.0042 CORE 99 SPRGSRPSW 79 14 1 1000 - - DO 15.0039 Core 57 QPRGRRQPI 92 24 CΛ 15.0218 Core 37 LPRRGPRLGV 92 29 61 1 1 . 4000 15.0060 NS5 2615 SPGQRVEFL 79 46 27500 - - 15.0043 Core 1 1 1 DPRRRSRNL 85 324 m 15.0063 NS5 2835 APTLWARMI 79 344 4583 CΛ 1292.17 NS5 2317 PPVVHGCPL 79 393 m 15.0239 NS4 1893 SPGALVVGVV 79 423 3438 m 15.0235 NS3 1621 TPLLYRLGAV 92 458 6875 909 C m Table XXVIII: HCV derived conserved B*0702 binding peptides B. Additional HCV derived B7 supermotif peptides. B7 ■supertype binding capacity (IC50 nM) Peptide Molecule 1st Position Sequence Consv. B*0702 B*3501 B*51 B*5301 B*5401 B7 XRN 29.0035 NS3 1378 IPFYGKAI 92 458 46 - 50 3 29.0040 Core 37 LPRRGPRL 92 0.85 306 - 5000 2 29.0036 Core 137 IPLVGAPL 79 13 2250 79 - 2857 2 16.0187 NS1/E2 680 LPCSFTTLPA 64 423 24000 9167 - 15 2 CΛ 29.0039 Core 169 LPGCSFSI 92 500 200 932 620 6250 2 C DO 15.0219 Core 142 APLGGAARAL 71 9.5 - - 12500 CΛ 29.0031 NS5 2869 APTLWARM 79 13 4583 - 4348 15.0231 NS3 1512 RPSGMFDSSV 71 153 - - - 29.0085 NS5 2474 LPINALSNSL 57 220 18000 1 170 - 1 11 1 1 m 29.0037 NS5 2608 KPARLIVF 85 367 3235 - 16667 CΛ 15.0237 NS4 1789 NPAIASLMAF 71 393 9000 5000 - - m 29.0118 NS5 2869 APTLWARMILM 79 423 - - 3030 m 29.0042 NS4 1720 LPYIEQGM 85 423 1375 - 7692 C. Engineered analogs of B 7 supermotif peptides. m B7- supertype binding capacity (IC50 nM) Peptide Molecule 1st Position Sequence Consv. B*0702 B*3501 B*51 B*5301 B*5401 B7 XRN 1145.12 Core 169 LPGCSFSIF 92 28 90 100 1 14 6667 4 1292.24 Core 169 LPGCSFSII 37 4364 5.3 262 1056 3 1 145.13 Core 169 FPGCSFSIF 19 1.6 132 3.2 6.7 5 A dash indicates IC50 nM >30,000. Table XXIX: HCV-derived Al- and A24-motif containing peptides A. A 1 -motif peptides HLA-A*0101 Peptide Molecule Position Sequence Conserv. binding (IC50 nM) 13.0019 NS5 2922 LSAFSLHSY 79 31 1.0509 NS5 2921 GLSAFSLHSY 79 61 1069.62 NS3 1 128 CTCGSSDLY 79 68 24.0093 NS5 2129 EVDGVRLHRY 100 167 13.0016 NS3 1241 STKVPAAY 85 1923 1.0125 NS3 1525 CYDAGCAWY 79 4032 24.0008 El 206 DCSNSSIVY 85 16667 24.0094 NS5 2720 TNSKGQNCGY 100 - 24.0096 NS3 1240 GKSTKVPAAY 85 - 24.0100 NS3 1292 TGAPITYSTY 85 - NS3 1263 VAATLGFGAY 100 NS5 2639 VMGSSYGFQY 79 NS5 2640 MGSSYGFQY 79 A dash indicates IC50 nM >25000 B. A24 -motif peptides HLA-A*2402 Peptide Molecule Position Sequence Conserv. binding (IC50 nM) 24.0092 NS4 1765 FWAKHMWNF 85 1.7 13.0075 NS4 1778 QYLAGLSTL 100 250 1073.18 NS1/E2 636 MYVGGVEHRL 92 444 13.0074 NS3 1297 TYSTYGKFL 85 522 13.0134 NS5 2647 QYSPGQRVEF 79 667 24.0091 NS4 1772 NFISGIQYL 100 706 13.0131 Core 135 GYIPLVGAPL 79 2105 24.0108 Core 173 SFSIFLLALL 100 2927 13.0132 NS3 1248 AYAAQGYKVL 79 13333 13.0133 NS4 1859 GYGAGVAGAL 85 - 1174.08 NS4 1769 HMWNFISGI 93 El 317 RMAWDMMMNW 85 NS1/E2 635 RMYVGGVEHRL 93 NS3 1422 YYRGLDVSVI 100 NS3 1468 DFSLDPTFTI 100 NS3 1608 SWDQMWKCL 79 NS3 1664 TWVLVGGVL 85 NS4 1732 QFKQKALGL 85 NS4 1732 QFKQKALGLL 85 NS4 1765 FWAKHMWNFI 85 NS4 1919 QWMNRLIAF 100 NS5 2241 LWRQEMGGNI 85 NS5 2669 GFSYDTRCF 79 NS5 2875 RMILMTHFF 85 A dash indicates IC50 nM >25000 Table XXX: Immunogenicity of A2-supertype cross-reactive binders Immunogenicity Human Transge nic mice Bamaba; Bamaba; Peptide Sequence Protein Position patients contacts Chisari Pape overall Frequency Response 1073.05 LLFNILGGWV NS4 1812 1/6 7/17 2/21 0/6 10/50 6/6 6.4 (1.7) CΛ 1090.18 FLLLADARV NS1/E2 728 2/6 7/17 1/21 0/6 10/50 5/6 9.5 (3.0) C DO 1013.02 YLVAYQATV NS4 1590 1/6 4/17 1/21 0/6 6/50 5/6 8.5 (3.7) CΛ 1090.22 RLIVFPDLGV NS5 2578 2/6 5/17 0/21 0/6 7/50 0/6 - 1013.1002 DLMGYIPLV Core 132 2/6 7/17 1/21 1/6 1 1/50 5/6 8.8 (2.6) 24.0073 WMNRLIAFA NS4 1920 1/6 3/17 2/21 1/6 7/50 0/6 - m 24.0075 VLVGGVLAA NS4 1666 1/6 6/17 3/21 1/6 1 1/50 0/6 - CΛ 1 174.08 HMWNFISGI NS4 1769 3/6 3/17 2/21 0/6 8/50 6/6 6.4 (1.7) m 1073.06 ILAGYGAGV NS4 1851 2/6 3/17 0/21 0/6 5/50 3/6 54.7 (3.3) m 1073.07 YLLPRRGPRL CORE 35 2/6 5/17 7/21 1/6 17/50 4/6 59.1 (7.2) 24.0071 LLFLLLADA NS1/E2 726 2/6 9/17 0/21 0/6 1 1/50 0/6 - 1.01 19 YLVTRHADV NS3 1 131 6/6 10/17 0/21 1/6 17/50 0/6 - m a. Data shown represents the number of positive responses over the total number of patients or contacts examined. b. Frequency represents the number of positive responses over the total number of mice examined. Response indicates the average magnitude (standard deviation) of the response in positive animals, measured in lytic units. Table XXXI: Immunogenicity of A3-supertype cross-reactive binders Immunogenicity a Human Transge nic mice Bamaba Bamaba; Peptide Sequence Protein Position patients contacts Chisari Pape overall Frequency Response 1.0952 KTSERSQPR CORE 51 2/16 1/4 3/12 0/6 6/38 3/6 23.4 (1.3) CΛ 1073.1 1 RLGVRATRK CORE 43 4/16 1/4 7/12 1/6 13/38 3/6 42.2 (1.2) C 1.0955 QLFTFSPRR ENV 290 1/16 0/4 6/12 1/6 8/38 DO CΛ 1073.13 RMYVGGVEHR NS1/E2 632 5/16 1/4 4/12 1/6 1 1/38 2/6 2.8 (1.1) 1.0123 LIFCHSKKK NS3 1396 6/16 1/4 4/12 2/6 13/38 3/6 4.4 (1.1) 1073.10 GVAGALVAFK NS4 1863 3/16 0/4 6/12 2/6 1 1/38 6/6 56.5 (1.7) 24.0090 VAGALVAFK NS4 1864 4/16 1/4 6/12 0/4 1 1/38 1/6 7.1 m 24.0086 TLGFGAYMSK NS3 1262 6/16 2/12 2/5 10/33 CΛ m a. Data shown represents the number of positive responses over the total number of patients or contacts examined. m b. Frequency represents the number of positive responses over the total number of mice examined. Response indicates the average magnitude (standard deviation) of the response in positive animals, measured in lytic units. m Table XXXII. Candidate HCV-derived HTL epitopes Selection Conservancy criteria Peptide Sequence Source Total Core A DR-supermotif 1283 01 GQIVGGVYLLPRRGPR HCV Core 28 93 93 conserved 15mers 1283 02 VYLLPRRGPRLGVRA HCV Core 34 93 93 1283 03 GWLLSPRGSRPSWGPT HCV Core 95 79 79 1283 04 LGKVIDTLTCGFADL HCV Core 119 79 86 1283 05 IDTLTCGFADLMGYI HCV Core 123 86 86 1283 06 ADLMGYIPLVGAPLG HCV Core 131 79 79 1283 07 GVRVLEDGVNYATGN HCV Core 154 86 86 1283 08 GVNYATGNLPGCSFS HCV Core 161 79 86 1283 09 GCSFSIFLLALLSCL HCV Core 171 86 100 1283 10 GHRMAWDM MNWSPT HCV El 315 86 86 1283 11 CGPVYCFTPSPVWG HCV NS1 E2 506 93 93 1283 12 VYCFTPSPWVGTTD HCV NS1 E2 509 93 93 1283 13 GNWFGCTWMNSTGFT HCV NS1 E2 550 79 86 1283 14 FTTLPALSTGLIHLH HCV NS1 E2 684 79 86 1283 17 DLYLVTRHADVIPVR HCV NS3 1134 79 79 1283 18 RAAVCTRGVAKAVDF HCV NS3 1186 79 79 1283 20 AQGYKVLVLNPSVAA HCV NS3 1251 79 100 1283 21 GYKVLVLNPSVAATL HCV NS3 1253 100 100 1283 22 VLVLNPSVAATLGFG HCV NS3 1256 100 100 1283 23 GTVLDQAETAGARLV HCV NS3 1335 86 86 1283 24 GARLVVLATATPPGS HCV NS3 1345 79 86 1283 25 GRHLIFCHSKKKCDE HCV NS3 1393 100 100 1283 27 DSVIDCNTCVTQTVD HCV NS3 1454 86 86 1283 28 TVDFSLDPTFTIETT HCV NS3 1466 79 100 1283 30 FTGLTHIDAHFLSQT HCV NS3 1567 93 93 1283 31 YLVA YQATVCARAQA HCV NS3 1591 79 93 1283 32 KPTLHGPTPLLYRLG HCV NS4 1620 79 79 1283 33 LEVVTSTWVLVGGVL HCV NS4 1658 86 86 1283 34 TWVLVGGVLAALAAY HCV NS4 1664 86 86 1283 35 AEQF Q ALGLLQTA HCV NS4 1730 86 86 1283 40 PAILSPGALVVGWCA HCV NS4 1889 79 93 1283 41 GALVVGVVCAAILRR HCV NS4 1895 79 79 1283 42 CAAILRRHVGPGEGA HCV NS4 1903 79 79 1283 43 AVQWMNRLIAFASRG HCV NS4 1917 100 100 1283 44 MNRLIAFASRGNHVS HCV NS4 1921 86 100 1283 48 ANLLWRQEMGGN1TR HCV NS5 2238 86 86 1283 49 RQEMGGN1TRVESEN HCV NS5 2243 86 86 1283 52 ARLIVFPDLGVRVCE HCV NS5 2610 79 79 1283 53 FPDLGVRVCEKMALY HCV NS5 2615 79 100 1283 54 GVRVCEKMALYDWS HCV NS5 2619 79 100 1283 56 QPEYDLEL1TSCSSN HCV NS5 2808 79 93 1283 57 LELITSCSSNVSVAH HCV NS5 2813 79 100 1283 58 PTLWARIVΠLMTHFFS HCV NS5 2870 79 86 1283 59 LHGLSAFSLHSYSPG HCV NS5 2919 79 79 1283 60 AFSLHSYSPGEINRV HCV NS5 2924 79 79 Table XXXII. Candidate HCV-derived HTL epitopes Selection Conservancy criteria Peptide Sequence Source Total Core B High algorithm 1283 15 WLLFLLLADARVCS HCV NS1/E2 724 29 100 conserved core 1283 16 SKGWRLLAPITAYAQ HCV NS3 1025 29 79 1283 19 PQTFQVAHLHAPTGS HCV NS3 1225 43 85 1283 26 DWVVATDALMTGYT HCV NS3 1436 43 79 1283 29 WESVFTGLTHIDAHF HCV NS3 1563 43 92 1283 45 LTSMLTDPSHITAET HCV NS5 2176 57 100 1283 46 ASQLSAPSLKATCTT HCV NS5 2208 50 79 1283 47 DADLIEANLLWRQEM HCV NS5 2232 50 85 1283 50 SYTWTGALΓTPCAAE HCV NS5 2456 64 79 1283 51 ΓΠMAKNEVFCVQPE HCV NS5 2589 64 85 1283 55 GSSYGFQYSPGQRVE HCV NS5 2641 71 79 1283 61 ASCLRKLGVPPLRVW HCV NS5 2939 50 85 C Collaborator F098 03 AAYAAQGYKVLVLNPSVAAT HCV NS3 1242-1261 71 100 F098 04 GYKVLVLNPSVAATLGFGAY HCV NS3 1248-1267 100 F098 05 GYKVLVLNPSVAAT HCV NS3 1248-1261 100 F134 01 RRPQDVKFPGGGQIVGGVY HCV Core 17-35 86 F134 02 DVKFPGGGQIVGGVYLLPRR HCV Core 21-40 86 F134 03 GYKVLVLNPSVAATLGFGAY HCV NS3 1253-1272 100 F13404 TLHGPTPLLYRLGAVQNEIT HCV NS4 1622-1641 79 F134 05 NFISGIQYLAGLSTLPGNPA HCV NS4 1772-1791 100 F134 06 LLFNILGGWVAAQLAAPGAA HCV NS4 1812-1831 86 F134 07 GPGEGAVQWMNRLIAFASRG HCV NS4 1912-1931 86 100 F134 08 GEGA VQWMNRLIAFASRGNHV HCV NS4 1914-1934 100 Pape 21 AIPLEVIKGGRHLIFCHSKR HCV NS3 1379-1398 21 100 Pape 22 GRHLIFCHSKRKCDELATKL HCV NS3 1388-1407 100 Pape 29 SVIDCNTCVTQTVDFSLDPT HCV NS3 1450-1469 86 D DR3 motif 35 0102 GVRVLEDGVNYATGN HCV 154 86 86 35 0103 SAMYVGDLCGSVFLV HCV 273 57 86 35 0104 GHRMAWDMMMNWSPT HCV 315 86 86 35 0105 SDLYLVTRHAOVIPV HCV 1133 79 86 35 0106 WWATDALMTGYTG HCV 1437 42 86 35 0107 TVDFSLDPTFTIETT HCV 1466 79 100 35 0108 DSSVLCECYDAGCAW HCV 1518 71 93 35 0109 GLPVCQDHLEFWΈSV HCV 1552 42 86 35 01 10 GMQLAEQFKQKALGL HCV 1726 57 86 35 0111 PTHYVPESDAAARVT HCV 1936 86 86 35 01 12 GSQLPCEPEPDVAVL HCV 2162 64 86 35 01 13 LTSMLTDPSHITAET HCV 2176 57 100 35 0114 MPPLEGEPGDPDLSD HCV 2401 79 100 35 0115 QPEYDLELITSCSSN HCV 2808 79 93 1283 25 GRHLIFCHSKKKCDE HCV NS3 1393-1407 Table XXXIII. HLA-DR screening panels Screening Representative Assay 1 Phenotypic Frequencies Panel Antigen Alleles Allele Alias Cauc. Blk. Jpn. Chn. Hisp. Avg. Primary DRl DRBl*0101-03 DRB1*0101 (DRl) 18.5 8.4 10.7 4.5 10.1 10.4 DR4 DRB1*0401-12 DRB 1*0401 (DR4w4) 23.6 6.1 40.4 21.9 29.8 24.4 DR7 DRB 1*0701-02 DRB 1*0701 (DR7) 26.2 11.1 1.0 15.0 16.6 14.0 Panel total 59.6 24.5 49.3 38.7 51.1 44.6 Secondary DR2 DRBl*1501-03 DRB1*1501 (DR2w2Bl) 19.9 14.8 30.9 22.0 15.0 20.5 CΛ C DR2 DRB5*0101 DRB5*0101 (DR2w2 B2) - - - - - - CO DR9 DRB 1*09011,09012 DRB 1*0901 (DR9) 3.6 4.7 24.5 19.9 6.7 11.9 CΛ DR13 DRBl*1301-06 DRB1*1302 (DR6wl9) 21.7 16.5 14.6 12.2 10.5 15.1 Panel total 42.0 33.9 61.0 48.9 30.5 43.2 m CΛ m Tertiary DR4 DRB 1*0405 DRB 1*0405 (DR4wl5) - - - - - - m DR8 DRB 1*0801-5 DRB 1*0802 (DR8w2) 5.5 10.9 25.0 10.7 23.3 15.1 DR11 DRBl*1101-05 DRB1*1101 (DR5wll) 17.0 18.0 4.9 19.4 18.1 15.5 Panel total 22.0 27.8 29.2 29.0 39.0 29.4 m Quarternary DR3 DRB 1*0301-2 DRB 1*0301 (DR3 l7) 17.7 19.5 0.4 7.3 14.4 11.9 DR12 DRBl*1201-02 DRB1*1201 (DR5 l2) 2.8 5.5 13.1 17.6 5.7 8.9 Panel total 20.2 24.4 13.5 24.2 19.7 20.4 Table XXXIV. HLA-DR binding capacity of target derived peptides: DR-supermotif and algorithm positive peptides. Table XXXV. HLA-DR binding capacity of 3 DR3 motif- containing peptides DR3 binding Peptide Sequence Source (IC50 nM) CΛ C 35.0106 VVVVATDALMTGYTG HCV 1437 427 m W 35.0107 TVDFSLDPTFTIETT HCV 1466 235 1283.25 GRHLIFCHSKKKCDE HCV NS3 1393 ND m CΛ X m m ro Table XXXVIb: HCV-derived HTL epitope candidates CΛ Region Peptide Motif 1 Sequence C CO HCV NS3 1025-1039 1283.16 DR SKGWRLLAPITAYAQ CΛ HCV NS3 1242-1267 F98.03 DR AAYAAQGY VLVLNPSVAAT * HCV NS3 1393-1407 1283.25 DR3 GRHLIFCHSKKKCDE . HCV NS3 1437-1451 35.0106 DR3 VVVVATDALMTGYTG , m HCV NS3 1466-1480 35.0107 DR3 TVDFSLDPTFTIETT * CΛ HCV NS4 1772-1790 F134.05 DR NFISGIQYLAGLSTLPGNPA * m HCV NS4 1914-1935 F134.08 DR GEGAVQWMNRLIAFASRGNHV- m HCV NS5 2641-2655 1283.55 DR GSSYGFQYSPGQRVE * HCV NS5 2939-2953 1283.61 DR ASCLRKLGVPPLRVW V m 1. Peptides identified on the basis of either the DR P 1 -P6 supermotif or by use of the DRl -4-7 algorithms are indicated by 'DR'. Peptides identified using the DR3 motif are indicated by 'DR3'. Table XXXVII. Estimated population coverage by a panel of HCV derived HTL epitopes Representative No. of Population coverage (phenotypic frequency) Antigen Alleles assay epitopes Cauc. Blk. Jpn. Chn. Hisp. Avg. DRl DRBl *0101-03 DRl 6 18.5 8.4 10.7 4.5 10.1 10.4 DR2 DRBl *1501-03 DR2w2 βl 3 19.9 14.8 30.9 22.0 15.0 20.5 DR2 DRB5*0101 DR2w2 B2 6 - - - - - - CΛ C DR3 DRB 1 *0301-2 DR3 2 17.7 19.5 0.40 7.3 14.4 1 1.9 00 CΛ DR4 DRB1*0401-12 DR4w4 5 23.6 6.1 40.4 21.9 29.8 24.4 DR4 DRB1*0401-12 DR4wl5 3 - - - - - - DR7 DRBl *0701-02 DR7 5 26.2 11.1 1.0 15.0 16.6 14.0 m CΛ DR8 DRBl*0801-5 DR8w2 5 5.5 10.9 25.0 10.7 23.3 15.1 m DR9 DRB1*09011,09012 DR9 3 3.6 4.7 24.5 19.9 6.7 11.9 m DR11 DRBl*1101-05 DR5wl l 5 17.0 18.0 4.9 19.4 18.1 15.5 DRl 3 DRBl*1301-06 DR6wl9 2 21.7 16.5 14.6 12.2 10.5 15.1 m Total' 98.5 95.1 97.1 91.3 94.3 95.1 1. Total population coverage has been adjusted to acount for the presence of DRX in many ethnic populations. It has been assumed that the range of specificities represented by DRX alleles will mirror those of previously characterized HLA-DR alleles. The proportion of DRX incorporated under each motif is representative of the frequency of the motif in the remainder of the population. Total coverage has not been adjusted to account for unknown gene types. 2. Number of epitopes represents a minimal estimate, considering only the epitopes shown in Table 6. Additional alleles possibly bound by nested epitopes have not been accounted. TABLE la If 2 is V, or Q, the C-term is not L Bolded residues are preferred, italicized residues are less preferred: A peptide is considered motif-bearing if it has primary anchors at each primary anchor position for a motif or supermotif as specified in the above table.

Claims: WHAT IS CLAIMED IS 1. A composition comprising a prepared hepatitis C virus (HCV) epitope consisting of an amino acid sequence selected from the group consisting of : FLLLADARV, YLVAYQATV, RLIVFPDLGV, DLMGYIPLV, WMNRLIAFA, VLVGGVLAA, HMWNFISGI, ILAGYGAGV, YLLPRRGPRL, LLFLLLADA, YLVTRHADV, KTSERSQPR, RLGVRATRK, QLFTFSPRR, RMYVGGVEHR, LIFCHSKKK, GVAGALVAFK, VAGALVAFK, TLGFGAYMSK, LPGCSFSIF, LSAFSLHSY, CTCGSSDLY, FWAKHMWNF, SKGWRLLAPITAYAQ, AAYAAQGYKVLVLNPSVAAT, GRHLIFCHSKKKCDE, VVVVATDALMTGYTG, TVDFSLDPTFTIETT, NFISGIQYLAGLSTLPGNPA, GEGAVQWMNRLIAFASRGNHV, GSSYGFQYSPGQRVE, ASCLRKLGVPPLRVW, and LTCGFADLMGY. 2. The composition of claim 1, further comprising two epitopes selected from the group in claim 1. 3. The composition of claim 2, further comprising three epitopes selected from the group in claim 1. 4. The composition of claim 1, wherein the composition further comprises a CTL epitope selected from the group consisting of LTDPSHITA, LADGGCSGGAY, RMILMTHFF, VMGSSYGF, FWAKHMWNFI, LLFNILGGWV, IPFYGKAI, and VGIYLLPNR. 5. The composition of claim 1, wherein the composition further comprises an HTL epitope. 6. The composition of claim 5, wherein the HTL epitope is a pan DR binding molecule. 7. The composition of claim 1, wherein the epitope is on or within a liposome. 8. The composition of claim 1 , wherein the peptide is joined to a lipid. 9. The composition of claim 1, wherein the epitope is bound to an HLA heavy chain, β2-microglobulin, and strepavidin complex, whereby a tetramer is formed. 10. The composition of claim 1, wherein the epitope is bound to an HLA molecule on an antigen presenting cell. 11. The composition of claim 10, wherein the antigen presenting cell is a dendritic cell. 12. The composition of claim 1, the composition further comprising a pharmaceutical excipient. 13. The composition of claim 1, further wherein the epitope is in a unit dose form. 14. A composition comprising a prepared peptide of less than 250 amino acid residues comprising at least two hepatitis C virus (HCV) peptide epitopes selected from the group consisting of: FLLLADARV, YLVAYQATV, RLIVFPDLGV, DLMGYIPLV, WMNRLIAFA, VLVGGVLAA, HMWNFISGI, ILAGYGAGV, YLLPRRGPRL, LLFLLLADA, YLVTRHADV, KTSERSQPR, RLGVRATRK, QLFTFSPRR, RMYVGGVEHR, LIFCHSKKK, GVAGALVAFK, VAGALVAFK, TLGFGAYMSK, LPGCSFSIF, LSAFSLHSY, CTCGSSDLY, FWAKHMWNF, SKGWRLLAPITAYAQ, AAYAAQGYKVLVLNPSVAAT, GRHLIFCHSKKKCDE, VVVVATDALMTGYTG, TVDFSLDPTFTIETT, NFISGIQYLAGLSTLPGNPA, GEGAVQWMNRLIAFASRGNHV, GSSYGFQYSPGQRVE, ASCLRKLGVPPLRVW, and LTCGFADLMGY. 15. The composition of claim 14, wherein at least two epitopes are linked via a spacer. 16. The composition of claim 14, further comprising a third epitope. 17. The composition of claim 16, wherein the third epitope is selected from the group consisting of LTDPSHITA, LADGGCSGGAY, RMILMTHFF, VMGSSYGF, FWAKHMWNFI, LLFNILGGWV, IPFYGKAI, and VGIYLLPNR. 18. The composition of claim 16, further comprising a third epitope that is an HTL epitope. 19. The composition of claim 18, wherein the HTL epitope is a panDR binding molecule. 20. The composition of claim 14, wherein the peptide is on or within a liposome. 21. The composition of claim 14, wherein the peptide is joined to a lipid. 22. The composition of claim 14, wherein the peptide further comprises at least three of the epitopes in the group of claim 14. 23. The composition of claim 14, wherein the peptide further comprises at least four of the epitopes in the group of claim 14. 24. The composition of claim 14, wherein the peptide further comprises at least five of the epitopes in the group of claim 14. 25. The composition of claim 14, wherein the peptide further comprises at least six of the epitopes in the group of claim 14. 26. The composition of claim 14, the composition further comprising a pharmaceutical excipient. 27. The composition of claim 14, further wherein the epitope is in a unit dose form. 28. A composition comprising at least six prepared HCV epitopes each consisting of an amino acid sequence selected from the group consisting of: FLLLADARV, YLVAYQATV, RLIVFPDLGV, DLMGYIPLV, WMNRLIAFA, VLVGGVLAA, HMWNFISGI, ILAGYGAGV, YLLPRRGPRL, LLFLLLADA, YLVTRHADV, KTSERSQPR, RLGVRATRK, QLFTFSPRR, RMYVGGVEHR, LIFCHSKKK, GVAGALVAFK, VAGALVAFK, TLGFGAYMSK, LPGCSFSIF, LSAFSLHSY, CTCGSSDLY, FWAKHMWNF, SKGWRLLAPITAYAQ, AAYAAQGYKVLVLNPSVAAT, GRHLIFCHSKKKCDE, VVVVATDALMTGYTG, TVDFSLDPTFTIETT, NFISGIQYLAGLSTLPGNPA, GEGAVQWMNRLIAFASRGNHV, GSSYGFQYSPGQRVE, ASCLRKLGVPPLRVW, and LTCGFADLMGY. 29. The composition of claim 28, further comprising at least one epitope selected from the group consisting of LTDPSHITA, LADGGCSGGAY, RMILMTHFF, VMGSSYGF, FWAKHMWNFI, LLFNILGGWV, IPFYGKAI, and VGIYLLPNR.

Inventors: BAKER DENISE MARIE, CELIS ESTEBAN, CHESNUT ROBERT, GREY HOWARD M, KUBO RALPH T, LIVINGSTON BRIAN D, SETTE ALESSANDRO, SIDNEY JOHN, SOUTHWOOD SCOTT, BAKER, DENISE, MARIE, CELIS, ESTEBAN, CHESNUT, ROBERT, GREY, HOWARD, M., KUBO, RALPH, T., LIVINGSTON, BRIAN, D., SETTE, ALESSANDRO, SIDNEY, JOHN, SOUTHWOOD, SCOTT
Applicants: BAKER DENISE MARIE, CELIS ESTEBAN, CHESNUT ROBERT, EPIMMUNE INC, GREY HOWARD M, KUBO RALPH T, LIVINGSTON BRIAN D, SETTE ALESSANDRO, SIDNEY JOHN, SOUTHWOOD SCOTT, BAKER, DENISE, MARIE, CELIS, ESTEBAN, CHESNUT, ROBERT, EPIMMUNE INC., GREY, HOWARD, M., KUBO, RALPH, T., LIVINGSTON, BRIAN, D., SETTE, ALESSANDRO, SIDNEY, JOHN, SOUTHWOOD, SCOTT
Application year: 2000
Main classification: A61K38
IPC codes: A61K9, A61K38, A61K39, A61K47, A61P1, A61P31, A61P37, C07K14